{"matching_results": 123791, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 2684, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1777}, {"key": "negative", "matching_results": 883}, {"key": "neutral", "matching_results": 24}]}]}, {"key": "mylubbocktv.com", "matching_results": 1330, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1017}, {"key": "negative", "matching_results": 310}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "watchlistnews.com", "matching_results": 1238, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 958}, {"key": "negative", "matching_results": 279}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "tickerreport.com", "matching_results": 1228, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1007}, {"key": "negative", "matching_results": 221}]}]}, {"key": "wkrb13.com", "matching_results": 1167, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 956}, {"key": "negative", "matching_results": 210}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 1164, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 853}, {"key": "negative", "matching_results": 310}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 1131, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 841}, {"key": "negative", "matching_results": 289}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 1102, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 861}, {"key": "negative", "matching_results": 239}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "marketscreener.com", "matching_results": 1101, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 772}, {"key": "negative", "matching_results": 319}, {"key": "neutral", "matching_results": 10}]}]}, {"key": "audioboom.com", "matching_results": 998, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "neutral", "matching_results": 371}, {"key": "positive", "matching_results": 349}, {"key": "negative", "matching_results": 278}]}]}]}], "results": [{"id": "JhA0TawKKiHBFLlI5nPuINqqp5ayjuDfRDI7i5ynWtZHlisx5MBHPnTsiEGknxoT", "result_metadata": {"score": 21.60848}, "author": "Trevor Kearing", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.433494, "label": "positive"}, "text": "Markel Co.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MKL", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,265.25", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Markel Co. (MKL)", "keywords": [{"text": "Co. (MKL)"}], "entities": [{"type": "Company", "text": "Markel Co."}, {"type": "Organization", "text": "MKL"}]}, "sentence": "Markel Co. (MKL) Receives $1,265.25 Average Target Price from Analysts", "object": {"text": "$1,265.25 Average Target Price", "keywords": [{"text": "Average Target Price"}], "entities": [{"type": "Quantity", "text": "$1,265.25"}]}, "action": {"verb": {"text": "Receives", "tense": "present"}, "text": "Receives", "normalized": "Receives"}}], "concepts": [{"text": "Markel", "relevance": 0.895888, "dbpedia_resource": "http://dbpedia.org/resource/Markel"}], "categories": [{"score": 0.528517, "label": "/real estate/buying and selling homes"}, {"score": 0.490151, "label": "/finance/financial news"}, {"score": 0.481312, "label": "/business and industrial/company/earnings"}], "relations": [], "keywords": [{"text": "Average Target Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.958114}, {"text": "Markel Co.", "sentiment": {"score": 0.433494, "label": "positive"}, "relevance": 0.771261}, {"text": "MKL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499925}, {"text": "Analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331816}]}, "crawl_date": "2018-11-12T22:21:14Z", "url": "https://www.dailypolitical.com/2018/11/12/markel-co-mkl-receives-1265-25-average-target-price-from-analysts.html", "host": "dailypolitical.com", "text": "Tweet Markel Co.", "main_image_url": "https://www.marketbeat.com/logos/markel-corp-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T21:40:00Z", "enriched_text": {"entities": [{"count": 13, "sentiment": {"score": -0.397326, "label": "negative"}, "text": "Markel", "relevance": 0.958814, "type": "Company"}, {"count": 9, "sentiment": {"score": 0.386293, "label": "positive"}, "text": "Manufacturers Life Insurance Company", "relevance": 0.583917, "type": "Company", "disambiguation": {"subtype": [], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}, {"count": 4, "sentiment": {"score": 0.390833, "label": "positive"}, "text": "Markel Co.", "relevance": 0.496204, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Markel Corporation", "relevance": 0.379859, "type": "Company", "disambiguation": {"subtype": [], "name": "Markel Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Markel_Corporation"}}, {"count": 2, "sentiment": {"score": -0.437168, "label": "negative"}, "text": "MKL", "relevance": 0.207399, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alaska Department of Revenue", "relevance": 0.200019, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MKL", "relevance": 0.198279, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "IFM Investors Pty Ltd", "relevance": 0.193785, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Principal Financial Group Inc.", "relevance": 0.193275, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.489611, "label": "negative"}, "text": "Millennium Management LLC", "relevance": 0.187958, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "International Insurance", "relevance": 0.184989, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities & Exchange Commission", "relevance": 0.168405, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.162814, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boenning Scattergood", "relevance": 0.162003, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.155766, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385582, "label": "negative"}, "text": "Alan I. Kirshner", "relevance": 0.153154, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "chief executive officer", "relevance": 0.150363, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Richard R. Whitt III", "relevance": 0.149981, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.565257, "label": "positive"}, "text": "ValuEngine", "relevance": 0.148742, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.146944, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.386293, "label": "positive"}, "text": "23,650", "relevance": 0.139529, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "analyst", "relevance": 0.134697, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,444", "relevance": 0.132772, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.127382, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Kingdom", "relevance": 0.123822, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "twelve month", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$12,562,043.20", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.58 billion", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$28,156,507.50", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.77 billion", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.81 billion", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$785,828,000", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$119,055.00", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$601,400.00", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,362,085", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3,137,000", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$6,208,000", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,020.00", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,100.66", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,190.55", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,202.80", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,228.32", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,265.25", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$691,000", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$721,000", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "90 days", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$21.33", "relevance": 0.123822, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$21.45", "relevance": 0.123822, "type": "Quantity"}], "sentiment": {"document": {"score": 0.421583, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "MKL)", "keywords": [{"text": "MKL"}]}, "sentence": "Tweet Markel Co. (NYSE:MKL) has received a consensus recommendation of \u201cBuy\u201d from the seven research firms that are presently covering the company, MarketBeat.com reports.", "object": {"text": "a consensus recommendation of \u201cBuy\u201d", "keywords": [{"text": "consensus recommendation"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "has received", "normalized": "have receive"}}, {"subject": {"text": "the company, MarketBeat.com reports", "keywords": [{"text": "MarketBeat.com reports"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}]}, "sentence": "Tweet Markel Co. (NYSE:MKL) has received a consensus recommendation of \u201cBuy\u201d from the seven research firms that are presently covering the company, MarketBeat.com reports.", "object": {"text": "the seven research firms", "keywords": [{"text": "research firms"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "are presently covering", "normalized": "be presently cover"}}, {"subject": {"text": "Four research analysts", "keywords": [{"text": "research analysts"}]}, "sentence": " Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "rate", "tense": "past"}, "text": "have rated", "normalized": "have rate"}}, {"subject": {"text": "two"}, "sentence": " Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company.", "object": {"text": "a buy rating", "keywords": [{"text": "buy rating"}]}, "action": {"verb": {"text": "assign", "tense": "past"}, "text": "have assigned", "normalized": "have assign"}}, {"subject": {"text": "one"}, "sentence": " Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company.", "object": {"text": "issued a strong buy rating on the company", "keywords": [{"text": "strong buy rating"}, {"text": "company"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "covered the stock", "keywords": [{"text": "stock"}]}, "sentence": " The average 1 year target price among brokers that have covered the stock in the last year is $1,265.25.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "the stock", "keywords": [{"text": "stock"}]}, "sentence": " The average 1 year target price among brokers that have covered the stock in the last year is $1,265.25.", "action": {"verb": {"text": "cover", "tense": "past"}, "text": "have covered", "normalized": "have cover"}}, {"subject": {"text": "The average 1 year target price among brokers that have covered the stock in the last year", "keywords": [{"text": "target price"}, {"text": "average"}, {"text": "brokers"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "1 year"}]}, "sentence": " The average 1 year target price among brokers that have covered the stock in the last year is $1,265.25.", "object": {"text": "$1,265.25", "entities": [{"type": "Quantity", "text": "$1,265.25"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "A number of analysts", "keywords": [{"text": "analysts"}, {"text": "number"}]}, "sentence": " A number of analysts recently commented on MKL shares.", "object": {"text": "on MKL shares", "keywords": [{"text": "MKL shares"}], "entities": [{"type": "Company", "text": "MKL"}]}, "action": {"verb": {"text": "comment", "tense": "past"}, "text": "commented", "normalized": "comment"}}, {"subject": {"text": "Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}]}, "sentence": " Zacks Investment Research lowered Markel from a \u201chold\u201d rating to a \u201csell\u201d rating in a research report on Tuesday, July 24th.", "object": {"text": "Markel", "keywords": [{"text": "Markel"}], "entities": [{"type": "Person", "text": "Markel Co."}]}, "action": {"verb": {"text": "lower", "tense": "past"}, "text": "lowered", "normalized": "lower"}}, {"subject": {"text": "Boenning Scattergood", "keywords": [{"text": "Scattergood"}], "entities": [{"type": "Person", "text": "Boenning Scattergood"}]}, "sentence": " Boenning Scattergood restated a \u201cbuy\u201d rating on shares of Markel in a research report on Wednesday, August 1st.", "object": {"text": "a \u201cbuy\u201d rating on shares of Markel in a research report on Wednesday", "keywords": [{"text": "Markel"}, {"text": "research report"}, {"text": "Wednesday"}, {"text": "buy"}], "entities": [{"type": "Company", "text": "Markel Co."}]}, "action": {"verb": {"text": "restate", "tense": "past"}, "text": "restated", "normalized": "restate"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}], "entities": [{"type": "Company", "text": "ValuEngine"}]}, "sentence": " Finally, ValuEngine upgraded Markel from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a research report on Thursday, August 2nd.", "object": {"text": "Markel", "keywords": [{"text": "Markel"}], "entities": [{"type": "Company", "text": "Markel Co."}]}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "upgraded", "normalized": "upgrade"}}, {"subject": {"text": "CEO Richard R. Whitt III", "keywords": [{"text": "Richard R. Whitt"}, {"text": "CEO"}], "entities": [{"type": "JobTitle", "text": "CEO"}, {"type": "Person", "text": "Richard R. Whitt III"}]}, "sentence": " In other news, CEO Richard R. Whitt III sold 500 shares of Markel stock in a transaction dated Wednesday, September 5th.", "object": {"text": "500 shares of Markel stock", "keywords": [{"text": "Markel stock"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Markel"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "a transaction", "keywords": [{"text": "transaction"}]}, "sentence": " In other news, CEO Richard R. Whitt III sold 500 shares of Markel stock in a transaction dated Wednesday, September 5th.", "action": {"verb": {"text": "date", "tense": "past"}, "text": "dated", "normalized": "date"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock was sold at an average price of $1,202.80, for a total transaction of $601,400.00.", "object": {"text": "sold at an average price of $1,202.80", "keywords": [{"text": "average price"}], "entities": [{"type": "Quantity", "text": "$1,202.80"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "the chief executive officer", "keywords": [{"text": "chief executive officer"}], "entities": [{"type": "JobTitle", "text": "chief executive officer"}]}, "sentence": " Following the transaction, the chief executive officer now owns 10,444 shares in the company, valued at approximately $12,562,043.20.", "object": {"text": "10,444 shares", "keywords": [{"text": "shares"}], "entities": [{"type": "Company", "text": "10,444"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .", "object": {"text": "disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website", "keywords": [{"text": "Exchange Commission"}, {"text": "SEC"}, {"text": "Securities"}, {"text": "document"}], "entities": [{"type": "Organization", "text": "Securities & Exchange Commission", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"type": "Organization", "text": "Securities & Exchange Commission", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The transaction", "keywords": [{"text": "transaction"}]}, "sentence": " The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .", "action": {"verb": {"text": "disclose", "tense": "past"}, "text": "was disclosed", "normalized": "be disclose"}}, {"subject": {"text": "the Securities & Exchange Commission", "keywords": [{"text": "Securities"}, {"text": "Exchange Commission"}], "entities": [{"type": "Organization", "text": "Securities & Exchange Commission", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}]}, "sentence": " The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .", "object": {"text": "available at the SEC website", "keywords": [{"text": "SEC"}, {"text": "website"}], "entities": [{"type": "Organization", "text": "Securities & Exchange Commission", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "insider Alan I. Kirshner", "keywords": [{"text": "Alan I. Kirshner"}, {"text": "insider"}], "entities": [{"type": "Person", "text": "Alan I. Kirshner"}]}, "sentence": " Also, insider Alan I. Kirshner sold 100 shares of Markel stock in a transaction dated Monday, October 1st.", "object": {"text": "100 shares of Markel stock", "keywords": [{"text": "Markel stock"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Markel"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "The shares", "keywords": [{"text": "shares"}]}, "sentence": " The shares were sold at an average price of $1,190.55, for a total value of $119,055.00.", "object": {"text": "sold at an average price of $1,190.55", "keywords": [{"text": "average price"}], "entities": [{"type": "Quantity", "text": "$1,190.55"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "the insider", "keywords": [{"text": "insider"}]}, "sentence": " Following the transaction, the insider now owns 23,650 shares in the company, valued at approximately $28,156,507.50.", "object": {"text": "23,650 shares", "keywords": [{"text": "shares"}], "entities": [{"type": "Company", "text": "23,650"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}]}, "sentence": " Following the transaction, the insider now owns 23,650 shares in the company, valued at approximately $28,156,507.50.", "object": {"text": "at approximately $28,156,507.50", "entities": [{"type": "Quantity", "text": "$28,156,507.50"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "valued", "normalized": "value"}}, {"subject": {"text": "The disclosure for this sale", "keywords": [{"text": "disclosure"}, {"text": "sale"}]}, "sentence": " The disclosure for this sale can be found here .", "object": {"text": "found here"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The disclosure for this sale", "keywords": [{"text": "disclosure"}, {"text": "sale"}]}, "sentence": " The disclosure for this sale can be found here .", "action": {"verb": {"text": "find", "tense": "future"}, "text": "can be found", "normalized": "can be find"}}, {"subject": {"text": "Insiders", "keywords": [{"text": "Insiders"}]}, "sentence": " Insiders have sold a total of 1,149 shares of company stock valued at $1,362,085 over the last 90 days.", "object": {"text": "sold a total of 1,149 shares of company stock valued at $1,362,085 over the last 90 days", "keywords": [{"text": "company stock"}, {"text": "total"}, {"text": "shares"}, {"text": "90 days"}], "entities": [{"type": "Quantity", "text": "$1,362,085"}, {"type": "Quantity", "text": "90 days"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Insiders", "keywords": [{"text": "Insiders"}]}, "sentence": " Insiders have sold a total of 1,149 shares of company stock valued at $1,362,085 over the last 90 days.", "object": {"text": "a total of 1,149 shares of company stock valued at $1,362,085", "keywords": [{"text": "company stock"}, {"text": "total"}, {"text": "shares"}], "entities": [{"type": "Quantity", "text": "$1,362,085"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "have sold", "normalized": "have sell"}}, {"subject": {"text": "Corporate insiders", "keywords": [{"text": "Corporate insiders"}]}, "sentence": " Corporate insiders own 2.53% of the company\u2019s stock.", "object": {"text": "2.53% of the company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}, {"type": "Quantity", "text": "2.53"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "own", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}]}, "sentence": " Corporate insiders own 2.53% of the company\u2019s stock.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Several large investors", "keywords": [{"text": "large investors"}]}, "sentence": " Several large investors have recently added to or reduced their stakes in MKL.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Several large investors", "keywords": [{"text": "large investors"}]}, "sentence": " Several large investors have recently added to or reduced their stakes in MKL.", "object": {"text": "to or reduced their stakes in MKL", "keywords": [{"text": "MKL"}, {"text": "stakes"}], "entities": [{"type": "Location", "text": "MKL", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "added", "normalized": "add"}}, {"subject": {"text": "Several large investors", "keywords": [{"text": "large investors"}]}, "sentence": " Several large investors have recently added to or reduced their stakes in MKL.", "object": {"text": "their stakes in MKL", "keywords": [{"text": "MKL"}, {"text": "stakes"}], "entities": [{"type": "Location", "text": "MKL", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "reduce", "tense": "past"}, "text": "reduced", "normalized": "reduce"}}, {"subject": {"text": "Principal Financial Group Inc.", "keywords": [{"text": "Principal Financial Group"}], "entities": [{"type": "Company", "text": "Principal Financial Group Inc."}]}, "sentence": " Principal Financial Group Inc. lifted its holdings in shares of Markel by 1.0% during the 1st quarter.", "object": {"text": "its holdings in shares of Markel", "keywords": [{"text": "Markel"}, {"text": "holdings"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Markel"}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "Principal Financial Group Inc.", "keywords": [{"text": "Principal Financial Group"}], "entities": [{"type": "Company", "text": "Principal Financial Group Inc."}]}, "sentence": " Principal Financial Group Inc. now owns 671,504 shares of the insurance provider\u2019s stock valued at $785,828,000 after purchasing an additional 6,453 shares in the last quarter.", "object": {"text": "671,504 shares of the insurance provider\u2019s stock valued at $785,828,000", "keywords": [{"text": "insurance provider"}, {"text": "shares"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$785,828,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock valued at $785,828,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$785,828,000"}]}, "sentence": " Principal Financial Group Inc. now owns 671,504 shares of the insurance provider\u2019s stock valued at $785,828,000 after purchasing an additional 6,453 shares in the last quarter.", "object": {"text": "the insurance provider", "keywords": [{"text": "insurance provider"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Principal Financial Group Inc.", "keywords": [{"text": "Principal Financial Group"}], "entities": [{"type": "Company", "text": "Principal Financial Group Inc."}]}, "sentence": " Principal Financial Group Inc. now owns 671,504 shares of the insurance provider\u2019s stock valued at $785,828,000 after purchasing an additional 6,453 shares in the last quarter.", "object": {"text": "an additional 6,453 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "The Manufacturers Life Insurance Company", "keywords": [{"text": "Manufacturers Life Insurance"}, {"text": "Company"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}]}, "sentence": " The Manufacturers Life Insurance Company lifted its holdings in shares of Markel by 10.7% during the 1st quarter.", "object": {"text": "its holdings in shares of Markel", "keywords": [{"text": "Markel"}, {"text": "holdings"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Markel"}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "The Manufacturers Life Insurance Company", "keywords": [{"text": "Manufacturers Life Insurance"}, {"text": "Company"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}]}, "sentence": " The Manufacturers Life Insurance Company now owns 590 shares of the insurance provider\u2019s stock valued at $691,000 after purchasing an additional 57 shares in the last quarter.", "object": {"text": "590 shares of the insurance provider\u2019s stock valued at $691,000", "keywords": [{"text": "insurance provider"}, {"text": "shares"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$691,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock valued at $691,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$691,000"}]}, "sentence": " The Manufacturers Life Insurance Company now owns 590 shares of the insurance provider\u2019s stock valued at $691,000 after purchasing an additional 57 shares in the last quarter.", "object": {"text": "the insurance provider", "keywords": [{"text": "insurance provider"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The Manufacturers Life Insurance Company", "keywords": [{"text": "Manufacturers Life Insurance"}, {"text": "Company"}], "entities": [{"type": "Company", "text": "Manufacturers Life Insurance Company", "disambiguation": {"subtype": ["Company"], "name": "Manulife Financial", "dbpedia_resource": "http://dbpedia.org/resource/Manulife_Financial"}}]}, "sentence": " The Manufacturers Life Insurance Company now owns 590 shares of the insurance provider\u2019s stock valued at $691,000 after purchasing an additional 57 shares in the last quarter.", "object": {"text": "an additional 57 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Millennium Management LLC", "keywords": [{"text": "Millennium Management LLC"}], "entities": [{"type": "Company", "text": "Millennium Management LLC"}]}, "sentence": " Millennium Management LLC lifted its holdings in shares of Markel by 583.6% during the 1st quarter.", "object": {"text": "its holdings in shares of Markel", "keywords": [{"text": "Markel"}, {"text": "holdings"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Markel"}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "Millennium Management LLC", "keywords": [{"text": "Millennium Management LLC"}], "entities": [{"type": "Company", "text": "Millennium Management LLC"}]}, "sentence": " Millennium Management LLC now owns 5,305 shares of the insurance provider\u2019s stock valued at $6,208,000 after purchasing an additional 4,529 shares in the last quarter.", "object": {"text": "5,305 shares of the insurance provider\u2019s stock valued at $6,208,000", "keywords": [{"text": "insurance provider"}, {"text": "shares"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$6,208,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock valued at $6,208,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$6,208,000"}]}, "sentence": " Millennium Management LLC now owns 5,305 shares of the insurance provider\u2019s stock valued at $6,208,000 after purchasing an additional 4,529 shares in the last quarter.", "object": {"text": "the insurance provider", "keywords": [{"text": "insurance provider"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Millennium Management LLC", "keywords": [{"text": "Millennium Management LLC"}], "entities": [{"type": "Company", "text": "Millennium Management LLC"}]}, "sentence": " Millennium Management LLC now owns 5,305 shares of the insurance provider\u2019s stock valued at $6,208,000 after purchasing an additional 4,529 shares in the last quarter.", "object": {"text": "an additional 4,529 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "IFM Investors Pty Ltd", "keywords": [{"text": "IFM Investors"}], "entities": [{"type": "Company", "text": "IFM Investors Pty Ltd"}]}, "sentence": " IFM Investors Pty Ltd lifted its holdings in shares of Markel by 41.2% during the 2nd quarter.", "object": {"text": "its holdings in shares of Markel", "keywords": [{"text": "Markel"}, {"text": "holdings"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Markel"}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "IFM Investors Pty Ltd", "keywords": [{"text": "IFM Investors"}], "entities": [{"type": "Company", "text": "IFM Investors Pty Ltd"}]}, "sentence": " IFM Investors Pty Ltd now owns 665 shares of the insurance provider\u2019s stock valued at $721,000 after purchasing an additional 194 shares in the last quarter.", "object": {"text": "665 shares of the insurance provider\u2019s stock valued at $721,000", "keywords": [{"text": "insurance provider"}, {"text": "shares"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$721,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock valued at $721,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$721,000"}]}, "sentence": " IFM Investors Pty Ltd now owns 665 shares of the insurance provider\u2019s stock valued at $721,000 after purchasing an additional 194 shares in the last quarter.", "object": {"text": "the insurance provider", "keywords": [{"text": "insurance provider"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "IFM Investors Pty Ltd", "keywords": [{"text": "IFM Investors"}], "entities": [{"type": "Company", "text": "IFM Investors Pty Ltd"}]}, "sentence": " IFM Investors Pty Ltd now owns 665 shares of the insurance provider\u2019s stock valued at $721,000 after purchasing an additional 194 shares in the last quarter.", "object": {"text": "an additional 194 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "State of Alaska Department of Revenue", "keywords": [{"text": "Revenue"}, {"text": "Alaska Department"}, {"text": "State"}], "entities": [{"type": "Organization", "text": "Alaska Department of Revenue"}]}, "sentence": " Finally, State of Alaska Department of Revenue lifted its holdings in shares of Markel by 24.5% during the 2nd quarter.", "object": {"text": "its holdings in shares of Markel", "keywords": [{"text": "Markel"}, {"text": "holdings"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Markel"}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "State of Alaska Department of Revenue", "keywords": [{"text": "Revenue"}, {"text": "Alaska Department"}, {"text": "State"}], "entities": [{"type": "Organization", "text": "Alaska Department of Revenue"}]}, "sentence": " State of Alaska Department of Revenue now owns 2,895 shares of the insurance provider\u2019s stock valued at $3,137,000 after purchasing an additional 570 shares in the last quarter.", "object": {"text": "2,895 shares of the insurance provider\u2019s stock valued at $3,137,000", "keywords": [{"text": "insurance provider"}, {"text": "shares"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$3,137,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}], "concepts": [{"text": "Markel", "relevance": 0.985477, "dbpedia_resource": "http://dbpedia.org/resource/Markel"}, {"text": "Stock", "relevance": 0.953383, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Underwriting", "relevance": 0.930909, "dbpedia_resource": "http://dbpedia.org/resource/Underwriting"}, {"text": "Insurance", "relevance": 0.928577, "dbpedia_resource": "http://dbpedia.org/resource/Insurance"}, {"text": "Financial ratio", "relevance": 0.896925, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Financial services", "relevance": 0.841389, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services"}, {"text": "Workers' compensation", "relevance": 0.838604, "dbpedia_resource": "http://dbpedia.org/resource/Workers'_compensation"}, {"text": "Holding company", "relevance": 0.802687, "dbpedia_resource": "http://dbpedia.org/resource/Holding_company"}, {"text": "Endowment policy", "relevance": 0.717096, "dbpedia_resource": "http://dbpedia.org/resource/Endowment_policy"}], "categories": [{"score": 0.548075, "label": "/finance/financial news"}, {"score": 0.475907, "label": "/finance/investing"}, {"score": 0.475907, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "partOf", "sentence": "Tweet Markel Co. (NYSE:MKL) has received a consensus recommendation of \"Buy\" from the seven research firms that are presently covering the company, MarketBeat.com reports.", "score": 0.586752, "arguments": [{"text": "firms", "location": [101, 106], "entities": [{"type": "Organization", "text": "website"}]}, {"text": "company", "location": [139, 146], "entities": [{"type": "Organization", "text": "MarketBeat.com", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Markel (NYSE:MKL) last announced its quarterly earnings data on Tuesday, October 30th.", "score": 0.81359, "arguments": [{"text": "NYSE:MKL", "location": [3867, 3875], "entities": [{"type": "Time", "text": "NYSE:MKL"}]}, {"text": "announced", "location": [3882, 3891], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "Markel (NYSE:MKL) last announced its quarterly earnings data on Tuesday, October 30th.", "score": 0.720675, "arguments": [{"text": "Tuesday", "location": [3923, 3930], "entities": [{"type": "Date", "text": "October 30th"}]}, {"text": "announced", "location": [3882, 3891], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "The insurance provider reported $28.50 EPS for the quarter, topping the Zacks' consensus estimate of $7.05 by $21.45.", "score": 0.705852, "arguments": [{"text": "insurance provider", "location": [3950, 3968], "entities": [{"type": "Organization", "text": "Insurance"}]}, {"text": "reported", "location": [3969, 3977], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The insurance provider reported $28.50 EPS for the quarter, topping the Zacks' consensus estimate of $7.05 by $21.45.", "score": 0.786758, "arguments": [{"text": "EPS", "location": [3985, 3988], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "$28.50", "location": [3978, 3984], "entities": [{"type": "Money", "text": "$28.50", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The firm had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.77 billion.", "score": 0.880224, "arguments": [{"text": "firm", "location": [4068, 4072], "entities": [{"type": "Organization", "text": "firm", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$1.81 billion", "location": [4088, 4101], "entities": [{"type": "Money", "text": "$1.81 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The firm had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.77 billion.", "score": 0.619125, "arguments": [{"text": "firm", "location": [4068, 4072], "entities": [{"type": "Organization", "text": "firm", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$1.77 billion", "location": [4155, 4168], "entities": [{"type": "Money", "text": "$1.77 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The firm had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.77 billion.", "score": 0.481025, "arguments": [{"text": "analyst", "location": [4134, 4141], "entities": [{"type": "Person", "text": "analyst"}]}, {"text": "$1.77 billion", "location": [4155, 4168], "entities": [{"type": "Money", "text": "$1.77 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "About Markel Markel Corporation, a diverse financial holding company, markets and underwrites specialty insurance products in the United States, the United Kingdom, Canada, and internationally.", "score": 0.511632, "arguments": [{"text": "United Kingdom", "location": [4489, 4503], "entities": [{"type": "GeopoliticalEntity", "text": "United Kingdom", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Canada", "location": [4505, 4511], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "It operates through three segments: U.S. Insurance, International Insurance, and Reinsurance.", "score": 0.98101, "arguments": [{"text": "Insurance", "location": [4575, 4584], "entities": [{"type": "Organization", "text": "Insurance"}]}, {"text": "U.S.", "location": [4570, 4574], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Receive News & Ratings for Markel analysts' ratings for Markel and related companies daily email", "score": 0.832543, "arguments": [{"text": "analysts", "location": [4904, 4912], "entities": [{"type": "Person", "text": "research analysts"}]}, {"text": "Markel", "location": [4897, 4903], "entities": [{"type": "Organization", "text": "Markel\nMarkel Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Get Markel alerts: In other news, CEO Richard R. Whitt III sold 500 shares of Markel stock in a transaction dated Wednesday, September 5th.", "score": 0.414617, "arguments": [{"text": "CEO", "location": [874, 877], "entities": [{"type": "Person", "text": "Richard R. Whitt III"}]}, {"text": "Markel alerts", "location": [844, 857], "entities": [{"type": "Organization", "text": "Markel\nMarkel Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .", "score": 0.920426, "arguments": [{"text": "website", "location": [1330, 1337], "entities": [{"type": "Organization", "text": "website"}]}, {"text": "SEC", "location": [1326, 1329], "entities": [{"type": "Organization", "text": "Securities & Exchange Commission", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "employedBy", "sentence": "Corporate insiders own 2.53% of the company's stock.", "score": 0.465639, "arguments": [{"text": "insiders", "location": [1817, 1825], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "Corporate", "location": [1807, 1816], "entities": [{"type": "Organization", "text": "Corporate"}]}]}, {"type": "managerOf", "sentence": "Principal Financial Group Inc. lifted its holdings in shares of Markel by 1.0% during the 1st quarter.", "score": 0.756871, "arguments": [{"text": "Principal", "location": [1939, 1948], "entities": [{"type": "Person", "text": "Principal"}]}, {"text": "Financial Group Inc.", "location": [1949, 1969], "entities": [{"type": "Organization", "text": "Financial Group Inc."}]}]}, {"type": "managerOf", "sentence": "Principal Financial Group Inc. now owns 671,504 shares of the insurance provider's stock valued at $785,828,000 after purchasing an additional 6,453 shares in the last quarter.", "score": 0.703418, "arguments": [{"text": "Principal", "location": [2042, 2051], "entities": [{"type": "Person", "text": "Principal"}]}, {"text": "Financial Group Inc.", "location": [2052, 2072], "entities": [{"type": "Organization", "text": "Financial Group Inc."}]}]}, {"type": "partOf", "sentence": "Finally, State of Alaska Department of Revenue lifted its holdings in shares of Markel by 24.5% during the 2nd quarter.", "score": 0.993445, "arguments": [{"text": "Department of Revenue", "location": [3055, 3076], "entities": [{"type": "Organization", "text": "Department of Revenue"}]}, {"text": "State of Alaska", "location": [3039, 3054], "entities": [{"type": "GeopoliticalEntity", "text": "State of Alaska"}]}]}, {"type": "partOf", "sentence": "State of Alaska Department of Revenue now owns 2,895 shares of the insurance provider's stock valued at $3,137,000 after purchasing an additional 570 shares in the last quarter.", "score": 0.996162, "arguments": [{"text": "Department of Revenue", "location": [3166, 3187], "entities": [{"type": "Organization", "text": "Department of Revenue"}]}, {"text": "State of Alaska", "location": [3150, 3165], "entities": [{"type": "GeopoliticalEntity", "text": "State of Alaska"}]}]}, {"type": "partOf", "sentence": "Finally, State of Alaska Department of Revenue lifted its holdings in shares of Markel by 24.5% during the 2nd quarter.", "score": 0.376628, "arguments": [{"text": "its", "location": [3084, 3087], "entities": [{"type": "Organization", "text": "Millennium Management LLC"}]}, {"text": "Markel", "location": [3110, 3116], "entities": [{"type": "Organization", "text": "Markel\nMarkel Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "populationOf", "sentence": "The company has a quick ratio of 0.59, a current ratio of 0.59 and a debt-to-equity ratio of 0.31.", "score": 0.360239, "arguments": [{"text": "0.59", "location": [3611, 3615], "entities": [{"type": "Cardinal", "text": "0.59"}]}, {"text": "company", "location": [3582, 3589], "entities": [{"type": "Organization", "text": "MarketBeat.com", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Markel", "sentiment": {"score": -0.211372, "label": "negative"}, "relevance": 0.998146}, {"text": "shares", "sentiment": {"score": -0.0928041, "label": "negative"}, "relevance": 0.84744}, {"text": "insurance provider", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.845566}, {"text": "Tweet\nMarkel Co.", "sentiment": {"score": 0.39604, "label": "positive"}, "relevance": 0.838377}, {"text": "Markel stock", "sentiment": {"score": -0.385582, "label": "negative"}, "relevance": 0.818142}, {"text": "Markel alerts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.756765}, {"text": "Financial Group Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.736891}, {"text": "Principal Financial Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.733955}, {"text": "Millennium Management LLC", "sentiment": {"score": -0.489611, "label": "negative"}, "relevance": 0.732104}, {"text": "Markel analysts", "sentiment": {"score": 0.347136, "label": "positive"}, "relevance": 0.726111}, {"text": "Markel Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.725313}, {"text": "Manufacturers Life Insurance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.714539}, {"text": "Life Insurance Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.712824}, {"text": "IFM Investors Pty", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.710329}, {"text": "quarter", "sentiment": {"score": -0.489611, "label": "negative"}, "relevance": 0.678875}, {"text": "research report", "sentiment": {"score": 0.211202, "label": "positive"}, "relevance": 0.67186}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.647407}, {"text": "strong buy rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.643517}, {"text": "MKL shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642717}, {"text": "average price", "sentiment": {"score": -0.297567, "label": "negative"}, "relevance": 0.631846}, {"text": "Richard R. Whitt", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629512}, {"text": "specialty insurance products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627557}, {"text": "insurance product lines", "sentiment": {"score": 0.221503, "label": "positive"}, "relevance": 0.62723}, {"text": "Alan I. Kirshner", "sentiment": {"score": -0.385582, "label": "negative"}, "relevance": 0.626624}, {"text": "Alaska Department", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626367}, {"text": "compensation insurance products", "sentiment": {"score": -0.226909, "label": "negative"}, "relevance": 0.626096}, {"text": "U.S. Insurance segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625568}, {"text": "financial holding company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.6212}, {"text": "chief executive officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620231}, {"text": "companies daily email", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612456}, {"text": "quarterly earnings data", "sentiment": {"score": -0.37847, "label": "negative"}, "relevance": 0.612379}, {"text": "MKL stock", "sentiment": {"score": -0.487158, "label": "negative"}, "relevance": 0.608446}, {"text": "company stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594709}, {"text": "research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585505}, {"text": "hold rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.582046}, {"text": "total transaction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581112}, {"text": "research firms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579535}, {"text": "International Insurance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576467}, {"text": "MarketBeat.com reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576068}, {"text": "consensus recommendation", "sentiment": {"score": 0.444686, "label": "positive"}, "relevance": 0.573228}, {"text": "target price", "sentiment": {"score": -0.500984, "label": "negative"}, "relevance": 0.571452}, {"text": "Corporate insiders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5688}, {"text": "Exchange Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568699}, {"text": "SEC website", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567302}, {"text": "total value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567086}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566664}, {"text": "debt-to-equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566565}, {"text": "Sell-side analysts", "sentiment": {"score": -0.826046, "label": "negative"}, "relevance": 0.566409}, {"text": "price-to-earnings ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566266}, {"text": "large investors", "sentiment": {"score": -0.437168, "label": "negative"}, "relevance": 0.566231}]}, "extracted_metadata": {"sha1": "919de6d1aa1c0c4ed3183eb8329c1cfb75e56542", "filename": "1542061274695.zip-23c4823f8a858766d07b6bff05375128.xml", "file_type": "json"}, "external_links": ["http://www.sec.gov/Archives/edgar/data/1096343/000109634318000180/xslF345X03/wf-form4_153635500303380.xml", "http://www.sec.gov/Archives/edgar/data/1096343/000109634318000184/xslF345X03/wf-form4_153859927652191.xml", "https://www.marketbeat.com/", "http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=MKL", "https://twitter.com/share", "https://www.marketbeat.com/newsletter/default.aspx", "https://www.marketbeat.com/stocks/NYSE/MKL/price-target/"], "title": "Markel Co. (MKL) Receives $1,265.25 Average Target Price from Analysts", "forum_title": "Daily Political"}, {"id": "a6V8FajM5IaXN3_nRc2-lL-qb4qgB4RSFfue1bDhZWztuuS5-ro7Q2Qt46WBsZ6W", "result_metadata": {"score": 21.407768}, "author": "ABMN Staff", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Russell Investments Group Ltd", "relevance": 0.963292, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Icon Plc", "relevance": 0.579112, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ICLR", "relevance": 0.14131, "type": "Company", "disambiguation": {"subtype": [], "name": "Incorporated Council of Law Reporting", "dbpedia_resource": "http://dbpedia.org/resource/Incorporated_Council_of_Law_Reporting"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Russell Indexes", "relevance": 0.9044, "dbpedia_resource": "http://dbpedia.org/resource/Russell_Indexes"}], "categories": [{"score": 0.646962, "label": "/finance/investing"}, {"score": 0.646962, "label": "/finance/investing/beginning investing"}, {"score": 0.229449, "label": "/finance/investing/funds/mutual funds"}], "relations": [{"type": "productOf", "sentence": "Russell Investments Group Ltd. Purchases 9,778 Shares of Icon Plc (ICLR)", "score": 0.944134, "arguments": [{"text": "Icon Plc", "location": [57, 65], "entities": [{"type": "Product", "text": "Icon Plc"}]}, {"text": "Russell Investments Group Ltd. Purchases", "location": [0, 40], "entities": [{"type": "Organization", "text": "Russell Investments Group Ltd. Purchases", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Russell Investments Group Ltd. Purchases 9,778 Shares of Icon Plc (ICLR)", "score": 0.663911, "arguments": [{"text": "Russell Investments Group Ltd. Purchases", "location": [0, 40], "entities": [{"type": "Organization", "text": "Russell Investments Group Ltd. Purchases", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "ICLR", "location": [67, 71], "entities": [{"type": "Ticker", "text": "ICLR"}]}]}], "keywords": [{"text": "Russell Investments Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.95217}, {"text": "Icon Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.701949}, {"text": "Purchases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.320152}]}, "crawl_date": "2018-11-12T17:51:23Z", "url": "https://www.americanbankingnews.com/2018/11/12/russell-investments-group-ltd-purchases-9778-shares-of-icon-plc-iclr.html", "host": "americanbankingnews.com", "text": "Massachusetts Financial Services Co.", "main_image_url": "https://www.marketbeat.com/logos/icon-plc-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T17:24:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.448796, "label": "negative"}, "text": "Icon Plc", "relevance": 0.793217, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ICON Public Limited Company", "relevance": 0.474593, "type": "Company"}, {"count": 6, "sentiment": {"score": -0.33153, "label": "negative"}, "text": "ICLR", "relevance": 0.446373, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Russell Investments Group Ltd.", "relevance": 0.382898, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.447906, "label": "positive"}, "text": "Alpha Cubed Investments LLC", "relevance": 0.346799, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eight Capital LP", "relevance": 0.292223, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "SEC", "relevance": 0.273985, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": -0.408108, "label": "negative"}, "text": "US", "relevance": 0.265247, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zacks Investment Research", "relevance": 0.263078, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Capital Advisors Ltd", "relevance": 0.258397, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Massachusetts Financial Services Co", "relevance": 0.256732, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Calamos Advisors LLC", "relevance": 0.243809, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.364313, "label": "positive"}, "text": "Robert W. Baird", "relevance": 0.240058, "type": "Person", "disambiguation": {"subtype": [], "name": "Robert W. Baird", "dbpedia_resource": "http://dbpedia.org/resource/Robert_W._Baird"}}, {"count": 1, "sentiment": {"score": 0.318593, "label": "positive"}, "text": "Mizuho", "relevance": 0.210787, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Banking News", "relevance": 0.210281, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ISI", "relevance": 0.209476, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.207954, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.514593, "label": "positive"}, "text": "BidaskClub", "relevance": 0.206337, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "analyst", "relevance": 0.20401, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ICLR", "relevance": 0.184198, "type": "Company", "disambiguation": {"subtype": [], "name": "Incorporated Council of Law Reporting", "dbpedia_resource": "http://dbpedia.org/resource/Incorporated_Council_of_Law_Reporting"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ireland", "relevance": 0.182903, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "12-month", "relevance": 0.182903, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.54", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$654.66 million", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$655.02 million", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$7.49 billion", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$164,561,000", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$14,548,000", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3,475,000", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$121,000", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$230,000", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$769,000", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$101.22", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$138.46", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$146.00", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$148.00", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$154.00", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$155.33", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$157.00", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12.88%", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "150.0%", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "26.08%", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "87.62%", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.18%", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.5%", "relevance": 0.182903, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12.9%", "relevance": 0.182903, "type": "Quantity"}], "sentiment": {"document": {"score": 0.355548, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Russell Investments Group Ltd.", "keywords": [{"text": "Russell Investments Group"}], "entities": [{"type": "Company", "text": "Russell Investments Group Ltd."}]}, "sentence": "Russell Investments Group Ltd. raised its position in Icon Plc (NASDAQ:ICLR) by 11.5% during the 3rd quarter, according to its most recent filing with the SEC.", "object": {"text": "its position in Icon Plc (NASDAQ", "keywords": [{"text": "Icon Plc"}, {"text": "position"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "Icon Plc"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "ICLR) by 11.5% during the 3rd quarter", "keywords": [{"text": "quarter"}, {"text": "ICLR"}], "entities": [{"type": "Location", "text": "ICLR", "disambiguation": {"subtype": ["City"]}}, {"type": "Quantity", "text": "11.5"}]}, "sentence": "Russell Investments Group Ltd. raised its position in Icon Plc (NASDAQ:ICLR) by 11.5% during the 3rd quarter, according to its most recent filing with the SEC.", "object": {"text": "to its most recent filing with the SEC", "keywords": [{"text": "recent filing"}, {"text": "SEC"}], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm owned 94,877 shares of the medical research company\u2019s stock after buying an additional 9,778 shares during the quarter.", "object": {"text": "94,877 shares of the medical research company\u2019s stock", "keywords": [{"text": "medical research company"}, {"text": "shares"}, {"text": "stock"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "owned", "normalized": "own"}}, {"subject": {"text": "stock", "keywords": [{"text": "stock"}]}, "sentence": " The firm owned 94,877 shares of the medical research company\u2019s stock after buying an additional 9,778 shares during the quarter.", "object": {"text": "The firm owned 94,877 shares of the medical research company", "keywords": [{"text": "medical research company"}, {"text": "firm"}, {"text": "shares"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The firm owned 94,877 shares of the medical research company\u2019s", "keywords": [{"text": "medical research company"}, {"text": "firm"}, {"text": "shares"}]}, "sentence": " The firm owned 94,877 shares of the medical research company\u2019s stock after buying an additional 9,778 shares during the quarter.", "object": {"text": "an additional 9,778 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "Russell Investments Group Ltd.", "keywords": [{"text": "Russell Investments Group"}], "entities": [{"type": "Company", "text": "Russell Investments Group Ltd."}]}, "sentence": " Russell Investments Group Ltd. owned about 0.18% of Icon worth $14,548,000 as of its most recent filing with the SEC.", "object": {"text": "about 0.18% of Icon worth $14,548,000 as of its most recent filing with the SEC", "keywords": [{"text": "recent filing"}, {"text": "SEC"}, {"text": "Icon"}], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"type": "Quantity", "text": "$14,548,000"}, {"type": "Quantity", "text": "0.18"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "owned", "normalized": "own"}}, {"subject": {"text": "A number of other institutional investors and hedge funds", "keywords": [{"text": "institutional investors"}, {"text": "number"}, {"text": "funds"}], "entities": []}, "sentence": " A number of other institutional investors and hedge funds have also recently made changes to their positions in ICLR.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "A number of other institutional investors and hedge funds", "keywords": [{"text": "institutional investors"}, {"text": "number"}, {"text": "funds"}], "entities": []}, "sentence": " A number of other institutional investors and hedge funds have also recently made changes to their positions in ICLR.", "object": {"text": "changes", "keywords": [{"text": "changes"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "Alpha Cubed Investments LLC", "keywords": [{"text": "Investments"}, {"text": "Alpha"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Alpha Cubed Investments LLC"}]}, "sentence": " Alpha Cubed Investments LLC purchased a new stake in shares of Icon in the 3rd quarter worth about $230,000.", "object": {"text": "a new stake in shares of Icon", "keywords": [{"text": "new stake"}, {"text": "Icon"}, {"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "past"}, "text": "purchased", "normalized": "purchase"}}, {"subject": {"text": "MA", "keywords": [{"text": "MA"}]}, "sentence": " MA boosted its position in shares of Icon by 12.9% in the 3rd quarter.", "object": {"text": "its position in shares of Icon", "keywords": [{"text": "Icon"}, {"text": "position"}, {"text": "shares"}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "boosted", "normalized": "boost"}}, {"subject": {"text": "MA", "keywords": [{"text": "MA"}]}, "sentence": " MA now owns 1,070,319 shares of the medical research company\u2019s stock worth $164,561,000 after buying an additional 121,970 shares in the last quarter.", "object": {"text": "1,070,319 shares of the medical research company\u2019s stock worth $164,561,000", "keywords": [{"text": "medical research company"}, {"text": "shares"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$164,561,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock worth $164,561,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$164,561,000"}]}, "sentence": " MA now owns 1,070,319 shares of the medical research company\u2019s stock worth $164,561,000 after buying an additional 121,970 shares in the last quarter.", "object": {"text": "the medical research company", "keywords": [{"text": "medical research company"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "an additional 121,970 shares", "keywords": [{"text": "shares"}]}, "sentence": " MA now owns 1,070,319 shares of the medical research company\u2019s stock worth $164,561,000 after buying an additional 121,970 shares in the last quarter.", "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "LLC", "keywords": [{"text": "LLC"}], "entities": [{"type": "Company", "text": "Alpha Cubed Investments LLC"}]}, "sentence": " LLC purchased a new stake in shares of Icon in the 3rd quarter worth about $121,000.", "object": {"text": "a new stake in shares of Icon", "keywords": [{"text": "new stake"}, {"text": "Icon"}, {"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "past"}, "text": "purchased", "normalized": "purchase"}}, {"subject": {"text": "Calamos Advisors LLC", "keywords": [{"text": "Calamos Advisors"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Calamos Advisors LLC"}]}, "sentence": " Calamos Advisors LLC purchased a new stake in shares of Icon in the 3rd quarter worth about $3,475,000.", "object": {"text": "a new stake in shares of Icon", "keywords": [{"text": "new stake"}, {"text": "Icon"}, {"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "past"}, "text": "purchased", "normalized": "purchase"}}, {"subject": {"text": "Seven Eight Capital LP", "keywords": [{"text": "Capital LP"}], "entities": [{"type": "Company", "text": "Eight Capital LP"}]}, "sentence": " Finally, Seven Eight Capital LP boosted its position in shares of Icon by 150.0% in the 3rd quarter.", "object": {"text": "its position in shares of Icon", "keywords": [{"text": "Icon"}, {"text": "position"}, {"text": "shares"}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "boosted", "normalized": "boost"}}, {"subject": {"text": "Seven Eight Capital LP", "keywords": [{"text": "Capital LP"}], "entities": [{"type": "Company", "text": "Eight Capital LP"}]}, "sentence": " Seven Eight Capital LP now owns 5,000 shares of the medical research company\u2019s stock worth $769,000 after buying an additional 3,000 shares in the last quarter.", "object": {"text": "5,000 shares of the medical research company\u2019s stock worth $769,000 after buying an additional 3,000 shares in the last quarter", "keywords": [{"text": "medical research company"}, {"text": "shares"}, {"text": "quarter"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$769,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock worth $769,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$769,000"}]}, "sentence": " Seven Eight Capital LP now owns 5,000 shares of the medical research company\u2019s stock worth $769,000 after buying an additional 3,000 shares in the last quarter.", "object": {"text": "the medical research company", "keywords": [{"text": "medical research company"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Seven Eight Capital LP", "keywords": [{"text": "Capital LP"}], "entities": [{"type": "Company", "text": "Eight Capital LP"}]}, "sentence": " Seven Eight Capital LP now owns 5,000 shares of the medical research company\u2019s stock worth $769,000 after buying an additional 3,000 shares in the last quarter.", "object": {"text": "an additional 3,000 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "87.62% of the stock", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "87.62"}]}, "sentence": " 87.62% of the stock is currently owned by institutional investors.", "object": {"text": "currently owned by institutional investors", "keywords": [{"text": "institutional investors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " 87.62% of the stock is currently owned by institutional investors.", "object": {"text": "87.62% of the stock", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "87.62"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "owned", "normalized": "own"}}, {"subject": {"text": "ICLR", "keywords": [{"text": "ICLR"}], "entities": [{"type": "Location", "text": "ICLR", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " ICLR has been the topic of several recent research reports.", "object": {"text": "the topic of several recent research reports", "keywords": [{"text": "recent research reports"}, {"text": "topic"}], "entities": [{"type": "Location", "text": "ICLR", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "Robert W. Baird", "keywords": [{"text": "Robert W. Baird"}], "entities": [{"type": "Person", "text": "Robert W. Baird", "disambiguation": {"subtype": ["Person"], "name": "Robert W. Baird", "dbpedia_resource": "http://dbpedia.org/resource/Robert_W._Baird"}}]}, "sentence": " Robert W. Baird boosted their price objective on shares of Icon from $154.00 to $157.00 and gave the stock an \u201coutperform\u201d rating in a research report on Tuesday, September 11th.", "object": {"text": "their price objective on shares of Icon", "keywords": [{"text": "Icon"}, {"text": "price"}, {"text": "shares"}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "boosted", "normalized": "boost"}}, {"subject": {"text": "Robert W. Baird", "keywords": [{"text": "Robert W. Baird"}], "entities": [{"type": "Person", "text": "Robert W. Baird", "disambiguation": {"subtype": ["Person"], "name": "Robert W. Baird", "dbpedia_resource": "http://dbpedia.org/resource/Robert_W._Baird"}}]}, "sentence": " Robert W. Baird boosted their price objective on shares of Icon from $154.00 to $157.00 and gave the stock an \u201coutperform\u201d rating in a research report on Tuesday, September 11th.", "object": {"text": "an \u201coutperform\u201d rating in a research report", "keywords": [{"text": "outperform"}, {"text": "research report"}, {"text": "rating"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "gave", "normalized": "give"}}, {"subject": {"text": "Evercore ISI", "entities": [{"type": "Organization", "text": "ISI"}]}, "sentence": " Evercore ISI upgraded shares of Icon from an \u201cin-line\u201d rating to an \u201coutperform\u201d rating in a report on Friday, October 26th.", "object": {"text": "shares of Icon", "keywords": [{"text": "Icon"}, {"text": "shares"}]}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "upgraded", "normalized": "upgrade"}}, {"subject": {"text": "BidaskClub", "keywords": [{"text": "BidaskClub"}], "entities": [{"type": "Company", "text": "BidaskClub"}]}, "sentence": " BidaskClub upgraded shares of Icon from a \u201cbuy\u201d rating to a \u201cstrong-buy\u201d rating in a report on Tuesday, September 25th.", "object": {"text": "shares of Icon", "keywords": [{"text": "Icon"}, {"text": "shares"}]}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "upgraded", "normalized": "upgrade"}}, {"subject": {"text": "Mizuho", "keywords": [{"text": "Mizuho"}], "entities": [{"type": "Company", "text": "Mizuho"}]}, "sentence": " Mizuho set a $146.00 target price on shares of Icon and gave the company a \u201chold\u201d rating in a report on Monday, August 6th.", "object": {"text": "a $146.00 target price", "keywords": [{"text": "target price"}], "entities": [{"type": "Quantity", "text": "$146.00"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Mizuho", "keywords": [{"text": "Mizuho"}], "entities": [{"type": "Company", "text": "Mizuho"}]}, "sentence": " Mizuho set a $146.00 target price on shares of Icon and gave the company a \u201chold\u201d rating in a report on Monday, August 6th.", "object": {"text": "a \u201chold\u201d rating in a report", "keywords": [{"text": "rating"}, {"text": "report"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "gave", "normalized": "give"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Mizuho set a $146.00 target price on shares of Icon and gave the company a \u201chold\u201d rating in a report on Monday, August 6th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "sentence": " Finally, Zacks Investment Research lowered shares of Icon from a \u201chold\u201d rating to a \u201csell\u201d rating in a report on Wednesday, October 24th.", "object": {"text": "shares of Icon", "keywords": [{"text": "Icon"}, {"text": "shares"}]}, "action": {"verb": {"text": "lower", "tense": "past"}, "text": "lowered", "normalized": "lower"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Finally, Zacks Investment Research lowered shares of Icon from a \u201chold\u201d rating to a \u201csell\u201d rating in a report on Wednesday, October 24th.", "object": {"text": "to a \u201csell\u201d rating in a report on Wednesday, October 24th", "keywords": [{"text": "Wednesday"}, {"text": "sell"}, {"text": "rating"}, {"text": "report"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Two research analysts", "keywords": [{"text": "research analysts"}]}, "sentence": " Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock.", "object": {"text": "rated the stock with a sell rating", "keywords": [{"text": "sell rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Two research analysts", "keywords": [{"text": "research analysts"}]}, "sentence": " Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "rate", "tense": "past"}, "text": "have rated", "normalized": "have rate"}}, {"subject": {"text": "one"}, "sentence": " Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock.", "object": {"text": "a hold rating, seven", "keywords": [{"text": "hold rating"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "has given", "normalized": "have give"}}, {"subject": {"text": "seven"}, "sentence": " Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock.", "object": {"text": "given a buy rating and one", "keywords": [{"text": "buy rating"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "seven"}, "sentence": " Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock.", "object": {"text": "a buy rating and one", "keywords": [{"text": "buy rating"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "have given", "normalized": "have give"}}, {"subject": {"text": "one"}, "sentence": " Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock.", "object": {"text": "given a strong buy rating to the stock", "keywords": [{"text": "strong buy rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company currently has a consensus rating of \u201cBuy\u201d and a consensus price target of $148.00.", "object": {"text": "a consensus rating of \u201cBuy\u201d and a consensus price target of $148.00", "keywords": [{"text": "consensus price target"}, {"text": "consensus rating"}], "entities": [{"type": "Quantity", "text": "$148.00"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "ICLR", "keywords": [{"text": "ICLR"}], "entities": [{"type": "Location", "text": "ICLR", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " NASDAQ:ICLR opened at $138.46 on Monday.", "action": {"verb": {"text": "open", "tense": "past"}, "text": "opened", "normalized": "open"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market capitalization of $7.49 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 1.99 and a beta of 0.50.", "object": {"text": "a market capitalization of $7.49 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 1.99 and a beta of 0.50", "keywords": [{"text": "PEG ratio"}, {"text": "price-to-earnings ratio"}, {"text": "market capitalization"}], "entities": [{"type": "Quantity", "text": "$7.49 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.17.", "object": {"text": "a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.17", "keywords": [{"text": "debt-to-equity ratio"}, {"text": "quick ratio"}, {"text": "current ratio"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Icon Plc", "keywords": [{"text": "Icon Plc"}], "entities": [{"type": "Company", "text": "Icon Plc"}]}, "sentence": " Icon Plc has a 12-month low of $101.22 and a 12-month high of $155.33.", "object": {"text": "a 12-month low of $101.22 and a 12-month high of $155.33", "keywords": [{"text": "12-month high"}], "entities": [{"type": "Quantity", "text": "12-month"}, {"type": "Quantity", "text": "$101.22"}, {"type": "Quantity", "text": "$155.33"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "ICLR)", "keywords": [{"text": "ICLR"}], "entities": [{"type": "Location", "text": "ICLR", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, October 24th.", "object": {"text": "its earnings results", "keywords": [{"text": "earnings results"}]}, "action": {"verb": {"text": "release", "tense": "past"}, "text": "released", "normalized": "release"}}, {"subject": {"text": "The medical research company", "keywords": [{"text": "medical research company"}]}, "sentence": " The medical research company reported $1.54 earnings per share (EPS) for the quarter, meeting the Zacks\u2019 consensus estimate of $1.54.", "object": {"text": "$1.54 earnings per share (EPS) for the quarter, meeting the Zacks\u2019 consensus estimate of $1.54", "keywords": [{"text": "consensus estimate"}, {"text": "Zacks"}, {"text": "earnings"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$1.54"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "The medical research company", "keywords": [{"text": "medical research company"}]}, "sentence": " The medical research company reported $1.54 earnings per share (EPS) for the quarter, meeting the Zacks\u2019 consensus estimate of $1.54.", "object": {"text": "the Zacks\u2019 consensus estimate of $1.54", "keywords": [{"text": "consensus estimate"}, {"text": "Zacks"}], "entities": [{"type": "Quantity", "text": "$1.54"}]}, "action": {"verb": {"text": "meet", "tense": "present"}, "text": "meeting", "normalized": "meet"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million.", "object": {"text": "revenue of $655.02 million for the quarter", "keywords": [{"text": "revenue"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$655.02 million"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "revenue of $655.02 million for the quarter", "keywords": [{"text": "revenue"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$655.02 million"}]}, "sentence": " The company had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million.", "object": {"text": "to analyst estimates of $654.66 million", "keywords": [{"text": "analyst estimates"}], "entities": [{"type": "JobTitle", "text": "analyst"}, {"type": "Quantity", "text": "$654.66 million"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Icon", "keywords": [{"text": "Icon"}]}, "sentence": " Icon had a net margin of 12.88% and a return on equity of 26.08%.", "object": {"text": "a net margin of 12.88% and a return on equity of 26.08%", "keywords": [{"text": "net margin"}, {"text": "return"}, {"text": "equity"}], "entities": [{"type": "Quantity", "text": "12.88"}, {"type": "Quantity", "text": "26.08"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Analysts", "keywords": [{"text": "Analysts"}]}, "sentence": " Analysts forecast that Icon Plc will post 6.08 earnings per share for the current year.", "object": {"text": "that Icon Plc will post 6.08 earnings per share for the current year", "keywords": [{"text": "Icon Plc"}, {"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Company", "text": "Icon Plc"}]}, "action": {"verb": {"text": "forecast", "tense": "present"}, "text": "forecast", "normalized": "forecast"}}, {"subject": {"text": "Purchases 9,778 Shares of Icon Plc (ICLR)\u201d", "keywords": [{"text": "Icon Plc"}, {"text": "Purchases"}, {"text": "Shares"}, {"text": "ICLR"}], "entities": [{"type": "Company", "text": "Icon Plc"}, {"type": "Company", "text": "ICLR", "disambiguation": {"subtype": ["Organization"], "name": "Incorporated Council of Law Reporting", "dbpedia_resource": "http://dbpedia.org/resource/Incorporated_Council_of_Law_Reporting"}}]}, "sentence": " Purchases 9,778 Shares of Icon Plc (ICLR)\u201d was originally published by American Banking News and is owned by of American Banking News.", "object": {"text": "originally published by American Banking News", "keywords": [{"text": "American Banking News"}], "entities": [{"type": "PrintMedia", "text": "American Banking News"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}], "concepts": [{"text": "Clinical trial", "relevance": 0.946414, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Financial ratios", "relevance": 0.834709, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratios"}, {"text": "Financial ratio", "relevance": 0.783454, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Limited company", "relevance": 0.652961, "dbpedia_resource": "http://dbpedia.org/resource/Limited_company"}, {"text": "Stock", "relevance": 0.652298, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Copyright", "relevance": 0.582031, "dbpedia_resource": "http://dbpedia.org/resource/Copyright"}, {"text": "Clinical research", "relevance": 0.555236, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "PEG ratio", "relevance": 0.51894, "dbpedia_resource": "http://dbpedia.org/resource/PEG_ratio"}, {"text": "Stock market", "relevance": 0.509885, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Investment", "relevance": 0.508841, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Financial services", "relevance": 0.492925, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services"}, {"text": "P/E ratio", "relevance": 0.461229, "dbpedia_resource": "http://dbpedia.org/resource/P/E_ratio"}, {"text": "Share", "relevance": 0.450713, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Medicine", "relevance": 0.432013, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "The Quarter at Tropicana", "relevance": 0.42987, "dbpedia_resource": "http://dbpedia.org/resource/The_Quarter_at_Tropicana"}, {"text": "Revenue", "relevance": 0.416941, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Public limited company", "relevance": 0.416335, "dbpedia_resource": "http://dbpedia.org/resource/Public_limited_company"}, {"text": "Owned", "relevance": 0.415439, "dbpedia_resource": "http://dbpedia.org/resource/Owned"}, {"text": "Russell Indexes", "relevance": 0.408797, "dbpedia_resource": "http://dbpedia.org/resource/Russell_Indexes"}, {"text": "United Kingdom company law", "relevance": 0.389112, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom_company_law"}], "categories": [{"score": 0.577051, "label": "/finance/investing"}, {"score": 0.577051, "label": "/finance/investing/beginning investing"}, {"score": 0.349472, "label": "/finance/financial news"}], "relations": [{"type": "productOf", "sentence": "Russell Investments Group Ltd. raised its position in Icon Plc (NASDAQ:ICLR) by 11.5% during the 3rd quarter, according to its most recent filing with the SEC.", "score": 0.499123, "arguments": [{"text": "Icon Plc", "location": [54, 62], "entities": [{"type": "Product", "text": "Icon Plc"}]}, {"text": "its", "location": [38, 41], "entities": [{"type": "Organization", "text": "Russell Investments Group Ltd. Purchases"}]}]}, {"type": "agentOf", "sentence": "The medical research company reported $1.54 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $1.54.", "score": 0.799464, "arguments": [{"text": "medical research company", "location": [2931, 2955], "entities": [{"type": "Organization", "text": "medical research company"}]}, {"text": "reported", "location": [2956, 2964], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "hasAttribute", "sentence": "The medical research company reported $1.54 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $1.54.", "score": 0.610112, "arguments": [{"text": "medical research company", "location": [2931, 2955], "entities": [{"type": "Organization", "text": "medical research company"}]}, {"text": "$1.54", "location": [2965, 2970], "entities": [{"type": "Money", "text": "$1.54", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The company had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million.", "score": 0.871813, "arguments": [{"text": "company", "location": [3065, 3072], "entities": [{"type": "Organization", "text": "medical research company"}]}, {"text": "$655.02 million", "location": [3088, 3103], "entities": [{"type": "Money", "text": "$655.02 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The company had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million.", "score": 0.587771, "arguments": [{"text": "analyst", "location": [3133, 3140], "entities": [{"type": "Person", "text": "analyst"}]}, {"text": "$654.66 million", "location": [3154, 3169], "entities": [{"type": "Money", "text": "$654.66 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "COPYRIGHT VIOLATION NOTICE: \"Russell Investments Group Ltd. Purchases 9,778 Shares of Icon Plc (ICLR)\" was originally published by American Banking News and is owned by of American Banking News.", "score": 0.680156, "arguments": [{"text": "Russell Investments Group Ltd. Purchases", "location": [3354, 3394], "entities": [{"type": "Organization", "text": "Russell Investments Group Ltd. Purchases"}]}, {"text": "ICLR", "location": [3421, 3425], "entities": [{"type": "Ticker", "text": "ICLR"}]}]}, {"type": "partOfMany", "sentence": "Receive News & Ratings for Icon analysts' ratings for Icon and related companies daily email newsletter . \u00ab", "score": 0.146995, "arguments": [{"text": "Icon", "location": [4306, 4310], "entities": [{"type": "Person", "text": "ICON"}]}, {"text": "analysts", "location": [4311, 4319], "entities": [{"type": "Person", "text": "analysts"}]}]}, {"type": "hasAttribute", "sentence": "Russell Investments Group Ltd. owned about 0.18% of Icon worth $14,548,000 as of its most recent filing with the SEC.", "score": 0.791337, "arguments": [{"text": "its", "location": [370, 373], "entities": [{"type": "Organization", "text": "Russell Investments Group Ltd. Purchases"}]}, {"text": "$14,548,000", "location": [352, 363], "entities": [{"type": "Money", "text": "$14,548,000", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "productOf", "sentence": "Alpha Cubed Investments LLC purchased a new stake in shares of Icon in the 3rd quarter worth about $230,000.", "score": 0.584066, "arguments": [{"text": "Icon", "location": [588, 592], "entities": [{"type": "Product", "text": "Icon Plc"}]}, {"text": "Investments LLC", "location": [537, 552], "entities": [{"type": "Organization", "text": "Investments LLC"}]}]}, {"type": "hasAttribute", "sentence": "Massachusetts Financial Services Co. MA now owns 1,070,319 shares of the medical research company's stock worth $164,561,000 after buying an additional 121,970 shares in the last quarter.", "score": 0.724369, "arguments": [{"text": "medical research company", "location": [815, 839], "entities": [{"type": "Organization", "text": "medical research company"}]}, {"text": "$164,561,000", "location": [854, 866], "entities": [{"type": "Money", "text": "$164,561,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "residesIn", "sentence": "Seven Eight Capital LP now owns 5,000 shares of the medical research company's stock worth $769,000 after buying an additional 3,000 shares in the last quarter.", "score": 0.319644, "arguments": [{"text": "LP", "location": [1262, 1264], "entities": [{"type": "Person", "text": "LP"}]}, {"text": "Capital", "location": [1254, 1261], "entities": [{"type": "GeopoliticalEntity", "text": "Capital"}]}]}, {"type": "hasAttribute", "sentence": "Seven Eight Capital LP now owns 5,000 shares of the medical research company's stock worth $769,000 after buying an additional 3,000 shares in the last quarter.", "score": 0.712356, "arguments": [{"text": "medical research company", "location": [1294, 1318], "entities": [{"type": "Organization", "text": "medical research company"}]}, {"text": "$769,000", "location": [1333, 1341], "entities": [{"type": "Money", "text": "$769,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "partOfMany", "sentence": "Robert W. Baird boosted their price objective on shares of Icon from $154.00 to $157.00 and gave the stock an \"outperform\" rating in a research report on Tuesday, September 11th.", "score": 0.572033, "arguments": [{"text": "Robert W. Baird", "location": [1547, 1562], "entities": [{"type": "Person", "text": "Robert W. Baird"}]}, {"text": "their", "location": [1571, 1576], "entities": [{"type": "Person", "text": "investors"}]}]}, {"type": "hasAttribute", "sentence": "Mizuho set a $146.00 target price on shares of Icon and gave the company a \"hold\" rating in a report on Monday, August 6th.", "score": 0.597143, "arguments": [{"text": "company", "location": [2036, 2043], "entities": [{"type": "Organization", "text": "Public Limited Company"}]}, {"text": "$146.00", "location": [1984, 1991], "entities": [{"type": "Money", "text": "$146.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "productOf", "sentence": "Finally, Zacks Investment Research lowered shares of Icon from a \"hold\" rating to a \"sell\" rating in a report on Wednesday, October 24th.", "score": 0.886809, "arguments": [{"text": "Icon", "location": [2148, 2152], "entities": [{"type": "Product", "text": "Icon Plc"}]}, {"text": "Zacks Investment Research", "location": [2104, 2129], "entities": [{"type": "Organization", "text": "Zacks Investment Research", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "icon", "sentiment": {"score": -0.0521633, "label": "negative"}, "relevance": 0.979313}, {"text": "medical research company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.914173}, {"text": "Russell Investments Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.773892}, {"text": "Icon Plc", "sentiment": {"score": -0.448796, "label": "negative"}, "relevance": 0.764804}, {"text": "shares", "sentiment": {"score": 0.411351, "label": "positive"}, "relevance": 0.660983}, {"text": "Investments Group Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.655765}, {"text": "Massachusetts Financial Services", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642657}, {"text": "ICON Public Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.639926}, {"text": "new stake", "sentiment": {"score": 0.447906, "label": "positive"}, "relevance": 0.617885}, {"text": "quarter worth", "sentiment": {"score": 0.447906, "label": "positive"}, "relevance": 0.613291}, {"text": "Icon alerts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.602626}, {"text": "American Banking News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601522}, {"text": "Icon analysts", "sentiment": {"score": 0.337761, "label": "positive"}, "relevance": 0.583905}, {"text": "Alpha Cubed Investments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548299}, {"text": "institutional investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54473}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542377}, {"text": "recent filing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538999}, {"text": "recent research reports", "sentiment": {"score": -0.33153, "label": "negative"}, "relevance": 0.537928}, {"text": "strong buy rating", "sentiment": {"score": 0.475041, "label": "positive"}, "relevance": 0.536761}, {"text": "Robert W. Baird", "sentiment": {"score": 0.364313, "label": "positive"}, "relevance": 0.52999}, {"text": "clinical research organization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52852}, {"text": "Capital LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526949}, {"text": "stock", "sentiment": {"score": 0.419677, "label": "positive"}, "relevance": 0.523951}, {"text": "consensus price target", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522608}, {"text": "I-IV clinical studies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522073}, {"text": "medical device industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520125}, {"text": "companies daily email", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519793}, {"text": "clinical development process", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518785}, {"text": "outsourced development services", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518589}, {"text": "COPYRIGHT VIOLATION NOTICE", "sentiment": {"score": -0.536216, "label": "negative"}, "relevance": 0.514962}, {"text": "international copyright laws", "sentiment": {"score": -0.408108, "label": "negative"}, "relevance": 0.513238}, {"text": "ICLR", "sentiment": {"score": -0.33153, "label": "negative"}, "relevance": 0.489699}, {"text": "consensus rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484562}, {"text": "hold rating", "sentiment": {"score": -0.233515, "label": "negative"}, "relevance": 0.483029}, {"text": "PEG ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47935}, {"text": "research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.479098}, {"text": "price-to-earnings ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478951}, {"text": "debt-to-equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478527}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478461}, {"text": "sell rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478065}, {"text": "current ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477028}, {"text": "Evercore ISI", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475373}, {"text": "12-month high", "sentiment": {"score": -0.448796, "label": "negative"}, "relevance": 0.474115}, {"text": "earnings results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471815}, {"text": "Capital Advisors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471274}, {"text": "Calamos Advisors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.469484}, {"text": "legal version", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.469284}, {"text": "market capitalization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468498}, {"text": "consensus estimate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467528}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466329}]}, "extracted_metadata": {"sha1": "cb0349ed2a091f8d897c612044a7d721c88c30fa", "filename": "1542045083729.zip-12d4d4ce8cb89e0f621834f2a8af08a1.xml", "file_type": "json"}, "external_links": ["https://www.marketbeat.com/stocks/NASDAQ/ICLR/sec-filings/", "http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "https://www.marketbeat.com/newsletter/default.aspx"], "title": "Russell Investments Group Ltd. Purchases 9,778 Shares of Icon Plc (ICLR)", "forum_title": "American Banking News"}, {"id": "IMBKG9QYdVxnFXIvbVR2-Y4kyOjRH-tlOVBWfwX1MplWW-Qz9PTl4gxtGjDmE5Ru", "result_metadata": {"score": 21.256039}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "147%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Generally Accepted Accounting Principles", "relevance": 0.862373, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}], "categories": [{"score": 0.938954, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Quarter Fiscal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.984225}, {"text": "Financial Results Feature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.868836}, {"text": "Revenues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413235}, {"text": "Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32599}, {"text": "Increase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315121}]}, "crawl_date": "2018-11-13T12:51:12Z", "url": "https://www.finanzen.at/nachrichten/aktien/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147percent-increase-in-revenues-1027720149", "host": "finanzen.at", "text": "Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "main_image_url": "http://www.finanzen.at/Images/FacebookIcon.jpg", "country": "HU", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T13:31:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0.563393, "label": "positive"}, "text": "InMotion", "relevance": 0.750069, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.606174, "label": "positive"}, "text": "BIONIK", "relevance": 0.613277, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories Corp", "relevance": 0.542737, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eric Dusseux", "relevance": 0.459908, "type": "Person"}, {"count": 4, "sentiment": {"score": 0.563012, "label": "positive"}, "text": "China", "relevance": 0.443211, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.37746, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Technology Co.", "relevance": 0.364224, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "partner", "relevance": 0.356116, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.352316, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bionik", "relevance": 0.33772, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.336969, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wistron Corporation", "relevance": 0.334367, "type": "Company", "disambiguation": {"subtype": [], "name": "Wistron Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Wistron_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.32616, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TORONTO", "relevance": 0.31766, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SEC", "relevance": 0.315434, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ginger Capital Investment Holding Ltd", "relevance": 0.311703, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.579065, "label": "positive"}, "text": "North America", "relevance": 0.308484, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "chief executive officer", "relevance": 0.307088, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.304606, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Audrey D. Th\u00e9venon", "relevance": 0.299639, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.630342, "label": "positive"}, "text": "State Drug Administration", "relevance": 0.294297, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Charles Matine", "relevance": 0.283453, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "Cogmedix", "relevance": 0.282389, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BOSTON", "relevance": 0.279935, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.554755, "label": "positive"}, "text": "Twitter", "relevance": 0.278302, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Facebook", "relevance": 0.253205, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Facebook", "dbpedia_resource": "http://dbpedia.org/resource/Facebook"}}, {"count": 1, "sentiment": {"score": 0.418092, "label": "positive"}, "text": "LinkedIn", "relevance": 0.242944, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "LinkedIn", "dbpedia_resource": "http://dbpedia.org/resource/LinkedIn"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$221,847", "relevance": 0.242944, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$547,085", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,582,997", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,742,335", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,970,167", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2,750,000", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5,692,853", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$122,667", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$134,161", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$162,022", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$163,012", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$305,757", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$507,311", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "147%", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "30%", "relevance": 0.242944, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "73%", "relevance": 0.242944, "type": "Quantity"}], "sentiment": {"document": {"score": 0.57815, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a robotics company", "keywords": [{"text": "robotics company"}], "entities": [{"type": "Company", "text": "BIONIK Laboratories"}]}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "object": {"text": "rehabilitation and assistive technology solutions", "keywords": [{"text": "assistive technology solutions"}, {"text": "rehabilitation"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "financial results", "keywords": [{"text": "financial results"}]}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the second quarter of fiscal year 2019,", "keywords": [{"text": "quarter"}], "entities": []}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "We"}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "seven InMotion systems", "keywords": [{"text": "InMotion systems"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "seven InMotion systems during the quarter", "keywords": [{"text": "InMotion systems"}, {"text": "quarter"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "with five in the first quarter and two in the same quarterly period a year ago", "keywords": [{"text": "quarter"}, {"text": "quarterly period"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "our renewed sales efforts on all fronts, from R&D to manufacturing and financing", "keywords": [{"text": "sales efforts"}, {"text": "fronts"}, {"text": "R&D"}, {"text": "financing"}]}, "sentence": " These results clearly reflect our renewed sales efforts on all fronts, from R&D to manufacturing and financing.", "object": {"text": "These results", "keywords": [{"text": "results"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflect", "normalized": "reflect"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "launched the next-generation InMotion ARM in Europe", "keywords": [{"text": "next-generation InMotion ARM"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "the next-generation InMotion ARM", "keywords": [{"text": "next-generation InMotion ARM"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "we"}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the first sale of this product", "keywords": [{"text": "sale"}, {"text": "product"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "object": {"text": "to a facility", "keywords": [{"text": "facility"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "a facility", "keywords": [{"text": "facility"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "We"}, "sentence": " We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "object": {"text": "continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US", "keywords": [{"text": "stroke survivors"}, {"text": "continued sales"}, {"text": "rehabilitation"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "The new InMotion ARM", "keywords": [{"text": "new InMotion ARM"}]}, "sentence": " The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "object": {"text": "with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation", "keywords": [{"text": "mobility impairment"}, {"text": "neurological conditions"}, {"text": "commercial product"}, {"text": "previous generation"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The new version", "keywords": [{"text": "new version"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "a modern design that is smaller", "keywords": [{"text": "modern design"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "a modern design", "keywords": [{"text": "modern design"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "smaller, sleeker", "keywords": [{"text": "sleeker"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "object": {"text": "We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd", "keywords": [{"text": "InMotion ARM therapy"}, {"text": "Ginger Capital Investment"}, {"text": "Medical Technology Co."}, {"text": "joint venture"}], "entities": [{"type": "Person", "text": "Bionik"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Company", "text": "Medical Technology Co."}, {"type": "Person", "text": "Bionik"}, {"type": "Company", "text": "Ginger Capital Investment Holding Ltd"}]}, "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "for testing to support State Drug Administration approval in China", "keywords": [{"text": "Drug Administration approval"}, {"text": "State"}, {"text": "China"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "will be used", "normalized": "will be use"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "State Drug Administration approval", "keywords": [{"text": "Drug Administration approval"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "very excited"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by this progress", "keywords": [{"text": "progress"}]}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "We"}, "action": {"verb": {"text": "excite", "tense": "past"}, "text": "are very excited", "normalized": "be very excite"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China", "keywords": [{"text": "new stroke patients"}, {"text": "rehabilitation"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "hope", "tense": "present"}, "text": "hope", "normalized": "hope"}}, {"subject": {"text": "we"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "rehabilitation", "keywords": [{"text": "rehabilitation"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}, {"subject": {"text": "by advancements with manufacturing partner Cogmedix leading to increased production capacity", "keywords": [{"text": "partner Cogmedix"}, {"text": "production capacity"}, {"text": "advancements"}], "entities": [{"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "Our sales efforts", "keywords": [{"text": "sales efforts"}]}, "action": {"verb": {"text": "support", "tense": "past"}, "text": "are supported", "normalized": "be support"}}, {"subject": {"text": "Cogmedix", "keywords": [{"text": "Cogmedix"}], "entities": [{"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "to increased production capacity", "keywords": [{"text": "production capacity"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "permitting us to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "permit", "tense": "present"}, "text": "is permitting", "normalized": "be permit"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "we took important steps to improve our capital structure and secure long-term growth capital", "keywords": [{"text": "secure long-term growth"}, {"text": "important steps"}, {"text": "capital structure"}]}, "action": {"verb": {"text": "conclude", "tense": "past"}, "text": "concluded", "normalized": "conclude"}}, {"subject": {"text": "we"}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "our capital structure", "keywords": [{"text": "capital structure"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "to improve", "normalized": "to improve"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "a consolidation of shares", "keywords": [{"text": "consolidation"}, {"text": "shares"}]}, "action": {"verb": {"text": "effect", "tense": "past"}, "text": "effected", "normalized": "effect"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "the minimum bid requirement for listing on the Nasdaq exchange", "keywords": [{"text": "minimum bid requirement"}, {"text": "Nasdaq exchange"}, {"text": "listing"}], "entities": []}, "action": {"verb": {"text": "meet", "tense": "future"}, "text": "meeting", "normalized": "meet"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "funds", "keywords": [{"text": "funds"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "to develop our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to continue to develop", "normalized": "to continue to develop"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "to completing"}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "these initiatives", "keywords": [{"text": "initiatives"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "completing", "normalized": "complete"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "important solutions", "keywords": [{"text": "important solutions"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "the sale of seven InMotion robots during the second quarter of fiscal 2019, compared with two robots in the prior-year quarter", "keywords": [{"text": "InMotion robots"}, {"text": "prior-year quarter"}, {"text": "sale"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "sentence": " The increase reflects the sale of seven InMotion robots during the second quarter of fiscal 2019, compared with two robots in the prior-year quarter.", "object": {"text": "The increase", "keywords": [{"text": "increase"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflects", "normalized": "reflect"}}, {"subject": {"text": "seven InMotion robots during the second quarter of fiscal 2019", "keywords": [{"text": "InMotion robots"}, {"text": "quarter"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "sentence": " The increase reflects the sale of seven InMotion robots during the second quarter of fiscal 2019, compared with two robots in the prior-year quarter.", "object": {"text": "with two robots in the prior-year quarter", "keywords": [{"text": "prior-year quarter"}, {"text": "robots"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "deferred revenue", "keywords": [{"text": "deferred revenue"}]}, "sentence": " In addition, deferred revenue, comprised of training to be provided and extended warranties, increased to $134,161 at September 30, 2018 from $122,667 at March 31, 2018 .", "object": {"text": "of training to be provided and extended warranties", "keywords": [{"text": "warranties"}, {"text": "training"}]}, "action": {"verb": {"text": "comprise", "tense": "past"}, "text": "comprised", "normalized": "comprise"}}, {"subject": {"text": "deferred revenue", "keywords": [{"text": "deferred revenue"}]}, "sentence": " In addition, deferred revenue, comprised of training to be provided and extended warranties, increased to $134,161 at September 30, 2018 from $122,667 at March 31, 2018 .", "object": {"text": "provided and extended warranties", "keywords": [{"text": "warranties"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "deferred revenue,", "keywords": [{"text": "deferred revenue"}]}, "sentence": " In addition, deferred revenue, comprised of training to be provided and extended warranties, increased to $134,161 at September 30, 2018 from $122,667 at March 31, 2018 .", "object": {"text": "warranties", "keywords": [{"text": "warranties"}]}, "action": {"verb": {"text": "extend", "tense": "past"}, "text": "extended", "normalized": "extend"}}, {"subject": {"text": "Extended warranties and training", "keywords": [{"text": "warranties"}, {"text": "training"}]}, "sentence": " Extended warranties and training are important and growing parts of the Company's business.", "object": {"text": "important"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the quarter", "keywords": [{"text": "quarter"}]}, "sentence": " Gross profit for the quarter ended September 30, 2018 was $163,012 or 30% of sales, compared with $162,022 , or 73% of sales for the quarter ended September 30, 2017 .", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "Gross profit for the quarter ended September 30, 2018", "keywords": [{"text": "Gross profit"}, {"text": "quarter"}]}, "sentence": " Gross profit for the quarter ended September 30, 2018 was $163,012 or 30% of sales, compared with $162,022 , or 73% of sales for the quarter ended September 30, 2017 .", "object": {"text": "$163,012 or 30% of sales", "keywords": [{"text": "sales"}], "entities": [{"type": "Quantity", "text": "$163,012"}, {"type": "Quantity", "text": "30"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "$163,012 or 30% of sales", "keywords": [{"text": "sales"}], "entities": [{"type": "Quantity", "text": "$163,012"}, {"type": "Quantity", "text": "30"}]}, "sentence": " Gross profit for the quarter ended September 30, 2018 was $163,012 or 30% of sales, compared with $162,022 , or 73% of sales for the quarter ended September 30, 2017 .", "object": {"text": "with $162,022 , or 73% of sales for the quarter ended September 30, 2017", "keywords": [{"text": "quarter"}, {"text": "sales"}], "entities": [{"type": "Quantity", "text": "$162,022"}, {"type": "Quantity", "text": "73"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "the quarter", "keywords": [{"text": "quarter"}]}, "sentence": " Gross profit for the quarter ended September 30, 2018 was $163,012 or 30% of sales, compared with $162,022 , or 73% of sales for the quarter ended September 30, 2017 .", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "The decline in gross margin", "keywords": [{"text": "gross margin"}, {"text": "decline"}], "entities": []}, "sentence": " The decline in gross margin compared to the prior period was negatively impacted by higher than normal manufacturing costs as the Company transitioned its production to an outsourcing arrangement.", "object": {"text": "to the prior period was negatively impacted by higher than normal manufacturing costs as the Company transitioned its production to an outsourcing arrangement", "keywords": [{"text": "normal manufacturing costs"}, {"text": "outsourcing arrangement"}, {"text": "prior period"}, {"text": "Company"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "The decline in gross margin compared to the prior period", "keywords": [{"text": "gross margin"}, {"text": "prior period"}, {"text": "decline"}], "entities": []}, "sentence": " The decline in gross margin compared to the prior period was negatively impacted by higher than normal manufacturing costs as the Company transitioned its production to an outsourcing arrangement.", "object": {"text": "negatively impacted by higher than normal manufacturing costs", "keywords": [{"text": "normal manufacturing costs"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by higher than normal manufacturing costs as the Company transitioned its production to an outsourcing arrangement", "keywords": [{"text": "normal manufacturing costs"}, {"text": "outsourcing arrangement"}, {"text": "Company"}, {"text": "production"}]}, "sentence": " The decline in gross margin compared to the prior period was negatively impacted by higher than normal manufacturing costs as the Company transitioned its production to an outsourcing arrangement.", "object": {"text": "The decline in gross margin compared to the prior period", "keywords": [{"text": "gross margin"}, {"text": "prior period"}, {"text": "decline"}], "entities": []}, "action": {"verb": {"text": "impact", "tense": "past"}, "text": "impacted", "normalized": "impact"}}], "concepts": [{"text": "Fiscal year", "relevance": 0.952188, "dbpedia_resource": "http://dbpedia.org/resource/Fiscal_year"}, {"text": "Generally Accepted Accounting Principles", "relevance": 0.645181, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Corporate finance", "relevance": 0.559312, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}], "categories": [{"score": 0.589124, "label": "/finance/financial news"}, {"score": 0.464662, "label": "/business and industrial/company/earnings"}, {"score": 0.445528, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.562025, "arguments": [{"text": "individuals", "location": [215, 226], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [232, 244], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "hasAttribute", "sentence": "About BIONIK Laboratories Corp. BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home.", "score": 0.562025, "arguments": [{"text": "individuals", "location": [7770, 7781], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [7787, 7799], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "partOf", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.814686, "arguments": [{"text": "board", "location": [1166, 1171], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "its", "location": [1162, 1165], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.34374, "arguments": [{"text": "directors", "location": [1175, 1184], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "board", "location": [1166, 1171], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "hasAttribute", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.40699, "arguments": [{"text": "investors", "location": [1658, 1667], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "$2,750,000", "location": [1677, 1687], "entities": [{"type": "Money", "text": "$2,750,000"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.804912, "arguments": [{"text": "Chairman", "location": [1750, 1758], "entities": [{"type": "Person", "text": "Effected"}]}, {"text": "company", "location": [1740, 1747], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.73019, "arguments": [{"text": "chief executive officer", "location": [1962, 1985], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "BIONIK", "location": [1953, 1959], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}]}, {"type": "locatedAt", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.485132, "arguments": [{"text": "We", "location": [2424, 2426], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "InMotion", "location": [2465, 2473], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "agentOf", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.933804, "arguments": [{"text": "we", "location": [2525, 2527], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "announced", "location": [2537, 2546], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.946332, "arguments": [{"text": "facility", "location": [2588, 2596], "entities": [{"type": "Facility", "text": "manufacturing facility"}]}, {"text": "France", "location": [2600, 2606], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "score": 0.386238, "arguments": [{"text": "survivors", "location": [2756, 2765], "entities": [{"type": "Person", "text": "survivors"}]}, {"text": "US", "location": [2778, 2780], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "score": 0.666528, "arguments": [{"text": "InMotion", "location": [2790, 2798], "entities": [{"type": "Person", "text": "InMotion robots"}]}, {"text": "ARM", "location": [2799, 2802], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}]}, {"type": "timeOf", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.634783, "arguments": [{"text": "today", "location": [292, 297], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [298, 307], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.995926, "arguments": [{"text": "Dusseux", "location": [3137, 3144], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "continued", "location": [3145, 3154], "entities": [{"type": "EventCommunication", "text": "continued"}]}]}, {"type": "partOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.482106, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3246, 3274], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BIONIK", "location": [3229, 3235], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.698726, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3246, 3274], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [3238, 3243], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.852432, "arguments": [{"text": "patients", "location": [3588, 3596], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [3581, 3587], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.591839, "arguments": [{"text": "patients", "location": [3588, 3596], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "China", "location": [3610, 3615], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "score": 0.736435, "arguments": [{"text": "Cogmedix", "location": [3694, 3702], "entities": [{"type": "Person", "text": "Cogmedix"}]}, {"text": "partner", "location": [3686, 3693], "entities": [{"type": "GeopoliticalEntity", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}]}, {"type": "agentOf", "sentence": "\" Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "score": 0.998234, "arguments": [{"text": "Dusseux", "location": [3854, 3861], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "concluded", "location": [3862, 3871], "entities": [{"type": "EventCommunication", "text": "concluded"}]}]}, {"type": "locatedAt", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.886308, "arguments": [{"text": "InMotion WRIST\u2122", "location": [4659, 4674], "entities": [{"type": "Person", "text": "InMotion WRIST\u2122"}]}, {"text": "hospitals", "location": [4705, 4714], "entities": [{"type": "Organization", "text": "manufacturing facility"}]}]}, {"type": "agentOf", "sentence": "The Company reported a comprehensive loss for the quarter ended September 30, 2018 of $(3,983,105) , or a loss per share of $(1.62) , compared with a comprehensive loss of $(3,615,361) , or a loss per share of $(5.33) , for the quarter ended September 30, 2017 .", "score": 0.886256, "arguments": [{"text": "Company", "location": [6444, 6451], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}, {"text": "reported", "location": [6452, 6460], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.", "score": 0.655292, "arguments": [{"text": "patients", "location": [7978, 7986], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [7943, 7949], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "timeOf", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.593404, "arguments": [{"text": "second quarter of fiscal year 2019", "location": [334, 368], "entities": [{"type": "Date", "text": "second quarter of fiscal year 2019"}]}, {"text": "announced", "location": [298, 307], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "For more information, please visit www.BIONIKlabs.com and connect with us on Twitter , LinkedIn , and Facebook .", "score": 0.453554, "arguments": [{"text": "Twitter", "location": [8156, 8163], "entities": [{"type": "Organization", "text": "Twitter"}]}, {"text": "LinkedIn", "location": [8166, 8174], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control.", "score": 0.421104, "arguments": [{"text": "Company", "location": [9857, 9864], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}, {"text": "which", "location": [9847, 9852], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "These and other factors are identified and described in more detail in the Company's filings with the SEC.", "score": 0.586541, "arguments": [{"text": "Company", "location": [10925, 10932], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp. BIONIK Laboratories"}]}, {"text": "SEC", "location": [10952, 10955], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "basedIn", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.835171, "arguments": [{"text": "ARM", "location": [616, 619], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [607, 615], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.787644, "arguments": [{"text": "ARM", "location": [2474, 2477], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [2465, 2473], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.732993, "arguments": [{"text": "ARM", "location": [3183, 3186], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [3174, 3182], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.881539, "arguments": [{"text": "ARM/HAND\u2122 Interactive Therapy System", "location": [4618, 4654], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [4609, 4617], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.809587, "arguments": [{"text": "independent", "location": [1092, 1103], "entities": [{"type": "Person", "text": "independent"}]}, {"text": "Appointed", "location": [1082, 1091], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.529991, "arguments": [{"text": "directors", "location": [1104, 1113], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Appointed", "location": [1082, 1091], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.860788, "arguments": [{"text": "Audrey D. Th\u00e9venon", "location": [1114, 1132], "entities": [{"type": "Person", "text": "Audrey D. Th\u00e9venon"}]}, {"text": "directors", "location": [1104, 1113], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.788308, "arguments": [{"text": "Ph.D.", "location": [1134, 1139], "entities": [{"type": "Person", "text": "Ph.D."}]}, {"text": "directors", "location": [1104, 1113], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.481698, "arguments": [{"text": "Charles Matine", "location": [1144, 1158], "entities": [{"type": "Person", "text": "Charles Matine"}]}, {"text": "board", "location": [1166, 1171], "entities": [{"type": "Organization", "text": "board"}]}]}], "keywords": [{"text": "inmotion arm", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.930565}, {"text": "forward-looking statements", "sentiment": {"score": -0.512597, "label": "negative"}, "relevance": 0.884482}, {"text": "InMotion ARM therapy", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.867353}, {"text": "quarter", "sentiment": {"score": 0.256846, "label": "positive"}, "relevance": 0.866572}, {"text": "prior-year quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.7718}, {"text": "Medical Technology Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.766561}, {"text": "company", "sentiment": {"score": 0.0394425, "label": "positive"}, "relevance": 0.762551}, {"text": "InMotion Home product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.761275}, {"text": "ARM therapy robots", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.760662}, {"text": "next-generation InMotion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759965}, {"text": "fiscal second quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759761}, {"text": "next-generation InMotion ARM\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.754671}, {"text": "bionik laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.751743}, {"text": "next-generation InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.751666}, {"text": "InMotion robotic products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.744556}, {"text": "new InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.742207}, {"text": "InMotion robots", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.741361}, {"text": "prior-year quarter Sold", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.740242}, {"text": "Quarter Financial Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.728748}, {"text": "InMotion ARM/HAND\u2122 Interactive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.723586}, {"text": "Nasdaq exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.716431}, {"text": "fiscal quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.715293}, {"text": "InMotion systems", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.686337}, {"text": "quarter end", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.67761}, {"text": "BIONIK Laboratories Corp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.667359}, {"text": "InMotion WRIST\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.666922}, {"text": "robotics company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.6614}, {"text": "Corporation Continued development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.659801}, {"text": "lower-limb assistive exoskeleton", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.650728}, {"text": "actual results", "sentiment": {"score": -0.570438, "label": "negative"}, "relevance": 0.649758}, {"text": "impaired mobility", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646902}, {"text": "sales", "sentiment": {"score": 0.500544, "label": "positive"}, "relevance": 0.646853}, {"text": "assistive technology solutions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646813}, {"text": "sales efforts", "sentiment": {"score": 0.500544, "label": "positive"}, "relevance": 0.64601}, {"text": "Nasdaq exchange Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.644684}, {"text": "robotic rehabilitation products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.643522}, {"text": "convertible promissory loans", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64202}, {"text": "joint venture", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.640305}, {"text": "mobility challenges", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.639989}, {"text": "Ginger Capital Investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63869}, {"text": "Audrey D. Th\u00e9venon", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.638319}, {"text": "Dr. Dusseux", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.637659}, {"text": "long-term growth capital", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.635034}, {"text": "capital structure", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.633123}, {"text": "neurological conditions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.632499}, {"text": "new stroke patients", "sentiment": {"score": 0.904343, "label": "positive"}, "relevance": 0.631981}, {"text": "reverse stock split", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.631638}, {"text": "outsourced manufacturing facility", "sentiment": {"score": 0.917225, "label": "positive"}, "relevance": 0.631488}, {"text": "chief executive officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629858}, {"text": "State Drug Administration", "sentiment": {"score": 0.630342, "label": "positive"}, "relevance": 0.628118}]}, "extracted_metadata": {"sha1": "49282c39999303c21976995abf4dfae9d7d9ee7e", "filename": "1542113472062.zip-e88e47b952116e55e12f4276cbc499d3.xml", "file_type": "json"}, "external_links": ["http://www.bioniklabs.com/", "https://blog.bioniklabs.com/news-media/press-releases/detail/44/chinese-fund-invests-in-bionik-laboratories-and-establishes", "https://www.linkedin.com/company/bionik-labs/", "http://www.bioniklabs.com/news-media/press-releases/detail/46/bionik-laboratories-and-wistron-corporation-partner-to", "https://www.facebook.com/bioniklab/", "https://twitter.com/bioniklab"], "title": "BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results Feature 147% Increase in Revenues", "forum_title": "\u00d6sterreich-Nachrihcten"}, {"id": "Wn2ZFjVYpz5oWtn3KH1ISiAg1f4KCMl8exdB19DfFAHPkCFGPMoOTlNvWcUD3T3y", "result_metadata": {"score": 21.08375}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [], "relations": [], "keywords": [{"text": "\u6f64\u3044\u30de\u30b9\u30b3\u30c3\u30c8 \u304a\u3059\u308f\u308a\u30a2\u30cb\u30de\u30eb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.909804}, {"text": "\uff5c\u30c7\u30b3\u30ec\uff5c\u30ed\u30d5\u30c8\u30cd\u30c3\u30c8\u30b9\u30c8\u30a2", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520503}]}, "crawl_date": "2018-11-13T13:25:58Z", "url": "https://loft.omni7.jp/detail/4527749921138", "host": "loft.omni7.jp", "text": "All Rights Reserved.Copyright \u00a9 Seven & i Holdings Co.", "country": "JP", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T00:00:00Z", "enriched_text": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.523115, "label": "/business and industrial/company/joint venture"}, {"score": 0.491855, "label": "/real estate/buying and selling homes"}, {"score": 0.485019, "label": "/business and industrial/business software"}], "relations": [], "keywords": [{"text": "LOFT Co.,Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.996426}, {"text": "Holdings Co.,Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.866996}, {"text": "Rights Reserved.Copyright", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526003}]}, "extracted_metadata": {"sha1": "4be90b8a5bc8af6f6c01738cc17eaf03f4ba58a8", "filename": "1542115558870.zip-cdf1c96a1239d1d88ae377194975e654.xml", "file_type": "json"}, "title": "\u81ea\u7136\u6c17\u5316\u5f0f\u52a0\u6e7f\u5668 \u6f64\u3044\u30de\u30b9\u30b3\u30c3\u30c8 \u304a\u3059\u308f\u308a\u30a2\u30cb\u30de\u30eb \u307f\u3051\uff5c\u30db\u30fc\u30e0\uff06\u30ad\u30c3\u30c1\u30f3 | \u751f\u6d3b\u5bb6\u96fb\u30fb\u7167\u660e | \u52a0\u6e7f\u5668 | \uff5c\u30c7\u30b3\u30ec\uff5c\u30ed\u30d5\u30c8\u30cd\u30c3\u30c8\u30b9\u30c8\u30a2"}, {"id": "qxYrYEv8IMhlPlGa_QOINvHO5LlApvEKUYCJLkB1LJwoQGKOTMqz2lhU_vAqzbAL", "result_metadata": {"score": 20.706486}, "author": "Bonnie Powley", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gulf International Bank UK Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CMS Energy Co.", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "CMS Energy", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}, {"text": "Atlantic Ocean", "relevance": 0.889852, "dbpedia_resource": "http://dbpedia.org/resource/Atlantic_Ocean"}, {"text": "Consumers Energy", "relevance": 0.8704, "dbpedia_resource": "http://dbpedia.org/resource/Consumers_Energy"}, {"text": "Scotland", "relevance": 0.834462, "dbpedia_resource": "http://dbpedia.org/resource/Scotland"}], "categories": [{"score": 0.845311, "label": "/business and industrial/energy"}, {"score": 0.613505, "label": "/business and industrial/green solutions"}], "relations": [{"type": "partOf", "sentence": "Gulf International Bank UK Ltd Increases Stake in CMS Energy Co. (CMS)", "score": 0.541865, "arguments": [{"text": "Gulf International Bank UK Ltd Increases Stake", "location": [0, 46], "entities": [{"type": "Organization", "text": "Gulf International Bank UK Ltd Increases Stake", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CMS Energy Co.", "location": [50, 64], "entities": [{"type": "Organization", "text": "CMS Energy Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "CMS Energy Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.960628}, {"text": "Gulf International Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.763657}, {"text": "(CMS)", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.712508}, {"text": "UK Ltd Increases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570297}, {"text": "Stake", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346257}]}, "crawl_date": "2018-11-12T16:21:13Z", "url": "https://zolmax.com/investing/gulf-international-bank-uk-ltd-increases-stake-in-cms-energy-co-cms/2682193.html", "host": "zolmax.com", "text": "Tweet Gulf International Bank UK Ltd lifted its stake in shares of CMS Energy Co.", "main_image_url": "https://www.marketbeat.com/logos/cms-energy-corporation-logo.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T15:12:00Z", "enriched_text": {"entities": [{"count": 16, "sentiment": {"score": 0.337058, "label": "positive"}, "text": "CMS Energy Corporation", "relevance": 0.917374, "type": "Company", "disambiguation": {"subtype": [], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}, {"count": 4, "sentiment": {"score": -0.626912, "label": "negative"}, "text": "CMS Energy Co.", "relevance": 0.536512, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.439015, "label": "positive"}, "text": "CMS Energy Company", "relevance": 0.345333, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.590783, "label": "positive"}, "text": "Securities and Exchange Commission", "relevance": 0.173112, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0.590783, "label": "positive"}, "text": "Gulf International Bank UK Ltd", "relevance": 0.169878, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bronfman E.L. Rothschild", "relevance": 0.129226, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Stratos Wealth Partners LTD.", "relevance": 0.124899, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.43554, "label": "positive"}, "text": "QUANTRES ASSET MANAGEMENT Ltd", "relevance": 0.119968, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.445624, "label": "positive"}, "text": "Piedmont Investment Advisors LLC", "relevance": 0.118392, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays", "relevance": 0.110849, "type": "Organization", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0.504217, "label": "positive"}, "text": "Greenleaf Trust", "relevance": 0.109825, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dhenuvakonda Rao Venkat", "relevance": 0.108983, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.577271, "label": "negative"}, "text": "US", "relevance": 0.107961, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Michigan", "relevance": 0.107429, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Michigan", "dbpedia_resource": "http://dbpedia.org/resource/Michigan"}}, {"count": 1, "sentiment": {"score": -0.256107, "label": "negative"}, "text": "Wolfe Research", "relevance": 0.105687, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "analyst", "relevance": 0.105486, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.213354, "label": "positive"}, "text": "KeyCorp", "relevance": 0.10109, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SVP", "relevance": 0.0981006, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zolmax", "relevance": 0.0933608, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brian F. Rich", "relevance": 0.0917986, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zolmax", "relevance": 0.0885767, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.0874591, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "12 month", "relevance": 0.0874591, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$51.00", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$14.21 billion", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.53 billion", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.60 billion", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$198,760.00", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4,864,000", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$48,770.00", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$134,000", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$148,000", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$156,000", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$221,000", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$229,000", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.3575", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$40.48", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$48.77", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$49.69", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$50.14", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$51.40", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$51.91", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "14.88%", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "267.1%", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "65.90%", "relevance": 0.0874591, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "89.94%", "relevance": 0.0874591, "type": "Quantity"}], "sentiment": {"document": {"score": 0.409725, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Gulf International Bank UK Ltd", "keywords": [{"text": "Gulf International Bank"}, {"text": "UK"}], "entities": [{"type": "Company", "text": "Gulf International Bank UK Ltd"}]}, "sentence": "Tweet Gulf International Bank UK Ltd lifted its stake in shares of CMS Energy Co. (NYSE:CMS) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission.", "object": {"text": "its stake in shares of CMS Energy Co.", "keywords": [{"text": "CMS Energy"}, {"text": "stake"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation"}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "CMS", "keywords": [{"text": "CMS"}]}, "sentence": "Tweet Gulf International Bank UK Ltd lifted its stake in shares of CMS Energy Co. (NYSE:CMS) by 13.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission.", "object": {"text": "to its most recent filing with the Securities and Exchange Commission", "keywords": [{"text": "recent filing"}, {"text": "Exchange Commission"}, {"text": "Securities"}], "entities": [{"type": "Organization", "text": "Securities and Exchange Commission", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm owned 99,268 shares of the utilities provider\u2019s stock after purchasing an additional 11,800 shares during the quarter.", "object": {"text": "99,268 shares of the utilities provider\u2019s stock", "keywords": [{"text": "utilities provider"}, {"text": "shares"}, {"text": "stock"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "owned", "normalized": "own"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm owned 99,268 shares of the utilities provider\u2019s stock after purchasing an additional 11,800 shares during the quarter.", "object": {"text": "an additional 11,800 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Gulf International Bank UK Ltd", "keywords": [{"text": "Gulf International Bank"}, {"text": "UK"}], "entities": [{"type": "Company", "text": "Gulf International Bank UK Ltd"}]}, "sentence": " Gulf International Bank UK Ltd\u2019s holdings in CMS Energy were worth $4,864,000 as of its most recent filing with the Securities and Exchange Commission.", "object": {"text": "holdings in CMS Energy", "keywords": [{"text": "CMS Energy"}, {"text": "holdings"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Gulf International Bank UK Ltd\u2019s holdings in CMS Energy", "keywords": [{"text": "Gulf International Bank"}, {"text": "CMS Energy"}, {"text": "holdings"}, {"text": "UK"}], "entities": [{"type": "Company", "text": "Gulf International Bank UK Ltd"}, {"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "sentence": " Gulf International Bank UK Ltd\u2019s holdings in CMS Energy were worth $4,864,000 as of its most recent filing with the Securities and Exchange Commission.", "object": {"text": "worth $4,864,000", "entities": [{"type": "Quantity", "text": "$4,864,000"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Several other institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " Several other institutional investors also recently made changes to their positions in CMS.", "object": {"text": "changes", "keywords": [{"text": "changes"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "Stratos Wealth Partners LTD.", "keywords": [{"text": "Stratos Wealth Partners"}], "entities": [{"type": "Company", "text": "Stratos Wealth Partners LTD."}]}, "sentence": " Stratos Wealth Partners LTD. acquired a new stake in shares of CMS Energy during the 3rd quarter worth approximately $134,000.", "object": {"text": "a new stake in shares of CMS Energy", "keywords": [{"text": "new stake"}, {"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "Bronfman E.L. Rothschild L.P.", "keywords": [{"text": "E.L. Rothschild L.P"}], "entities": [{"type": "Person", "text": "Bronfman E.L. Rothschild"}]}, "sentence": " Bronfman E.L. Rothschild L.P. raised its position in shares of CMS Energy by 267.1% during the 2nd quarter.", "object": {"text": "its position in shares of CMS Energy", "keywords": [{"text": "CMS Energy"}, {"text": "position"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "Bronfman E.L. Rothschild L.P.", "keywords": [{"text": "E.L. Rothschild L.P"}], "entities": [{"type": "Person", "text": "Bronfman E.L. Rothschild"}]}, "sentence": " Bronfman E.L. Rothschild L.P. now owns 3,128 shares of the utilities provider\u2019s stock worth $148,000 after purchasing an additional 2,276 shares during the period.", "object": {"text": "3,128 shares of the utilities provider\u2019s stock worth $148,000 after purchasing an additional 2,276 shares during the period", "keywords": [{"text": "utilities provider"}, {"text": "shares"}, {"text": "period"}], "entities": [{"type": "Quantity", "text": "$148,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "worth $148,000", "entities": [{"type": "Quantity", "text": "$148,000"}]}, "sentence": " Bronfman E.L. Rothschild L.P. now owns 3,128 shares of the utilities provider\u2019s stock worth $148,000 after purchasing an additional 2,276 shares during the period.", "action": {"verb": {"text": "stock", "tense": "present"}, "text": "stock", "normalized": "stock"}}, {"subject": {"text": "Bronfman E.L. Rothschild L.P.", "keywords": [{"text": "E.L. Rothschild L.P"}], "entities": [{"type": "Person", "text": "Bronfman E.L. Rothschild"}]}, "sentence": " Bronfman E.L. Rothschild L.P. now owns 3,128 shares of the utilities provider\u2019s stock worth $148,000 after purchasing an additional 2,276 shares during the period.", "object": {"text": "an additional 2,276 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Piedmont Investment Advisors LLC", "keywords": [{"text": "Piedmont Investment Advisors"}], "entities": [{"type": "Company", "text": "Piedmont Investment Advisors LLC"}]}, "sentence": " Piedmont Investment Advisors LLC acquired a new stake in CMS Energy in the 2nd quarter valued at approximately $156,000.", "object": {"text": "a new stake in CMS Energy", "keywords": [{"text": "new stake"}, {"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "QUANTRES ASSET MANAGEMENT Ltd", "keywords": [{"text": "QUANTRES ASSET MANAGEMENT"}], "entities": [{"type": "Company", "text": "QUANTRES ASSET MANAGEMENT Ltd"}]}, "sentence": " QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in CMS Energy in the 3rd quarter valued at approximately $221,000.", "object": {"text": "a new stake in CMS Energy", "keywords": [{"text": "new stake"}, {"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "Greenleaf Trust", "keywords": [{"text": "Greenleaf Trust"}], "entities": [{"type": "Company", "text": "Greenleaf Trust"}]}, "sentence": " Finally, Greenleaf Trust acquired a new stake in CMS Energy in the 2nd quarter valued at approximately $229,000.", "object": {"text": "a new stake in CMS Energy", "keywords": [{"text": "new stake"}, {"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "funds", "keywords": [{"text": "funds"}]}, "sentence": " Institutional investors and hedge funds own 89.94% of the company\u2019s stock.", "object": {"text": "own 89.94% of the company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "89.94"}]}, "action": {"verb": {"text": "hedge", "tense": "present"}, "text": "hedge", "normalized": "hedge"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Institutional investors and hedge funds own 89.94% of the company\u2019s stock.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "CMS", "keywords": [{"text": "CMS"}]}, "sentence": " CMS opened at $50.14 on Monday.", "action": {"verb": {"text": "open", "tense": "past"}, "text": "opened", "normalized": "open"}}, {"subject": {"text": "CMS Energy Co.", "keywords": [{"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation"}]}, "sentence": " CMS Energy Co. has a 12 month low of $40.48 and a 12 month high of $51.91.", "object": {"text": "a 12 month low of $40.48 and a 12 month high of $51.91", "entities": [{"type": "Quantity", "text": "12 month"}, {"type": "Quantity", "text": "$40.48"}, {"type": "Quantity", "text": "$51.91"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a debt-to-equity ratio of 1.87, a quick ratio of 0.47 and a current ratio of 0.69.", "object": {"text": "a debt-to-equity ratio of 1.87", "keywords": [{"text": "debt-to-equity ratio"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a market capitalization of $14.21 billion and a P/E ratio of 23.11.", "object": {"text": "a market capitalization of $14.21 billion and a P/E ratio of 23.11", "keywords": [{"text": "market capitalization"}, {"text": "P/E ratio"}], "entities": [{"type": "Quantity", "text": "$14.21 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "CMS)", "keywords": [{"text": "CMS"}]}, "sentence": " CMS Energy (NYSE:CMS) last issued its quarterly earnings results on Thursday, October 25th.", "object": {"text": "its quarterly earnings results", "keywords": [{"text": "quarterly earnings"}, {"text": "results"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "The utilities provider", "keywords": [{"text": "utilities"}, {"text": "provider"}]}, "sentence": " The utilities provider reported $0.59 earnings per share (EPS) for the quarter, beating analysts\u2019 consensus estimates of $0.57 by $0.02.", "object": {"text": "$0.59 earnings per share (EPS)", "keywords": [{"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "$0.59"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.53 billion.", "object": {"text": "revenue of $1.60 billion", "keywords": [{"text": "revenue"}], "entities": [{"type": "Quantity", "text": "$1.60 billion"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "revenue of $1.60 billion during the quarter", "keywords": [{"text": "revenue"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$1.60 billion"}]}, "sentence": " The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.53 billion.", "object": {"text": "to analyst estimates of $1.53 billion", "keywords": [{"text": "analyst estimates"}], "entities": [{"type": "JobTitle", "text": "analyst"}, {"type": "Quantity", "text": "$1.53 billion"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "CMS Energy", "keywords": [{"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "sentence": " CMS Energy had a return on equity of 14.88% and a net margin of 8.00%.", "object": {"text": "a return on equity of 14.88% and a net margin of 8.00%", "keywords": [{"text": "net margin"}, {"text": "return"}, {"text": "equity"}], "entities": [{"type": "Quantity", "text": "14.88"}, {"type": "Quantity", "text": "8.00"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " During the same period last year, the company posted $0.62 EPS.", "object": {"text": "$0.62 EPS", "keywords": [{"text": "EPS"}], "entities": [{"type": "Quantity", "text": "$0.62"}]}, "action": {"verb": {"text": "post", "tense": "past"}, "text": "posted", "normalized": "post"}}, {"subject": {"text": "research analysts", "keywords": [{"text": "research analysts"}]}, "sentence": " As a group, research analysts expect that CMS Energy Co. will post 2.34 earnings per share for the current fiscal year.", "object": {"text": "that CMS Energy Co. will post 2.34 earnings per share for the current fiscal year", "keywords": [{"text": "CMS Energy Co."}, {"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company also recently declared a quarterly dividend, which will be paid on Friday, November 30th.", "object": {"text": "a quarterly dividend, which will be paid on Friday, November 30th", "keywords": [{"text": "quarterly dividend"}, {"text": "Friday"}]}, "action": {"verb": {"text": "declare", "tense": "past"}, "text": "declared", "normalized": "declare"}}, {"subject": {"text": "a quarterly dividend", "keywords": [{"text": "quarterly dividend"}]}, "sentence": " The company also recently declared a quarterly dividend, which will be paid on Friday, November 30th.", "action": {"verb": {"text": "pay", "tense": "future"}, "text": "will be paid", "normalized": "will be pay"}}, {"subject": {"text": "Shareholders of record on Friday, November 2nd", "keywords": [{"text": "Shareholders"}, {"text": "Friday"}, {"text": "record"}]}, "sentence": " Shareholders of record on Friday, November 2nd will be paid a dividend of $0.3575 per share.", "object": {"text": "paid a dividend of $0.3575 per share", "keywords": [{"text": "dividend"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "$0.3575"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "a dividend of $0.3575 per share", "keywords": [{"text": "dividend"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "$0.3575"}]}, "sentence": " Shareholders of record on Friday, November 2nd will be paid a dividend of $0.3575 per share.", "object": {"text": "Shareholders of record on Friday, November 2nd", "keywords": [{"text": "Shareholders"}, {"text": "Friday"}, {"text": "record"}]}, "action": {"verb": {"text": "pay", "tense": "future"}, "text": "will be paid", "normalized": "will be pay"}}, {"subject": {"text": "This"}, "sentence": " This represents a $1.43 dividend on an annualized basis and a yield of 2.85%.", "object": {"text": "a $1.43 dividend on an annualized basis and a yield of 2.85%", "keywords": [{"text": "annualized basis"}, {"text": "dividend"}, {"text": "yield"}], "entities": [{"type": "Quantity", "text": "$1.43"}, {"type": "Quantity", "text": "2.85"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "The ex-dividend date", "keywords": [{"text": "ex-dividend date"}]}, "sentence": " The ex-dividend date is Thursday, November 1st.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "CMS Energy\u2019s payout ratio", "keywords": [{"text": "payout ratio"}, {"text": "CMS"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "sentence": " CMS Energy\u2019s payout ratio is currently 65.90%.", "object": {"text": "currently 65.90%", "entities": [{"type": "Quantity", "text": "65.90"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Several analysts", "keywords": [{"text": "analysts"}]}, "sentence": " Several analysts recently commented on CMS shares.", "object": {"text": "on CMS shares", "keywords": [{"text": "CMS shares"}]}, "action": {"verb": {"text": "comment", "tense": "past"}, "text": "commented", "normalized": "comment"}}, {"subject": {"text": "Wolfe Research", "keywords": [{"text": "Wolfe Research"}], "entities": [{"type": "Company", "text": "Wolfe Research"}]}, "sentence": " Wolfe Research cut CMS Energy from an \u201coutperform\u201d rating to a \u201cmarket perform\u201d rating in a research report on Friday, October 26th.", "object": {"text": "CMS Energy", "keywords": [{"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}]}, "sentence": " ValuEngine upgraded CMS Energy from a \u201chold\u201d rating to a \u201cbuy\u201d rating in a research report on Wednesday, October 24th.", "object": {"text": "CMS Energy", "keywords": [{"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "upgrade", "tense": "past"}, "text": "upgraded", "normalized": "upgrade"}}, {"subject": {"text": "Barclays", "keywords": [{"text": "Barclays"}], "entities": [{"type": "Organization", "text": "Barclays", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays started coverage on CMS Energy in a research report on Wednesday, August 15th.", "object": {"text": "coverage", "keywords": [{"text": "coverage"}]}, "action": {"verb": {"text": "start", "tense": "past"}, "text": "started", "normalized": "start"}}, {"subject": {"text": "They"}, "sentence": " They issued an \u201cequal weight\u201d rating and a $51.00 target price on the stock.", "object": {"text": "an \u201cequal weight\u201d rating and a $51.00 target price on the stock", "keywords": [{"text": "equal weight"}, {"text": "target price"}, {"text": "rating"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$51.00"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}]}, "sentence": " Zacks Investment Research cut CMS Energy from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research report on Wednesday, September 26th.", "object": {"text": "CMS Energy", "keywords": [{"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Zacks Investment Research cut CMS Energy from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a research report on Wednesday, September 26th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "KeyCorp", "keywords": [{"text": "KeyCorp"}], "entities": [{"type": "Person", "text": "KeyCorp"}]}, "sentence": " Finally, KeyCorp restated a \u201cbuy\u201d rating and issued a $51.00 target price on shares of CMS Energy in a research report on Thursday, August 16th.", "object": {"text": "a \u201cbuy\u201d rating", "keywords": [{"text": "buy"}, {"text": "rating"}]}, "action": {"verb": {"text": "restate", "tense": "past"}, "text": "restated", "normalized": "restate"}}, {"subject": {"text": "KeyCorp", "keywords": [{"text": "KeyCorp"}], "entities": [{"type": "Person", "text": "KeyCorp"}]}, "sentence": " Finally, KeyCorp restated a \u201cbuy\u201d rating and issued a $51.00 target price on shares of CMS Energy in a research report on Thursday, August 16th.", "object": {"text": "a $51.00 target price", "keywords": [{"text": "target price"}], "entities": [{"type": "Quantity", "text": "$51.00"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "Eight investment analysts", "keywords": [{"text": "investment analysts"}]}, "sentence": " Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company\u2019s stock.", "object": {"text": "rated the stock with a hold rating and seven", "keywords": [{"text": "hold rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Eight investment analysts", "keywords": [{"text": "investment analysts"}]}, "sentence": " Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company\u2019s stock.", "object": {"text": "with a hold rating and seven", "keywords": [{"text": "hold rating"}]}, "action": {"verb": {"text": "rate", "tense": "past"}, "text": "have rated", "normalized": "have rate"}}, {"subject": {"text": "seven"}, "sentence": " Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company\u2019s stock.", "object": {"text": "given a buy rating to the company\u2019s stock", "keywords": [{"text": "buy rating"}, {"text": "company"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "seven"}, "sentence": " Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company\u2019s stock.", "object": {"text": "a buy rating to the company\u2019s stock", "keywords": [{"text": "buy rating"}, {"text": "company"}, {"text": "stock"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "have given", "normalized": "have give"}}, {"subject": {"text": "CMS Energy", "keywords": [{"text": "CMS Energy"}], "entities": [{"type": "Company", "text": "CMS Energy Corporation", "disambiguation": {"subtype": ["Organization", "Company"], "name": "CMS Energy", "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}}]}, "sentence": " CMS Energy currently has an average rating of \u201cHold\u201d and an average target price of $51.40.", "object": {"text": "an average rating of \u201cHold\u201d and an average target price of $51.40", "keywords": [{"text": "average target price"}, {"text": "average rating"}], "entities": [{"type": "Quantity", "text": "$51.40"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "insider Dhenuvakonda Rao Venkat", "keywords": [{"text": "Dhenuvakonda Rao Venkat"}, {"text": "insider"}], "entities": [{"type": "Person", "text": "Dhenuvakonda Rao Venkat"}]}, "sentence": " In other CMS Energy news, insider Dhenuvakonda Rao Venkat sold 1,000 shares of the stock in a transaction on Tuesday, August 14th.", "object": {"text": "1,000 shares of the stock", "keywords": [{"text": "shares"}, {"text": "stock"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}], "concepts": [{"text": "Financial ratio", "relevance": 0.965612, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Stock", "relevance": 0.943073, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Financial ratios", "relevance": 0.93177, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratios"}, {"text": "CMS Energy", "relevance": 0.801, "dbpedia_resource": "http://dbpedia.org/resource/CMS_Energy"}, {"text": "U.S. Securities and Exchange Commission", "relevance": 0.787322, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Stock market", "relevance": 0.787227, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Consumers Energy", "relevance": 0.777, "dbpedia_resource": "http://dbpedia.org/resource/Consumers_Energy"}, {"text": "P/E ratio", "relevance": 0.705305, "dbpedia_resource": "http://dbpedia.org/resource/P/E_ratio"}], "categories": [{"score": 0.596866, "label": "/finance/investing"}, {"score": 0.596866, "label": "/finance/investing/beginning investing"}, {"score": 0.313276, "label": "/business and industrial/company"}], "relations": [{"type": "employedBy", "sentence": "Several other institutional investors also recently made changes to their positions in CMS.", "score": 0.44133, "arguments": [{"text": "their", "location": [557, 562], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "CMS", "location": [576, 579], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "The company has a market capitalization of $14.21 billion and a P/E ratio of 23.11.", "score": 0.765225, "arguments": [{"text": "company", "location": [1640, 1647], "entities": [{"type": "Organization", "text": "utilities provider"}]}, {"text": "$14.21 billion", "location": [1679, 1693], "entities": [{"type": "Money", "text": "$14.21 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "The utilities provider reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.02.", "score": 0.830243, "arguments": [{"text": "utilities provider", "location": [1816, 1834], "entities": [{"type": "Organization", "text": "utilities provider"}]}, {"text": "reported", "location": [1835, 1843], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The utilities provider reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.02.", "score": 0.504376, "arguments": [{"text": "utilities provider", "location": [1816, 1834], "entities": [{"type": "Organization", "text": "utilities provider"}]}, {"text": "$0.59", "location": [1844, 1849], "entities": [{"type": "Money", "text": "$0.59", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.53 billion.", "score": 0.725974, "arguments": [{"text": "firm", "location": [1953, 1957], "entities": [{"type": "Organization", "text": "utilities provider"}]}, {"text": "$1.60 billion", "location": [1973, 1986], "entities": [{"type": "Money", "text": "$1.60 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.53 billion.", "score": 0.544922, "arguments": [{"text": "analyst", "location": [2019, 2026], "entities": [{"type": "Person", "text": "analyst"}]}, {"text": "$1.53 billion", "location": [2040, 2053], "entities": [{"type": "Money", "text": "$1.53 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "During the same period last year, the company posted $0.62 EPS.", "score": 0.743502, "arguments": [{"text": "company", "location": [2164, 2171], "entities": [{"type": "Organization", "text": "utilities provider"}]}, {"text": "$0.62", "location": [2179, 2184], "entities": [{"type": "Money", "text": "$0.62", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "During the same period last year, the company posted $0.62 EPS.", "score": 0.865232, "arguments": [{"text": "EPS", "location": [2185, 2188], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "$0.62", "location": [2179, 2184], "entities": [{"type": "Money", "text": "$0.62", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "timeOf", "sentence": "The company also recently declared a quarterly dividend, which will be paid on Friday, November 30th.", "score": 0.518951, "arguments": [{"text": "Friday", "location": [2389, 2395], "entities": [{"type": "Date", "text": "November 30th"}]}, {"text": "declared", "location": [2336, 2344], "entities": [{"type": "EventCommunication", "text": "declared"}]}]}, {"type": "agentOf", "sentence": "Several analysts recently commented on CMS shares.", "score": 0.73493, "arguments": [{"text": "analysts", "location": [2686, 2694], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "commented", "location": [2704, 2713], "entities": [{"type": "EventCommunication", "text": "commented"}]}]}, {"type": "affectedBy", "sentence": "Several analysts recently commented on CMS shares.", "score": 0.476752, "arguments": [{"text": "CMS", "location": [2717, 2720], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "commented", "location": [2704, 2713], "entities": [{"type": "EventCommunication", "text": "commented"}]}]}, {"type": "partOf", "sentence": "Bronfman E.L. Rothschild L.P. raised its position in shares of CMS Energy by 267.1% during the 2nd quarter.", "score": 0.373565, "arguments": [{"text": "its", "location": [745, 748], "entities": [{"type": "Organization", "text": "Gulf International Bank UK Ltd Increases Stake"}]}, {"text": "CMS Energy", "location": [771, 781], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "TRADEMARK VIOLATION NOTICE: \"Gulf International Bank UK Ltd Increases Stake in CMS Energy Co. (CMS)\" was posted by Zolmax and is the property of of Zolmax.", "score": 0.406847, "arguments": [{"text": "Gulf International Bank UK Ltd Increases Stake", "location": [4304, 4350], "entities": [{"type": "Organization", "text": "Gulf International Bank UK Ltd Increases Stake"}]}, {"text": "CMS Energy Co.", "location": [4354, 4368], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Wolfe Research cut CMS Energy from an \"outperform\" rating to a \"market perform\" rating in a research report on Friday, October 26th.", "score": 0.51062, "arguments": [{"text": "Wolfe", "location": [2729, 2734], "entities": [{"type": "Person", "text": "Wolfe"}]}, {"text": "CMS Energy", "location": [2748, 2758], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "They issued an \"equal weight\" rating and a $51.00 target price on the stock.", "score": 0.993193, "arguments": [{"text": "They", "location": [3069, 3073], "entities": [{"type": "Person", "text": "They"}]}, {"text": "issued", "location": [3074, 3080], "entities": [{"type": "EventCommunication", "text": "issued"}]}]}, {"type": "agentOf", "sentence": "Finally, KeyCorp restated a \"buy\" rating and issued a $51.00 target price on shares of CMS Energy in a research report on Thursday, August 16th.", "score": 0.991053, "arguments": [{"text": "KeyCorp", "location": [3286, 3293], "entities": [{"type": "Organization", "text": "KeyCorp", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "restated", "location": [3294, 3302], "entities": [{"type": "EventCommunication", "text": "restated"}]}]}, {"type": "hasAttribute", "sentence": "Finally, KeyCorp restated a \"buy\" rating and issued a $51.00 target price on shares of CMS Energy in a research report on Thursday, August 16th.", "score": 0.53534, "arguments": [{"text": "KeyCorp", "location": [3286, 3293], "entities": [{"type": "Organization", "text": "KeyCorp", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$51.00", "location": [3331, 3337], "entities": [{"type": "Money", "text": "$51.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Finally, KeyCorp restated a \"buy\" rating and issued a $51.00 target price on shares of CMS Energy in a research report on Thursday, August 16th.", "score": 0.749527, "arguments": [{"text": "CMS Energy", "location": [3364, 3374], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$51.00", "location": [3331, 3337], "entities": [{"type": "Money", "text": "$51.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "Company insiders own 0.65% of the company's stock.", "score": 0.659549, "arguments": [{"text": "insiders", "location": [4232, 4240], "entities": [{"type": "Person", "text": "insiders"}]}, {"text": "Company", "location": [4224, 4231], "entities": [{"type": "Organization", "text": "utilities provider"}]}]}, {"type": "agentOf", "sentence": "If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws.", "score": 0.518272, "arguments": [{"text": "you", "location": [4434, 4437], "entities": [{"type": "Person", "text": "you"}]}, {"text": "stolen", "location": [4495, 4501], "entities": [{"type": "Crime", "text": "stolen"}]}]}, {"type": "locatedAt", "sentence": "CMS Energy Company Profile CMS Energy Corporation operates as an energy company primarily in Michigan.", "score": 0.636352, "arguments": [{"text": "energy company", "location": [4806, 4820], "entities": [{"type": "Organization", "text": "utilities provider"}]}, {"text": "Michigan", "location": [4834, 4842], "entities": [{"type": "GeopoliticalEntity", "text": "Michigan"}]}]}, {"type": "agentOf", "sentence": "Piedmont Investment Advisors LLC acquired a new stake in CMS Energy in the 2nd quarter valued at approximately $156,000.", "score": 0.905368, "arguments": [{"text": "Piedmont Investment Advisors LLC", "location": [980, 1012], "entities": [{"type": "Organization", "text": "Piedmont Investment Advisors LLC", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [1013, 1021], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "affectedBy", "sentence": "Piedmont Investment Advisors LLC acquired a new stake in CMS Energy in the 2nd quarter valued at approximately $156,000.", "score": 0.546067, "arguments": [{"text": "CMS Energy", "location": [1037, 1047], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [1013, 1021], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "affectedBy", "sentence": "QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in CMS Energy in the 3rd quarter valued at approximately $221,000.", "score": 0.546067, "arguments": [{"text": "CMS Energy", "location": [1155, 1165], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [1131, 1139], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Piedmont Investment Advisors LLC acquired a new stake in CMS Energy in the 2nd quarter valued at approximately $156,000.", "score": 0.868105, "arguments": [{"text": "2nd quarter", "location": [1055, 1066], "entities": [{"type": "Date", "text": "2nd quarter"}]}, {"text": "acquired", "location": [1013, 1021], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "agentOf", "sentence": "QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in CMS Energy in the 3rd quarter valued at approximately $221,000.", "score": 0.916735, "arguments": [{"text": "ASSET MANAGEMENT Ltd", "location": [1110, 1130], "entities": [{"type": "Organization", "text": "ASSET MANAGEMENT Ltd"}]}, {"text": "acquired", "location": [1131, 1139], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "QUANTRES ASSET MANAGEMENT Ltd acquired a new stake in CMS Energy in the 3rd quarter valued at approximately $221,000.", "score": 0.868105, "arguments": [{"text": "3rd quarter", "location": [1173, 1184], "entities": [{"type": "Date", "text": "3rd quarter"}]}, {"text": "acquired", "location": [1131, 1139], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "employedBy", "sentence": "Finally, Greenleaf Trust acquired a new stake in CMS Energy in the 2nd quarter valued at approximately $229,000.", "score": 0.721495, "arguments": [{"text": "Greenleaf", "location": [1228, 1237], "entities": [{"type": "Person", "text": "Greenleaf"}]}, {"text": "CMS Energy", "location": [1268, 1278], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Get CMS Energy alerts: CMS opened at $50.14 on Monday.", "score": 0.559669, "arguments": [{"text": "CMS", "location": [1430, 1433], "entities": [{"type": "Organization", "text": "CMS Energy Company Profile\nCMS Energy Corporation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$50.14", "location": [1444, 1450], "entities": [{"type": "Money", "text": "$50.14"}]}]}], "keywords": [{"text": "CMS Energy", "sentiment": {"score": -0.00514805, "label": "negative"}, "relevance": 0.945783}, {"text": "CMS Energy Co.", "sentiment": {"score": -0.626911, "label": "negative"}, "relevance": 0.713918}, {"text": "International Bank UK", "sentiment": {"score": 0.590783, "label": "positive"}, "relevance": 0.56445}, {"text": "Gulf International Bank", "sentiment": {"score": 0.590783, "label": "positive"}, "relevance": 0.562938}, {"text": "CMS Energy alerts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557587}, {"text": "CMS Energy Company", "sentiment": {"score": 0.439015, "label": "positive"}, "relevance": 0.54838}, {"text": "CMS Energy Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543466}, {"text": "CMS Energy news", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542964}, {"text": "new stake", "sentiment": {"score": 0.461793, "label": "positive"}, "relevance": 0.524023}, {"text": "research report", "sentiment": {"score": 0.210082, "label": "positive"}, "relevance": 0.519869}, {"text": "CMS shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517011}, {"text": "Bronfman E.L. Rothschild", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512385}, {"text": "E.L. Rothschild L.P.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512373}, {"text": "utilities provider", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50148}, {"text": "Exchange Commission", "sentiment": {"score": 0.590783, "label": "positive"}, "relevance": 0.491847}, {"text": "target price", "sentiment": {"score": 0.210082, "label": "positive"}, "relevance": 0.478068}, {"text": "Tweet\nGulf International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464051}, {"text": "institutional investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462676}, {"text": "Wealth Partners LTD.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462537}, {"text": "recent filing", "sentiment": {"score": 0.590783, "label": "positive"}, "relevance": 0.462167}, {"text": "QUANTRES ASSET MANAGEMENT", "sentiment": {"score": 0.43554, "label": "positive"}, "relevance": 0.459532}, {"text": "quarterly earnings results", "sentiment": {"score": -0.235704, "label": "negative"}, "relevance": 0.459269}, {"text": "Investment Advisors LLC", "sentiment": {"score": 0.445624, "label": "positive"}, "relevance": 0.45817}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458007}, {"text": "average target price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454352}, {"text": "average price", "sentiment": {"score": -0.297567, "label": "negative"}, "relevance": 0.454202}, {"text": "Dhenuvakonda Rao Venkat", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453717}, {"text": "SVP Brian F.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453101}, {"text": "rating", "sentiment": {"score": 0.389592, "label": "positive"}, "relevance": 0.451899}, {"text": "Electric Utility segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.451517}, {"text": "stock", "sentiment": {"score": 0.183676, "label": "positive"}, "relevance": 0.449425}, {"text": "TRADEMARK VIOLATION NOTICE", "sentiment": {"score": -0.381902, "label": "negative"}, "relevance": 0.449424}, {"text": "Energy\u2019s payout", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.445186}, {"text": "renewable energy", "sentiment": {"score": 0.551246, "label": "positive"}, "relevance": 0.441212}, {"text": "provider\u2019s stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440468}, {"text": "Increases Stake", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437818}, {"text": "research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436771}, {"text": "debt-to-equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436512}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436487}, {"text": "P/E ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436319}, {"text": "current ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435906}, {"text": "hold rating", "sentiment": {"score": 0.479347, "label": "positive"}, "relevance": 0.435754}, {"text": "average rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435539}, {"text": "buy rating", "sentiment": {"score": 0.479347, "label": "positive"}, "relevance": 0.43468}, {"text": "quarterly dividend", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434269}, {"text": "Wolfe Research", "sentiment": {"score": -0.256107, "label": "negative"}, "relevance": 0.432609}, {"text": "Company insiders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43244}, {"text": "Greenleaf Trust", "sentiment": {"score": 0.504217, "label": "positive"}, "relevance": 0.432372}]}, "extracted_metadata": {"sha1": "a32962cda2524cfa7a1bcaeb31406c2da56017ca", "filename": "1542039673496.zip-aec84cc26ab1a40a2854b1ba0da3440c.xml", "file_type": "json"}, "external_links": ["http://www.sec.gov/Archives/edgar/data/811156/000124636018002447/xslF345X03/form.xml", "http://www.sec.gov/Archives/edgar/data/811156/000124636018002027/xslF345X03/form.xml", "https://www.marketbeat.com/stocks/NYSE/CMS/sec-filings/", "http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "http://twitter.com/share", "http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=CMS", "https://www.marketbeat.com/newsletter/default.aspx"], "title": "Gulf International Bank UK Ltd Increases Stake in CMS Energy Co. (CMS)", "forum_title": "Zolmax"}, {"id": "yd8ENTFlZSzZRd1vsoqLNDSHbZqHC3UoZ-UQuOdgrRCxchPdEASay8vdBbFXb-yt", "result_metadata": {"score": 20.705126}, "author": "ABMN Staff", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co.", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRK", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oakbrook Investments LLC", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.600626, "label": "/finance/investing"}, {"score": 0.600626, "label": "/finance/investing/beginning investing"}, {"score": 0.306581, "label": "/business and industrial/company"}], "relations": [], "keywords": [{"text": "Oakbrook Investments LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.979089}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422567}, {"text": "Sells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226941}, {"text": "Shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.22648}, {"text": "Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225559}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225099}, {"text": "MRK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.224408}]}, "crawl_date": "2018-11-12T17:42:21Z", "url": "https://www.americanbankingnews.com/2018/11/12/oakbrook-investments-llc-sells-34366-shares-of-merck-co-inc-mrk.html", "host": "americanbankingnews.com", "text": "Delek Group Ltd. grew its position in Merck & Co., Inc. by 20.2% in the first quarter.", "main_image_url": "https://www.marketbeat.com/logos/merck--co-inc-logo.gif", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-12T17:08:00Z", "enriched_text": {"entities": [{"count": 23, "sentiment": {"score": -0.332723, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.905363, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 7, "sentiment": {"score": -0.34811, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.585922, "type": "Company"}, {"count": 18, "sentiment": {"score": 0.135142, "label": "positive"}, "text": "Inc.", "relevance": 0.359501, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.333074, "label": "negative"}, "text": "Oakbrook Investments LLC", "relevance": 0.249438, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ancora Advisors LLC", "relevance": 0.185056, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Securities & Exchange Commission", "relevance": 0.182649, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.178169, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "One Seven LLC", "relevance": 0.17749, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Delek Group Ltd.", "relevance": 0.175539, "type": "Company", "disambiguation": {"subtype": [], "name": "Delek", "dbpedia_resource": "http://dbpedia.org/resource/Delek"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Natixis", "relevance": 0.174555, "type": "Company", "disambiguation": {"subtype": [], "name": "Natixis", "dbpedia_resource": "http://dbpedia.org/resource/Natixis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Principal Financial Group Inc.", "relevance": 0.164473, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.69372, "label": "negative"}, "text": "allergic rhinitis", "relevance": 0.14873, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Allergic rhinitis", "dbpedia_resource": "http://dbpedia.org/resource/Allergic_rhinitis"}}, {"count": 1, "sentiment": {"score": -0.249099, "label": "negative"}, "text": "SunTrust Banks", "relevance": 0.148718, "type": "Company", "disambiguation": {"subtype": [], "name": "SunTrust Banks", "dbpedia_resource": "http://dbpedia.org/resource/SunTrust_Banks"}}, {"count": 1, "sentiment": {"score": 0.205957, "label": "positive"}, "text": "BMO Capital Markets", "relevance": 0.147404, "type": "Company", "disambiguation": {"subtype": [], "name": "BMO Capital Markets", "dbpedia_resource": "http://dbpedia.org/resource/BMO_Capital_Markets"}}, {"count": 1, "sentiment": {"score": -0.349558, "label": "negative"}, "text": "Citigroup", "relevance": 0.145948, "type": "Company", "disambiguation": {"subtype": [], "name": "Citigroup", "dbpedia_resource": "http://dbpedia.org/resource/Citigroup"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman Kenneth C. Frazier", "relevance": 0.143009, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.326118, "label": "negative"}, "text": "Bank of America", "relevance": 0.142805, "type": "Company", "disambiguation": {"subtype": [], "name": "Bank of America", "dbpedia_resource": "http://dbpedia.org/resource/Bank_of_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "chairman", "relevance": 0.142466, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Banking News", "relevance": 0.126389, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roger M. Perlmutter", "relevance": 0.126128, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.743453, "label": "negative"}, "text": "chronic hepatitis C", "relevance": 0.121224, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRK", "relevance": 0.117517, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "twelve month", "relevance": 0.117517, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$70.00", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$201.84 billion", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$10.00 billion", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$10.79 billion", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$10.87 billion", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$16,969,094.61", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$19,611,958.08", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$27,623,939.46", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$68,103,814.08", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$165,636,000", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$392,303,000", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "three months", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$39,968,000", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$92,845,846", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,023,000", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2,018,000", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$7,771,000", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$52.83", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$70.08", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$71.92", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$74.00", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$74.86", "relevance": 0.117517, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$75.27", "relevance": 0.117517, "type": "Quantity"}], "sentiment": {"document": {"score": 0.195574, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "by ABMN Staff", "keywords": [{"text": "ABMN Staff"}]}, "sentence": "Posted by ABMN Staff on Nov 12th, 2018 // No Comments", "object": {"text": "// No Comments", "keywords": [{"text": "Comments"}]}, "action": {"verb": {"text": "Posted", "tense": "past"}, "text": "Posted", "normalized": "Posted"}}, {"subject": {"text": "Oakbrook Investments LLC", "keywords": [{"text": "Oakbrook Investments"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Oakbrook Investments LLC"}]}, "sentence": " Oakbrook Investments LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 5.7% in the third quarter, according to its most recent 13F filing with the SEC.", "object": {"text": "its position in shares of Merck & Co., Inc. (NYSE:MRK)", "keywords": [{"text": "Merck"}, {"text": "NYSE"}, {"text": "position"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Company", "text": "NYSE"}]}, "action": {"verb": {"text": "lower", "tense": "past"}, "text": "lowered", "normalized": "lower"}}, {"subject": {"text": "MRK) by 5.7% in the third quarter", "keywords": [{"text": "quarter"}, {"text": "MRK"}], "entities": [{"type": "Quantity", "text": "5.7"}]}, "sentence": " Oakbrook Investments LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 5.7% in the third quarter, according to its most recent 13F filing with the SEC.", "object": {"text": "to its most recent 13F filing with the SEC", "keywords": [{"text": "SEC"}], "entities": [{"type": "Organization", "text": "Securities & Exchange Commission", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm owned 563,399 shares of the company\u2019s stock after selling 34,366 shares during the quarter.", "object": {"text": "563,399 shares of the company\u2019s stock", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "owned", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " The firm owned 563,399 shares of the company\u2019s stock after selling 34,366 shares during the quarter.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm owned 563,399 shares of the company\u2019s stock after selling 34,366 shares during the quarter.", "object": {"text": "34,366 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "sell", "tense": "present"}, "text": "selling", "normalized": "sell"}}, {"subject": {"text": "holdings", "keywords": [{"text": "holdings"}]}, "sentence": " Merck & Co., Inc. comprises approximately 2.2% of Oakbrook Investments LLC\u2019s holdings, making the stock its 6th largest holding.", "object": {"text": "approximately 2.2% of Oakbrook Investments LLC", "keywords": [{"text": "Oakbrook Investments LLC"}], "entities": [{"type": "Company", "text": "Oakbrook Investments LLC"}, {"type": "Quantity", "text": "2.2"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Merck & Co., Inc. comprises approximately 2.2% of Oakbrook Investments LLC\u2019s holdings,", "keywords": [{"text": "Oakbrook Investments LLC"}, {"text": "Merck"}, {"text": "holdings"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Company", "text": "Oakbrook Investments LLC"}, {"type": "Quantity", "text": "2.2"}]}, "sentence": " Merck & Co., Inc. comprises approximately 2.2% of Oakbrook Investments LLC\u2019s holdings, making the stock its 6th largest holding.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Oakbrook Investments LLC", "keywords": [{"text": "Oakbrook Investments"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Oakbrook Investments LLC"}]}, "sentence": " Oakbrook Investments LLC\u2019s holdings in Merck & Co., Inc. were worth $39,968,000 at the end of the most recent quarter.", "object": {"text": "holdings in Merck & Co.", "keywords": [{"text": "Merck"}, {"text": "holdings"}], "entities": [{"type": "Company", "text": "Merck & Co., Inc."}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Oakbrook Investments LLC\u2019s holdings in Merck & Co., Inc.", "keywords": [{"text": "Oakbrook Investments LLC"}, {"text": "Merck"}, {"text": "holdings"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Oakbrook Investments LLC"}, {"type": "Company", "text": "Merck & Co., Inc."}]}, "sentence": " Oakbrook Investments LLC\u2019s holdings in Merck & Co., Inc. were worth $39,968,000 at the end of the most recent quarter.", "object": {"text": "worth $39,968,000", "entities": [{"type": "Quantity", "text": "$39,968,000"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Several other large investors", "keywords": [{"text": "large investors"}]}, "sentence": " Several other large investors have also recently modified their holdings of the company.", "object": {"text": "their holdings", "keywords": [{"text": "holdings"}]}, "action": {"verb": {"text": "modify", "tense": "past"}, "text": "modified", "normalized": "modify"}}, {"subject": {"text": "Principal Financial Group Inc.", "keywords": [{"text": "Principal Financial Group"}], "entities": [{"type": "Company", "text": "Principal Financial Group Inc."}]}, "sentence": " Principal Financial Group Inc. grew its position in Merck & Co., Inc. by 3.0% in the first quarter.", "object": {"text": "its position in Merck & Co., Inc. by 3.0% in the first quarter", "keywords": [{"text": "Merck"}, {"text": "position"}, {"text": "quarter"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Quantity", "text": "3.0"}]}, "action": {"verb": {"text": "grow", "tense": "past"}, "text": "grew", "normalized": "grow"}}, {"subject": {"text": "Principal Financial Group Inc.", "keywords": [{"text": "Principal Financial Group"}], "entities": [{"type": "Company", "text": "Principal Financial Group Inc."}]}, "sentence": " Principal Financial Group Inc. now owns 7,202,189 shares of the company\u2019s stock worth $392,303,000 after acquiring an additional 209,459 shares in the last quarter.", "object": {"text": "7,202,189 shares of the company\u2019s stock worth $392,303,000 after acquiring an additional 209,459 shares in the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$392,303,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Principal Financial Group Inc. now owns 7,202,189 shares of the company\u2019s stock worth $392,303,000 after acquiring an additional 209,459 shares in the last quarter.", "object": {"text": "stock worth $392,303,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$392,303,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Principal Financial Group Inc.", "keywords": [{"text": "Principal Financial Group"}], "entities": [{"type": "Company", "text": "Principal Financial Group Inc."}]}, "sentence": " Principal Financial Group Inc. now owns 7,202,189 shares of the company\u2019s stock worth $392,303,000 after acquiring an additional 209,459 shares in the last quarter.", "object": {"text": "an additional 209,459 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "Natixis", "keywords": [{"text": "Natixis"}], "entities": [{"type": "Company", "text": "Natixis", "disambiguation": {"subtype": ["Company"], "name": "Natixis", "dbpedia_resource": "http://dbpedia.org/resource/Natixis"}}]}, "sentence": " Natixis grew its position in Merck & Co., Inc. by 303.8% in the first quarter.", "object": {"text": "its position in Merck & Co., Inc. by 303.8% in the first quarter", "keywords": [{"text": "Merck"}, {"text": "position"}, {"text": "quarter"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Quantity", "text": "303.8"}]}, "action": {"verb": {"text": "grow", "tense": "past"}, "text": "grew", "normalized": "grow"}}, {"subject": {"text": "Natixis", "keywords": [{"text": "Natixis"}], "entities": [{"type": "Company", "text": "Natixis", "disambiguation": {"subtype": ["Company"], "name": "Natixis", "dbpedia_resource": "http://dbpedia.org/resource/Natixis"}}]}, "sentence": " Natixis now owns 3,040,858 shares of the company\u2019s stock worth $165,636,000 after acquiring an additional 2,287,728 shares in the last quarter.", "object": {"text": "3,040,858 shares of the company\u2019s stock worth $165,636,000 after acquiring an additional 2,287,728 shares in the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$165,636,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Natixis now owns 3,040,858 shares of the company\u2019s stock worth $165,636,000 after acquiring an additional 2,287,728 shares in the last quarter.", "object": {"text": "stock worth $165,636,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$165,636,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "an additional 2,287,728 shares", "keywords": [{"text": "shares"}]}, "sentence": " Natixis now owns 3,040,858 shares of the company\u2019s stock worth $165,636,000 after acquiring an additional 2,287,728 shares in the last quarter.", "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "Ancora Advisors LLC", "keywords": [{"text": "Advisors"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Ancora Advisors LLC"}]}, "sentence": " Ancora Advisors LLC grew its position in Merck & Co., Inc. by 6.7% in the first quarter.", "object": {"text": "its position in Merck & Co., Inc. by 6.7% in the first quarter", "keywords": [{"text": "Merck"}, {"text": "position"}, {"text": "quarter"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Quantity", "text": "6.7"}]}, "action": {"verb": {"text": "grow", "tense": "past"}, "text": "grew", "normalized": "grow"}}, {"subject": {"text": "Ancora Advisors LLC", "keywords": [{"text": "Advisors"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Ancora Advisors LLC"}]}, "sentence": " Ancora Advisors LLC now owns 37,046 shares of the company\u2019s stock worth $2,018,000 after acquiring an additional 2,315 shares in the last quarter.", "object": {"text": "37,046 shares of the company\u2019s stock worth $2,018,000 after acquiring an additional 2,315 shares in the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$2,018,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Ancora Advisors LLC now owns 37,046 shares of the company\u2019s stock worth $2,018,000 after acquiring an additional 2,315 shares in the last quarter.", "object": {"text": "stock worth $2,018,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$2,018,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Ancora Advisors LLC", "keywords": [{"text": "Advisors"}, {"text": "LLC"}], "entities": [{"type": "Company", "text": "Ancora Advisors LLC"}]}, "sentence": " Ancora Advisors LLC now owns 37,046 shares of the company\u2019s stock worth $2,018,000 after acquiring an additional 2,315 shares in the last quarter.", "object": {"text": "an additional 2,315 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "Delek Group Ltd.", "keywords": [{"text": "Delek Group"}], "entities": [{"type": "Company", "text": "Delek Group Ltd.", "disambiguation": {"subtype": [], "name": "Delek", "dbpedia_resource": "http://dbpedia.org/resource/Delek"}}]}, "sentence": " Delek Group Ltd. grew its position in Merck & Co., Inc. by 20.2% in the first quarter.", "object": {"text": "its position in Merck & Co., Inc. by 20.2% in the first quarter", "keywords": [{"text": "Merck"}, {"text": "position"}, {"text": "quarter"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Quantity", "text": "20.2"}]}, "action": {"verb": {"text": "grow", "tense": "past"}, "text": "grew", "normalized": "grow"}}, {"subject": {"text": "Delek Group Ltd.", "keywords": [{"text": "Delek Group"}], "entities": [{"type": "Company", "text": "Delek Group Ltd.", "disambiguation": {"subtype": [], "name": "Delek", "dbpedia_resource": "http://dbpedia.org/resource/Delek"}}]}, "sentence": " Delek Group Ltd. now owns 141,620 shares of the company\u2019s stock worth $7,771,000 after acquiring an additional 23,800 shares in the last quarter.", "object": {"text": "141,620 shares of the company\u2019s stock worth $7,771,000 after acquiring an additional 23,800 shares in the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$7,771,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Delek Group Ltd. now owns 141,620 shares of the company\u2019s stock worth $7,771,000 after acquiring an additional 23,800 shares in the last quarter.", "object": {"text": "stock worth $7,771,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$7,771,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Delek Group Ltd.", "keywords": [{"text": "Delek Group"}], "entities": [{"type": "Company", "text": "Delek Group Ltd.", "disambiguation": {"subtype": [], "name": "Delek", "dbpedia_resource": "http://dbpedia.org/resource/Delek"}}]}, "sentence": " Delek Group Ltd. now owns 141,620 shares of the company\u2019s stock worth $7,771,000 after acquiring an additional 23,800 shares in the last quarter.", "object": {"text": "an additional 23,800 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "We"}, "sentence": " Finally, We Are One Seven LLC grew its position in Merck & Co., Inc. by 9.4% in the first quarter.", "object": {"text": "One Seven LLC", "keywords": [{"text": "LLC"}], "entities": [{"type": "Company", "text": "One Seven LLC"}]}, "action": {"verb": {"text": "Are", "tense": "present"}, "text": "Are", "normalized": "Are"}}, {"subject": {"text": "One Seven LLC", "keywords": [{"text": "LLC"}], "entities": [{"type": "Company", "text": "One Seven LLC"}]}, "sentence": " Finally, We Are One Seven LLC grew its position in Merck & Co., Inc. by 9.4% in the first quarter.", "object": {"text": "its position in Merck & Co., Inc. by 9.4% in the first quarter", "keywords": [{"text": "Merck"}, {"text": "position"}, {"text": "quarter"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Quantity", "text": "9.4"}]}, "action": {"verb": {"text": "grow", "tense": "past"}, "text": "grew", "normalized": "grow"}}, {"subject": {"text": "One Seven LLC", "keywords": [{"text": "LLC"}], "entities": [{"type": "Company", "text": "One Seven LLC"}]}, "sentence": " We Are One Seven LLC now owns 18,783 shares of the company\u2019s stock worth $1,023,000 after acquiring an additional 1,621 shares in the last quarter.", "object": {"text": "18,783 shares of the company\u2019s stock worth $1,023,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "$1,023,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock worth $1,023,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$1,023,000"}]}, "sentence": " We Are One Seven LLC now owns 18,783 shares of the company\u2019s stock worth $1,023,000 after acquiring an additional 1,621 shares in the last quarter.", "object": {"text": "the company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "an additional 1,621 shares", "keywords": [{"text": "shares"}]}, "sentence": " We Are One Seven LLC now owns 18,783 shares of the company\u2019s stock worth $1,023,000 after acquiring an additional 1,621 shares in the last quarter.", "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "funds", "keywords": [{"text": "funds"}]}, "sentence": " Institutional investors and hedge funds own 72.32% of the company\u2019s stock.", "object": {"text": "own 72.32% of the company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "72.32"}]}, "action": {"verb": {"text": "hedge", "tense": "present"}, "text": "hedge", "normalized": "hedge"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Institutional investors and hedge funds own 72.32% of the company\u2019s stock.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Inc. stock", "keywords": [{"text": "Inc. stock"}]}, "sentence": " Merck & Co., Inc. stock opened at $74.86 on Monday.", "action": {"verb": {"text": "open", "tense": "past"}, "text": "opened", "normalized": "open"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a quick ratio of 1.04, a current ratio of 1.44 and a debt-to-equity ratio of 0.61.", "object": {"text": "a quick ratio of 1.04, a current ratio of 1.44 and a debt-to-equity ratio of 0.61", "keywords": [{"text": "quick ratio"}, {"text": "current ratio"}, {"text": "debt-to-equity ratio"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm has a market capitalization of $201.84 billion, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 2.03 and a beta of 0.73.", "object": {"text": "a market capitalization of $201.84 billion, a price-to-earnings ratio of 18.81, a price-to-earnings-growth ratio of 2.03 and a beta of 0.73", "keywords": [{"text": "price-to-earnings ratio"}, {"text": "price-to-earnings-growth ratio"}, {"text": "market capitalization"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$201.84 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Merck & Co., Inc.", "keywords": [{"text": "Merck"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co., Inc."}]}, "sentence": " Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $75.99.", "object": {"text": "a twelve month low of $52.83 and a twelve month high of $75.99", "entities": [{"type": "Quantity", "text": "twelve month"}, {"type": "Quantity", "text": "$52.83"}, {"type": "Quantity", "text": "$75.99"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Merck & Co., Inc. (NYSE:MRK)", "keywords": [{"text": "Merck"}, {"text": "NYSE"}, {"text": "Inc."}, {"text": "MRK"}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Company", "text": "NYSE"}]}, "sentence": " Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, October 25th.", "object": {"text": "its quarterly earnings results", "keywords": [{"text": "quarterly earnings"}, {"text": "results"}]}, "action": {"verb": {"text": "post", "tense": "past"}, "text": "posted", "normalized": "post"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05.", "object": {"text": "$1.19 earnings per share", "keywords": [{"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "$1.19"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "The business", "keywords": [{"text": "business"}]}, "sentence": " The business had revenue of $10.79 billion during the quarter, compared to the consensus estimate of $10.87 billion.", "object": {"text": "revenue of $10.79 billion", "keywords": [{"text": "revenue"}], "entities": [{"type": "Quantity", "text": "$10.79 billion"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "revenue of $10.79 billion during the quarter", "keywords": [{"text": "revenue"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$10.79 billion"}]}, "sentence": " The business had revenue of $10.79 billion during the quarter, compared to the consensus estimate of $10.87 billion.", "object": {"text": "to the consensus estimate of $10.87 billion", "keywords": [{"text": "consensus estimate"}], "entities": [{"type": "Quantity", "text": "$10.87 billion"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Merck & Co., Inc.", "keywords": [{"text": "Merck"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co., Inc."}]}, "sentence": " Merck & Co., Inc. had a net margin of 8.44% and a return on equity of 34.48%.", "object": {"text": "a net margin of 8.44% and a return on equity of 34.48%", "keywords": [{"text": "net margin"}, {"text": "return"}, {"text": "equity"}], "entities": [{"type": "Quantity", "text": "34.48"}, {"type": "Quantity", "text": "8.44"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "equities analysts", "keywords": [{"text": "equities analysts"}]}, "sentence": " On average, equities analysts anticipate that Merck & Co., Inc. will post 4.34 EPS for the current fiscal year.", "object": {"text": "that Merck & Co., Inc. will post 4.34 EPS for the current fiscal year", "keywords": [{"text": "Merck"}, {"text": "EPS"}, {"text": "Co."}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Merck & Co., Inc."}]}, "action": {"verb": {"text": "anticipate", "tense": "present"}, "text": "anticipate", "normalized": "anticipate"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 8th.", "object": {"text": "a quarterly dividend, which will be paid on Tuesday, January 8th", "keywords": [{"text": "quarterly dividend"}, {"text": "Tuesday"}]}, "action": {"verb": {"text": "declare", "tense": "past"}, "text": "declared", "normalized": "declare"}}, {"subject": {"text": "a quarterly dividend", "keywords": [{"text": "quarterly dividend"}]}, "sentence": " The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 8th.", "action": {"verb": {"text": "pay", "tense": "future"}, "text": "will be paid", "normalized": "will be pay"}}, {"subject": {"text": "December 17th"}, "sentence": " Shareholders of record on Monday, December 17th will be paid a $0.55 dividend.", "object": {"text": "paid a $0.55 dividend", "keywords": [{"text": "dividend"}], "entities": [{"type": "Quantity", "text": "$0.55"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "a $0.55 dividend", "keywords": [{"text": "dividend"}], "entities": [{"type": "Quantity", "text": "$0.55"}]}, "sentence": " Shareholders of record on Monday, December 17th will be paid a $0.55 dividend.", "object": {"text": "Shareholders of record on Monday", "keywords": [{"text": "Shareholders"}, {"text": "Monday"}, {"text": "record"}]}, "action": {"verb": {"text": "pay", "tense": "future"}, "text": "will be paid", "normalized": "will be pay"}}, {"subject": {"text": "The ex-dividend date", "keywords": [{"text": "ex-dividend date"}]}, "sentence": " The ex-dividend date is Friday, December 14th.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This"}, "sentence": " This is an increase from Merck & Co., Inc.\u2019s previous quarterly dividend of $0.48.", "object": {"text": "an increase from Merck & Co., Inc.\u2019s previous quarterly dividend of $0.48", "keywords": [{"text": "previous quarterly dividend"}, {"text": "Merck"}, {"text": "increase"}, {"text": "Co."}], "entities": [{"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Quantity", "text": "$0.48"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Stock market", "relevance": 0.973571, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Stock", "relevance": 0.864154, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Financial ratio", "relevance": 0.668146, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Financial ratios", "relevance": 0.64835, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratios"}, {"text": "Share repurchase", "relevance": 0.621169, "dbpedia_resource": "http://dbpedia.org/resource/Share_repurchase"}, {"text": "Finance", "relevance": 0.583174, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "P/E ratio", "relevance": 0.486972, "dbpedia_resource": "http://dbpedia.org/resource/P/E_ratio"}, {"text": "Share", "relevance": 0.446297, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Dividend yield", "relevance": 0.442592, "dbpedia_resource": "http://dbpedia.org/resource/Dividend_yield"}, {"text": "The Quarter at Tropicana", "relevance": 0.42987, "dbpedia_resource": "http://dbpedia.org/resource/The_Quarter_at_Tropicana"}, {"text": "Shareholder", "relevance": 0.426755, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "Board of directors", "relevance": 0.423073, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}, {"text": "Des Moines, Iowa", "relevance": 0.419831, "dbpedia_resource": "http://dbpedia.org/resource/Des_Moines,_Iowa"}, {"text": "Average", "relevance": 0.416571, "dbpedia_resource": "http://dbpedia.org/resource/Average"}, {"text": "Principal Financial Group", "relevance": 0.401055, "dbpedia_resource": "http://dbpedia.org/resource/Principal_Financial_Group"}], "categories": [{"score": 0.528826, "label": "/finance/investing"}, {"score": 0.528826, "label": "/finance/investing/beginning investing"}, {"score": 0.442538, "label": "/finance/financial news"}], "relations": [{"type": "agentOf", "sentence": "Posted by ABMN Staff on Nov 12th, 2018 // No Comments Oakbrook Investments LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 5.7% in the third quarter, according to its most recent 13F filing with the SEC.", "score": 0.907358, "arguments": [{"text": "ABMN Staff", "location": [10, 20], "entities": [{"type": "Organization", "text": "ABMN Staff"}]}, {"text": "Posted", "location": [0, 6], "entities": [{"type": "EventCommunication", "text": "Posted"}]}]}, {"type": "hasAttribute", "sentence": "Natixis now owns 3,040,858 shares of the company's stock worth $165,636,000 after acquiring an additional 2,287,728 shares in the last quarter.", "score": 0.766779, "arguments": [{"text": "company", "location": [1049, 1056], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "$165,636,000", "location": [1071, 1083], "entities": [{"type": "Money", "text": "$165,636,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "partOf", "sentence": "Ancora Advisors LLC grew its position in Merck & Co., Inc. by 6.7% in the first quarter.", "score": 0.544545, "arguments": [{"text": "its", "location": [1177, 1180], "entities": [{"type": "Organization", "text": "Ancora Advisors LLC"}]}, {"text": "Merck & Co., Inc.", "location": [1193, 1210], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Ancora Advisors LLC now owns 37,046 shares of the company's stock worth $2,018,000 after acquiring an additional 2,315 shares in the last quarter.", "score": 0.766779, "arguments": [{"text": "company", "location": [1291, 1298], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "$2,018,000", "location": [1313, 1323], "entities": [{"type": "Money", "text": "$2,018,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "hasAttribute", "sentence": "Delek Group Ltd. now owns 141,620 shares of the company's stock worth $7,771,000 after acquiring an additional 23,800 shares in the last quarter.", "score": 0.766779, "arguments": [{"text": "company", "location": [1523, 1530], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "$7,771,000", "location": [1545, 1555], "entities": [{"type": "Money", "text": "$7,771,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "hasAttribute", "sentence": "We Are One Seven LLC now owns 18,783 shares of the company's stock worth $1,023,000 after acquiring an additional 1,621 shares in the last quarter.", "score": 0.766779, "arguments": [{"text": "company", "location": [1771, 1778], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "$1,023,000", "location": [1793, 1803], "entities": [{"type": "Money", "text": "$1,023,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "hasAttribute", "sentence": "Get Merck & Co. Inc. alerts: Merck & Co., Inc. stock opened at $74.86 on Monday.", "score": 0.488053, "arguments": [{"text": "Merck & Co., Inc.", "location": [1972, 1989], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$74.86", "location": [2006, 2012], "entities": [{"type": "Money", "text": "$74.86"}]}]}, {"type": "agentOf", "sentence": "The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05.", "score": 0.851261, "arguments": [{"text": "company", "location": [2466, 2473], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "reported", "location": [2474, 2482], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "agentOf", "sentence": "Merck & Co., Inc. announced that its board has authorized a stock repurchase program on Thursday, October 25th that allows the company to repurchase $10.00 billion in shares.", "score": 0.966849, "arguments": [{"text": "Merck & Co., Inc.", "location": [3309, 3326], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [3327, 3336], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Merck & Co., Inc. announced that its board has authorized a stock repurchase program on Thursday, October 25th that allows the company to repurchase $10.00 billion in shares.", "score": 0.640561, "arguments": [{"text": "board", "location": [3346, 3351], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "its", "location": [3342, 3345], "entities": [{"type": "Organization", "text": "Citigroup"}]}]}, {"type": "timeOf", "sentence": "Merck & Co., Inc. announced that its board has authorized a stock repurchase program on Thursday, October 25th that allows the company to repurchase $10.00 billion in shares.", "score": 0.710106, "arguments": [{"text": "Thursday", "location": [3397, 3405], "entities": [{"type": "Date", "text": "October 25th"}]}, {"text": "authorized", "location": [3356, 3366], "entities": [{"type": "EventCommunication", "text": "authorized"}]}]}, {"type": "partOf", "sentence": "Oakbrook Investments LLC's holdings in Merck & Co., Inc. were worth $39,968,000 at the end of the most recent quarter.", "score": 0.450857, "arguments": [{"text": "Oakbrook Investments LLC\u2019s", "location": [456, 482], "entities": [{"type": "Organization", "text": "Oakbrook Investments LLC Sells"}]}, {"text": "Merck & Co., Inc.", "location": [495, 512], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Finally, We Are One Seven LLC grew its position in Merck & Co., Inc. by 9.4% in the first quarter.", "score": 0.544545, "arguments": [{"text": "its", "location": [1656, 1659], "entities": [{"type": "Organization", "text": "Oakbrook Investments LLC Sells"}]}, {"text": "Merck & Co., Inc.", "location": [1672, 1689], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Merck & Co., Inc. announced that its board has authorized a stock repurchase program on Thursday, October 25th that allows the company to repurchase $10.00 billion in shares.", "score": 0.770029, "arguments": [{"text": "company", "location": [3436, 3443], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "$10.00 billion", "location": [3458, 3472], "entities": [{"type": "Money", "text": "$10.00 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Bank of America upped their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a \"buy\" rating in a research report on Monday, July 30th.", "score": 0.446284, "arguments": [{"text": "Bank of America", "location": [3926, 3941], "entities": [{"type": "Organization", "text": "Bank of America", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$70.00", "location": [4003, 4009], "entities": [{"type": "Money", "text": "$70.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "Bank of America upped their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a \"buy\" rating in a research report on Monday, July 30th.", "score": 0.450884, "arguments": [{"text": "their", "location": [3948, 3953], "entities": [{"type": "Person", "text": "their"}]}, {"text": "Merck & Co., Inc.", "location": [3980, 3997], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Citigroup upped their target price on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the stock a \"buy\" rating in a research report on Wednesday, October 31st.", "score": 0.450884, "arguments": [{"text": "their", "location": [4113, 4118], "entities": [{"type": "Person", "text": "their"}]}, {"text": "Merck & Co., Inc.", "location": [4145, 4162], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "SunTrust Banks upped their target price on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the stock a \"buy\" rating in a research report on Monday, October 29th.", "score": 0.450884, "arguments": [{"text": "their", "location": [4289, 4294], "entities": [{"type": "Person", "text": "their"}]}, {"text": "Merck & Co., Inc.", "location": [4321, 4338], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Bank of America upped their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a \"buy\" rating in a research report on Monday, July 30th.", "score": 0.830267, "arguments": [{"text": "Merck & Co., Inc.", "location": [3980, 3997], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$70.00", "location": [4003, 4009], "entities": [{"type": "Money", "text": "$70.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Bank of America upped their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a \"buy\" rating in a research report on Monday, July 30th.", "score": 0.6882, "arguments": [{"text": "Merck & Co., Inc.", "location": [3980, 3997], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$74.00", "location": [4013, 4019], "entities": [{"type": "Money", "text": "$74.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Citigroup upped their target price on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the stock a \"buy\" rating in a research report on Wednesday, October 31st.", "score": 0.465595, "arguments": [{"text": "Merck & Co., Inc.", "location": [4145, 4162], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$84.00", "location": [4178, 4184], "entities": [{"type": "Money", "text": "$84.00"}]}]}, {"type": "hasAttribute", "sentence": "SunTrust Banks upped their target price on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the stock a \"buy\" rating in a research report on Monday, October 29th.", "score": 0.465595, "arguments": [{"text": "Merck & Co., Inc.", "location": [4321, 4338], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$80.00", "location": [4354, 4360], "entities": [{"type": "Money", "text": "$80.00"}]}]}, {"type": "agentOf", "sentence": "Finally, BMO Capital Markets reiterated a \"buy\" rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd.", "score": 0.990712, "arguments": [{"text": "BMO Capital Markets", "location": [4450, 4469], "entities": [{"type": "Organization", "text": "BMO Capital Markets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reiterated", "location": [4470, 4480], "entities": [{"type": "EventCommunication", "text": "reiterated"}]}]}, {"type": "hasAttribute", "sentence": "Finally, BMO Capital Markets reiterated a \"buy\" rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd.", "score": 0.553561, "arguments": [{"text": "BMO Capital Markets", "location": [4450, 4469], "entities": [{"type": "Organization", "text": "BMO Capital Markets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$70.00", "location": [4509, 4515], "entities": [{"type": "Money", "text": "$70.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Finally, BMO Capital Markets reiterated a \"buy\" rating and issued a $70.00 target price on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd.", "score": 0.829167, "arguments": [{"text": "Merck & Co., Inc.", "location": [4542, 4559], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$70.00", "location": [4509, 4515], "entities": [{"type": "Money", "text": "$70.00", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Oakbrook Investments LLC's holdings in Merck & Co., Inc. were worth $39,968,000 at the end of the most recent quarter.", "score": 0.482218, "arguments": [{"text": "Merck & Co., Inc.", "location": [495, 512], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$39,968,000", "location": [524, 535], "entities": [{"type": "Money", "text": "$39,968,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "partOf", "sentence": "The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website .", "score": 0.916102, "arguments": [{"text": "website", "location": [5317, 5324], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "SEC", "location": [5313, 5316], "entities": [{"type": "Organization", "text": "Securities & Exchange Commission", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "agentOf", "sentence": "ILLEGAL ACTIVITY NOTICE: \"Oakbrook Investments LLC Sells 34,366 Shares of Merck & Co., Inc. (MRK)\" was reported by American Banking News and is owned by of American Banking News.", "score": 0.855394, "arguments": [{"text": "American Banking News", "location": [5990, 6011], "entities": [{"type": "Organization", "text": "American Banking News"}]}, {"text": "reported", "location": [5978, 5986], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "agentOf", "sentence": "If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law.", "score": 0.518272, "arguments": [{"text": "you", "location": [6057, 6060], "entities": [{"type": "Person", "text": "you"}]}, {"text": "stolen", "location": [6125, 6131], "entities": [{"type": "Crime", "text": "stolen"}]}]}, {"type": "employedBy", "sentence": "The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.", "score": 0.351795, "arguments": [{"text": "agents", "location": [6598, 6604], "entities": [{"type": "Person", "text": "agents"}]}, {"text": "company", "location": [6556, 6563], "entities": [{"type": "Organization", "text": "Citigroup"}]}]}, {"type": "employedBy", "sentence": "Receive News & Ratings for Merck & Co. Inc. analysts' ratings for Merck & Co. Inc. and related companies daily email newsletter . \u00ab", "score": 0.838598, "arguments": [{"text": "analysts", "location": [7116, 7124], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "Merck & Co. Inc.", "location": [7099, 7115], "entities": [{"type": "Organization", "text": "Merck & Co. Inc. alerts", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Several other large investors have also recently modified their holdings of the company.", "score": 0.320476, "arguments": [{"text": "their", "location": [633, 638], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "company", "location": [655, 662], "entities": [{"type": "Organization", "text": "Citigroup"}]}]}, {"type": "managerOf", "sentence": "Principal Financial Group Inc. grew its position in Merck & Co., Inc. by 3.0% in the first quarter.", "score": 0.756871, "arguments": [{"text": "Principal", "location": [664, 673], "entities": [{"type": "Person", "text": "Principal"}]}, {"text": "Financial Group Inc.", "location": [674, 694], "entities": [{"type": "Organization", "text": "Financial Group Inc."}]}]}, {"type": "partOf", "sentence": "Principal Financial Group Inc. grew its position in Merck & Co., Inc. by 3.0% in the first quarter.", "score": 0.50182, "arguments": [{"text": "its", "location": [700, 703], "entities": [{"type": "Organization", "text": "Financial Group Inc."}]}, {"text": "Merck & Co., Inc.", "location": [716, 733], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Principal Financial Group Inc. now owns 7,202,189 shares of the company's stock worth $392,303,000 after acquiring an additional 209,459 shares in the last quarter.", "score": 0.703418, "arguments": [{"text": "Principal", "location": [764, 773], "entities": [{"type": "Person", "text": "Principal"}]}, {"text": "Financial Group Inc.", "location": [774, 794], "entities": [{"type": "Organization", "text": "Financial Group Inc."}]}]}, {"type": "hasAttribute", "sentence": "Principal Financial Group Inc. now owns 7,202,189 shares of the company's stock worth $392,303,000 after acquiring an additional 209,459 shares in the last quarter.", "score": 0.729491, "arguments": [{"text": "company", "location": [828, 835], "entities": [{"type": "Organization", "text": "Citigroup"}]}, {"text": "$392,303,000", "location": [850, 862], "entities": [{"type": "Money", "text": "$392,303,000", "disambiguation": {"subtype": ["Worth"]}}]}]}, {"type": "partOf", "sentence": "Natixis grew its position in Merck & Co., Inc. by 303.8% in the first quarter.", "score": 0.544545, "arguments": [{"text": "its", "location": [942, 945], "entities": [{"type": "Organization", "text": "Natixis"}]}, {"text": "Merck & Co., Inc.", "location": [958, 975], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Delek Group Ltd. grew its position in Merck & Co., Inc. by 20.2% in the first quarter.", "score": 0.575703, "arguments": [{"text": "its", "location": [1410, 1413], "entities": [{"type": "Organization", "text": "Natixis"}]}, {"text": "Merck & Co., Inc.", "location": [1426, 1443], "entities": [{"type": "Organization", "text": "Merck & Co., Inc. Profile\nMerck & Co", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Merck", "sentiment": {"score": -0.337531, "label": "negative"}, "relevance": 0.937527}, {"text": "Inc.", "sentiment": {"score": -0.115735, "label": "negative"}, "relevance": 0.751904}, {"text": "Co.", "sentiment": {"score": -0.339928, "label": "negative"}, "relevance": 0.735482}, {"text": "Oakbrook Investments LLC", "sentiment": {"score": -0.333074, "label": "negative"}, "relevance": 0.698346}, {"text": "shares", "sentiment": {"score": 0.224873, "label": "positive"}, "relevance": 0.692888}, {"text": "stock", "sentiment": {"score": 0.0826706, "label": "positive"}, "relevance": 0.628014}, {"text": "company", "sentiment": {"score": -0.242437, "label": "negative"}, "relevance": 0.566247}, {"text": "target price", "sentiment": {"score": -0.308258, "label": "negative"}, "relevance": 0.529314}, {"text": "quarter", "sentiment": {"score": -0.108122, "label": "negative"}, "relevance": 0.515073}, {"text": "Financial Group Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513483}, {"text": "research report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505501}, {"text": "Principal Financial Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499341}, {"text": "Delek Group Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.499223}, {"text": "Ancora Advisors LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497259}, {"text": "American Banking News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463461}, {"text": "Co. Inc.", "sentiment": {"score": -0.36926, "label": "negative"}, "relevance": 0.448196}, {"text": "Shares repurchase programs", "sentiment": {"score": 0.567683, "label": "positive"}, "relevance": 0.445894}, {"text": "stock repurchase program", "sentiment": {"score": 0.339045, "label": "positive"}, "relevance": 0.442135}, {"text": "quarterly dividend", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.41622}, {"text": "consensus estimate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414942}, {"text": "business\u2019s stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410477}, {"text": "previous quarterly dividend", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408697}, {"text": "Inc. stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406934}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.406044}, {"text": "quarterly earnings results", "sentiment": {"score": -0.450572, "label": "negative"}, "relevance": 0.403658}, {"text": "research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.403591}, {"text": "equities research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40148}, {"text": "average target price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.401342}, {"text": "BMO Capital Markets", "sentiment": {"score": 0.205957, "label": "positive"}, "relevance": 0.400463}, {"text": "Roger M. Perlmutter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399917}, {"text": "open market purchases", "sentiment": {"score": 0.580976, "label": "positive"}, "relevance": 0.399362}, {"text": "average price", "sentiment": {"score": -0.297567, "label": "negative"}, "relevance": 0.399027}, {"text": "companies daily email", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.396793}, {"text": "Investments LLC Sells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.395914}, {"text": "nasal allergy symptoms", "sentiment": {"score": -0.428964, "label": "negative"}, "relevance": 0.395744}, {"text": "Kenneth C. Frazier", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.394823}, {"text": "recent quarter", "sentiment": {"score": 0.419492, "label": "positive"}, "relevance": 0.392327}, {"text": "company stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384271}, {"text": "rating", "sentiment": {"score": -0.284518, "label": "negative"}, "relevance": 0.382098}, {"text": "Inc. news", "sentiment": {"score": 0.30034, "label": "positive"}, "relevance": 0.37824}, {"text": "position", "sentiment": {"score": -0.333074, "label": "negative"}, "relevance": 0.369924}, {"text": "ABMN Staff", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.36599}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364968}, {"text": "debt-to-equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364906}, {"text": "price-to-earnings ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364717}, {"text": "price-to-earnings-growth ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364686}, {"text": "current ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363398}, {"text": "payout ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362523}, {"text": "buy rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.360697}, {"text": "large investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.360098}]}, "extracted_metadata": {"sha1": "dab251101dd8403a74e72fb5cc5f88b2c6b576f7", "filename": "1542044541707.zip-7666c05e937a0e43aae293954927b4df.xml", "file_type": "json"}, "external_links": ["https://www.sec.gov/Archives/edgar/data/310158/000122520818015318/xslF345X03/doc4.xml", "https://www.sec.gov/Archives/edgar/data/310158/000122520818013571/xslF345X03/doc4.xml", "https://www.marketbeat.com/stocks/NYSE/MRK/sec-filings/", "http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "https://www.marketbeat.com/financial-terms/technical-analysis-stocks/", "https://www.holdingschannel.com/hedge-funds/holding-mrk/", "https://www.marketbeat.com/newsletter/default.aspx"], "title": "Oakbrook Investments LLC Sells 34,366 Shares of Merck & Co., Inc. (MRK)", "forum_title": "American Banking News"}, {"id": "_HGqxWJUPcRdKGJJ3fOz6gej1dDh92odlX64VcjghpwLw6TZyqe3AXQSW1fGnChc", "result_metadata": {"score": 20.672098}, "author": "mylubbocktv.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.970048, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Quarter Fiscal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.978287}, {"text": "Financial Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.604852}, {"text": "Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551353}, {"text": "BIONIK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.322025}]}, "crawl_date": "2018-11-13T13:41:59Z", "url": "http://www.mylubbocktv.com/story/39469927/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues", "host": "mylubbocktv.com", "text": "Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T00:00:00-05:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories Corp", "relevance": 0.91277, "type": "Company"}, {"count": 9, "sentiment": {"score": 0.679723, "label": "positive"}, "text": "InMotion", "relevance": 0.815057, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.550115, "label": "positive"}, "text": "US", "relevance": 0.703346, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 7, "sentiment": {"score": 0.685767, "label": "positive"}, "text": "BIONIK", "relevance": 0.679805, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0.563843, "label": "positive"}, "text": "China", "relevance": 0.542025, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 3, "sentiment": {"score": -0.314878, "label": "negative"}, "text": "SEC", "relevance": 0.539731, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eric Dusseux", "relevance": 0.501202, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bionik", "relevance": 0.485135, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.473638, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.473068, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0.716823, "label": "positive"}, "text": "North America", "relevance": 0.456566, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.451996, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "partner", "relevance": 0.451608, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wistron Corporation", "relevance": 0.442719, "type": "Company", "disambiguation": {"subtype": [], "name": "Wistron Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Wistron_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ginger Capital Investment Holding Ltd", "relevance": 0.439756, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Technology Co.", "relevance": 0.43378, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.630342, "label": "positive"}, "text": "State Drug Administration", "relevance": 0.432991, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.421722, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "Cogmedix", "relevance": 0.418618, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "principal", "relevance": 0.416239, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "chief executive officer", "relevance": 0.416102, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TORONTO", "relevance": 0.405315, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.554755, "label": "positive"}, "text": "Twitter", "relevance": 0.398949, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Audrey D. Th\u00e9venon", "relevance": 0.394963, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Charles Matine", "relevance": 0.375282, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BOSTON", "relevance": 0.371891, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Facebook", "relevance": 0.365602, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Facebook", "dbpedia_resource": "http://dbpedia.org/resource/Facebook"}}, {"count": 1, "sentiment": {"score": 0.418092, "label": "positive"}, "text": "LinkedIn", "relevance": 0.350972, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "LinkedIn", "dbpedia_resource": "http://dbpedia.org/resource/LinkedIn"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Six months", "relevance": 0.350972, "type": "Quantity"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.001", "relevance": 0.350972, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Three months", "relevance": 0.350972, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$221,847", "relevance": 0.350972, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$547,085", "relevance": 0.350972, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "2017\n$", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,582,997", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,742,335", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,970,167", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2,750,000", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5,692,853", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six months", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six month", "relevance": 0.350972, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$122,667", "relevance": 0.350972, "type": "Quantity"}], "sentiment": {"document": {"score": 0.530341, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a robotics company", "keywords": [{"text": "robotics company"}], "entities": [{"type": "Company", "text": "BIONIK Laboratories"}]}, "sentence": " TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "object": {"text": "rehabilitation and assistive technology solutions", "keywords": [{"text": "assistive technology solutions"}, {"text": "rehabilitation"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "financial results", "keywords": [{"text": "financial results"}]}, "sentence": " TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the second quarter of fiscal year 2019,", "keywords": [{"text": "quarter"}], "entities": []}, "sentence": " TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "$547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots", "keywords": [{"text": "prior-year quarter Sold"}, {"text": "InMotion robots"}], "entities": [{"type": "Company", "text": "InMotion"}, {"type": "Quantity", "text": "$221,847"}, {"type": "Quantity", "text": "$547,085"}, {"type": "Quantity", "text": "147"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end", "keywords": [{"text": "quarter"}, {"text": "prior-year quarter"}, {"text": "quarter end"}, {"text": "Borrowings"}], "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "$1,742,335", "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "into shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "convert", "tense": "past"}, "text": "were converted", "normalized": "be convert"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000", "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "from the company's Chairman Effected a 1-for-150 reverse stock split on October 29", "keywords": [{"text": "reverse stock split"}, {"text": "Chairman Effected"}, {"text": "company"}], "entities": [{"type": "JobTitle", "text": "Chairman"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000 in convertible promissory loans", "keywords": [{"text": "convertible promissory loans"}], "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Organization", "text": "BIONIK"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "on the quarter", "keywords": [{"text": "quarter"}]}, "action": {"verb": {"text": "Commenting", "tense": "present"}, "text": "Commenting", "normalized": "Commenting"}}, {"subject": {"text": "Eric Dusseux, M.D., BIONIK's chief executive officer,", "keywords": [{"text": "chief executive officer"}, {"text": "Eric Dusseux"}, {"text": "M.D."}, {"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}, {"type": "Organization", "text": "BIONIK"}, {"type": "JobTitle", "text": "chief executive officer"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "Our sales momentum continued during the fiscal second quarter and recent weeks", "keywords": [{"text": "fiscal second quarter"}, {"text": "sales momentum"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Our sales momentum", "keywords": [{"text": "sales momentum"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "I"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "very pleased with the excellent progress we made towards achieving multiple milestones", "keywords": [{"text": "excellent progress"}, {"text": "multiple milestones"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "the excellent progress", "keywords": [{"text": "excellent progress"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "multiple milestones", "keywords": [{"text": "multiple milestones"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "We"}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "seven InMotion systems", "keywords": [{"text": "InMotion systems"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "seven InMotion systems during the quarter", "keywords": [{"text": "InMotion systems"}, {"text": "quarter"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "with five in the first quarter and two in the same quarterly period a year ago", "keywords": [{"text": "quarter"}, {"text": "quarterly period"}], "entities": []}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "our renewed sales efforts on all fronts, from R&D to manufacturing and financing", "keywords": [{"text": "sales efforts"}, {"text": "fronts"}, {"text": "R&D"}, {"text": "financing"}]}, "sentence": " These results clearly reflect our renewed sales efforts on all fronts, from R&D to manufacturing and financing.", "object": {"text": "These results", "keywords": [{"text": "results"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflect", "normalized": "reflect"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "launched the next-generation InMotion ARM in Europe", "keywords": [{"text": "next-generation InMotion ARM"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "the next-generation InMotion ARM", "keywords": [{"text": "next-generation InMotion ARM"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "we"}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the first sale of this product", "keywords": [{"text": "sale"}, {"text": "product"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "object": {"text": "to a facility", "keywords": [{"text": "facility"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "a facility", "keywords": [{"text": "facility"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "We"}, "sentence": " We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "object": {"text": "continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US", "keywords": [{"text": "stroke survivors"}, {"text": "continued sales"}, {"text": "rehabilitation"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "The new InMotion ARM", "keywords": [{"text": "new InMotion ARM"}]}, "sentence": " The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "object": {"text": "with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation", "keywords": [{"text": "mobility impairment"}, {"text": "neurological conditions"}, {"text": "commercial product"}, {"text": "previous generation"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The new version", "keywords": [{"text": "new version"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "a modern design that is smaller", "keywords": [{"text": "modern design"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "a modern design", "keywords": [{"text": "modern design"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "smaller, sleeker", "keywords": [{"text": "sleeker"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "object": {"text": "We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd", "keywords": [{"text": "InMotion ARM therapy"}, {"text": "Ginger Capital Investment"}, {"text": "Medical Technology Co."}, {"text": "joint venture"}], "entities": [{"type": "Person", "text": "Bionik"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Company", "text": "Medical Technology Co."}, {"type": "Person", "text": "Bionik"}, {"type": "Company", "text": "Ginger Capital Investment Holding Ltd"}]}, "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "for testing to support State Drug Administration approval in China", "keywords": [{"text": "Drug Administration approval"}, {"text": "State"}, {"text": "China"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "will be used", "normalized": "will be use"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "State Drug Administration approval", "keywords": [{"text": "Drug Administration approval"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "very excited"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by this progress", "keywords": [{"text": "progress"}]}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "We"}, "action": {"verb": {"text": "excite", "tense": "past"}, "text": "are very excited", "normalized": "be very excite"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China", "keywords": [{"text": "new stroke patients"}, {"text": "rehabilitation"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "hope", "tense": "present"}, "text": "hope", "normalized": "hope"}}, {"subject": {"text": "we"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "rehabilitation", "keywords": [{"text": "rehabilitation"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}, {"subject": {"text": "by advancements with manufacturing partner Cogmedix leading to increased production capacity", "keywords": [{"text": "partner Cogmedix"}, {"text": "production capacity"}, {"text": "advancements"}], "entities": [{"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "Our sales efforts", "keywords": [{"text": "sales efforts"}]}, "action": {"verb": {"text": "support", "tense": "past"}, "text": "are supported", "normalized": "be support"}}, {"subject": {"text": "Cogmedix", "keywords": [{"text": "Cogmedix"}], "entities": [{"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "to increased production capacity", "keywords": [{"text": "production capacity"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "permitting us to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "permit", "tense": "present"}, "text": "is permitting", "normalized": "be permit"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "we took important steps to improve our capital structure and secure long-term growth capital", "keywords": [{"text": "secure long-term growth"}, {"text": "important steps"}, {"text": "capital structure"}]}, "action": {"verb": {"text": "conclude", "tense": "past"}, "text": "concluded", "normalized": "conclude"}}, {"subject": {"text": "we"}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "our capital structure", "keywords": [{"text": "capital structure"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "to improve", "normalized": "to improve"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "a consolidation of shares", "keywords": [{"text": "consolidation"}, {"text": "shares"}]}, "action": {"verb": {"text": "effect", "tense": "past"}, "text": "effected", "normalized": "effect"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "the minimum bid requirement for listing on the Nasdaq exchange", "keywords": [{"text": "minimum bid requirement"}, {"text": "Nasdaq exchange"}, {"text": "listing"}], "entities": []}, "action": {"verb": {"text": "meet", "tense": "future"}, "text": "meeting", "normalized": "meet"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "funds", "keywords": [{"text": "funds"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "to develop our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to continue to develop", "normalized": "to continue to develop"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "to completing"}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "these initiatives", "keywords": [{"text": "initiatives"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "completing", "normalized": "complete"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "important solutions", "keywords": [{"text": "important solutions"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to expect to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "continue", "tense": "present"}, "text": "continues", "normalized": "continue"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "expect", "tense": "future"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "action": {"verb": {"text": "achieve", "tense": "future"}, "text": "continues to expect to achieve", "normalized": "continue to expect to achieve"}}], "concepts": [{"text": "Balance sheet", "relevance": 0.983271, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Generally Accepted Accounting Principles", "relevance": 0.817289, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Asset", "relevance": 0.683806, "dbpedia_resource": "http://dbpedia.org/resource/Asset"}, {"text": "Operating expense", "relevance": 0.626881, "dbpedia_resource": "http://dbpedia.org/resource/Operating_expense"}, {"text": "Income statement", "relevance": 0.615328, "dbpedia_resource": "http://dbpedia.org/resource/Income_statement"}, {"text": "Corporate finance", "relevance": 0.606382, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Fiscal year", "relevance": 0.587294, "dbpedia_resource": "http://dbpedia.org/resource/Fiscal_year"}, {"text": "Expense", "relevance": 0.529948, "dbpedia_resource": "http://dbpedia.org/resource/Expense"}, {"text": "Inventory", "relevance": 0.493167, "dbpedia_resource": "http://dbpedia.org/resource/Inventory"}, {"text": "Liability", "relevance": 0.442057, "dbpedia_resource": "http://dbpedia.org/resource/Liability_(financial_accounting)"}, {"text": "Shares authorized", "relevance": 0.430328, "dbpedia_resource": "http://dbpedia.org/resource/Shares_authorized"}, {"text": "Gross profit", "relevance": 0.411949, "dbpedia_resource": "http://dbpedia.org/resource/Gross_profit"}, {"text": "Stock", "relevance": 0.361234, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Revenue", "relevance": 0.359061, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Finance", "relevance": 0.358779, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Preferred stock", "relevance": 0.327965, "dbpedia_resource": "http://dbpedia.org/resource/Preferred_stock"}, {"text": "2010s", "relevance": 0.326674, "dbpedia_resource": "http://dbpedia.org/resource/2010s"}, {"text": "Stock market", "relevance": 0.32023, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.599198, "label": "/finance/financial news"}, {"score": 0.449903, "label": "/finance/investing"}, {"score": 0.449903, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.562025, "arguments": [{"text": "individuals", "location": [241, 252], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [258, 270], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "hasAttribute", "sentence": "About BIONIK Laboratories Corp. BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home.", "score": 0.562025, "arguments": [{"text": "individuals", "location": [7796, 7807], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [7813, 7825], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.34374, "arguments": [{"text": "directors", "location": [1201, 1210], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "board", "location": [1192, 1197], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "hasAttribute", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.40699, "arguments": [{"text": "investors", "location": [1684, 1693], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "$2,750,000", "location": [1703, 1713], "entities": [{"type": "Money", "text": "$2,750,000"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.804912, "arguments": [{"text": "Chairman", "location": [1776, 1784], "entities": [{"type": "Person", "text": "Effected"}]}, {"text": "company", "location": [1766, 1773], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.73019, "arguments": [{"text": "chief executive officer", "location": [1988, 2011], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "BIONIK", "location": [1979, 1985], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "locatedAt", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.485132, "arguments": [{"text": "We", "location": [2450, 2452], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "InMotion", "location": [2491, 2499], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "agentOf", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.933804, "arguments": [{"text": "we", "location": [2551, 2553], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "announced", "location": [2563, 2572], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.946332, "arguments": [{"text": "facility", "location": [2614, 2622], "entities": [{"type": "Facility", "text": "manufacturing facility"}]}, {"text": "France", "location": [2626, 2632], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "score": 0.386238, "arguments": [{"text": "survivors", "location": [2782, 2791], "entities": [{"type": "Person", "text": "survivors"}]}, {"text": "US", "location": [2804, 2806], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "score": 0.666528, "arguments": [{"text": "InMotion", "location": [2816, 2824], "entities": [{"type": "Person", "text": "InMotion robots"}]}, {"text": "ARM", "location": [2825, 2828], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}]}, {"type": "agentOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.995926, "arguments": [{"text": "Dusseux", "location": [3163, 3170], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "continued", "location": [3171, 3180], "entities": [{"type": "EventCommunication", "text": "continued"}]}]}, {"type": "timeOf", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.664948, "arguments": [{"text": "today", "location": [318, 323], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [324, 333], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.482106, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3272, 3300], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BIONIK", "location": [3255, 3261], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.698726, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3272, 3300], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [3264, 3269], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.852432, "arguments": [{"text": "patients", "location": [3614, 3622], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [3607, 3613], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.591839, "arguments": [{"text": "patients", "location": [3614, 3622], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "China", "location": [3636, 3641], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "score": 0.736435, "arguments": [{"text": "Cogmedix", "location": [3720, 3728], "entities": [{"type": "Person", "text": "Cogmedix"}]}, {"text": "partner", "location": [3712, 3719], "entities": [{"type": "GeopoliticalEntity", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}]}, {"type": "agentOf", "sentence": "\" Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "score": 0.998234, "arguments": [{"text": "Dusseux", "location": [3880, 3887], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "concluded", "location": [3888, 3897], "entities": [{"type": "EventCommunication", "text": "concluded"}]}]}, {"type": "locatedAt", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.886308, "arguments": [{"text": "InMotion WRIST\u2122", "location": [4685, 4700], "entities": [{"type": "Person", "text": "InMotion WRIST\u2122"}]}, {"text": "hospitals", "location": [4731, 4740], "entities": [{"type": "Organization", "text": "manufacturing facility"}]}]}, {"type": "agentOf", "sentence": "The Company reported a comprehensive loss for the quarter ended September 30, 2018 of $(3,983,105) , or a loss per share of $(1.62) , compared with a comprehensive loss of $(3,615,361) , or a loss per share of $(5.33) , for the quarter ended September 30, 2017 .", "score": 0.886256, "arguments": [{"text": "Company", "location": [6470, 6477], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "reported", "location": [6478, 6486], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.", "score": 0.655292, "arguments": [{"text": "patients", "location": [8004, 8012], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [7969, 7975], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "partOf", "sentence": "For more information, please visit www.BIONIKlabs.com and connect with us on Twitter , LinkedIn , and Facebook .", "score": 0.453554, "arguments": [{"text": "Twitter", "location": [8182, 8189], "entities": [{"type": "Organization", "text": "Twitter"}]}, {"text": "LinkedIn", "location": [8192, 8200], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.835171, "arguments": [{"text": "ARM", "location": [642, 645], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [633, 641], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.787644, "arguments": [{"text": "ARM", "location": [2500, 2503], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [2491, 2499], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.732993, "arguments": [{"text": "ARM", "location": [3209, 3212], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [3200, 3208], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.881539, "arguments": [{"text": "ARM/HAND\u2122 Interactive Therapy System", "location": [4644, 4680], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [4635, 4643], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "partOf", "sentence": "Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control.", "score": 0.421104, "arguments": [{"text": "Company", "location": [9883, 9890], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "which", "location": [9873, 9878], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "These and other factors are identified and described in more detail in the Company's filings with the SEC.", "score": 0.586541, "arguments": [{"text": "Company", "location": [10951, 10958], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "SEC", "location": [10978, 10981], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "locatedAt", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.771425, "arguments": [{"text": "Dollars", "location": [11155, 11162], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "US", "location": [11152, 11154], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.699858, "arguments": [{"text": "Dollars", "location": [12887, 12894], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [12882, 12886], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.788373, "arguments": [{"text": "Dollars", "location": [14510, 14517], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [14505, 14509], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.425193, "arguments": [{"text": "Total Assets", "location": [11675, 11687], "entities": [{"type": "Organization", "text": "Total Assets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Goodwill", "location": [11644, 11652], "entities": [{"type": "Organization", "text": "Goodwill"}]}]}, {"type": "partOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.613876, "arguments": [{"text": "Authorized", "location": [12139, 12149], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}, {"text": "Authorized", "location": [12067, 12077], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}]}, {"type": "agentOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.980693, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [12681, 12737], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [12738, 12748], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.984382, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [14328, 14384], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [14385, 14395], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "employedBy", "sentence": "Three months Six months Three months Six months ended ended ended ended September 30, 2018 September 30, 2018 September 30, 2017 September 30, 2017 $ $ $ $ Sales 547,085 1,048,418 221,847 309,367 Cost of Sales 384,073 637,236 59,825 89,125 Gross Margin 163,012 411,182 162,022 220,242 Operating expenses Sales and marketing 427,325 969,984 435,294 880,817 Research and development 679,049 1,355,792 715,400 1,401,309 General and administrative 931,477 1,910,956 1,505,528 2,133,134 Share-based compensation expense 439,328 1,034,740 762,208 1,013,256 Amortization 69,315 140,368 76,985 169,934 Depreciation 16,626 34,221 23,820 48,372 Total operating expenses 2,563,120 5,446,061 3,519,235 5,646,822 Other (income) expenses Foreign exchange (27,872) (69,006) 15,595 114,156 Accretion expense 1,970,167 2,104,418 74,073 74,073 Fair Value Adjustment (382,010) (337,923) - - Gain on mark to market reevaluation - (2,048,697) - -", "score": 0.395149, "arguments": [{"text": "Accretion", "location": [13670, 13679], "entities": [{"type": "Person", "text": "Accretion"}]}, {"text": "Fair Value Adjustment", "location": [13722, 13743], "entities": [{"type": "Organization", "text": "Fair Value Adjustment"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.698989, "arguments": [{"text": "Cash Flows", "location": [14399, 14409], "entities": [{"type": "Person", "text": "Cash Flows"}]}, {"text": "Statements", "location": [14385, 14395], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "timeOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.604194, "arguments": [{"text": "September 30, 2018", "location": [14443, 14461], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "Statements", "location": [14385, 14395], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "agentOf", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.980082, "arguments": [{"text": "Repayment of Demand", "location": [15814, 15833], "entities": [{"type": "Organization", "text": "Repayment of Demand"}]}, {"text": "notes", "location": [15834, 15839], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.809587, "arguments": [{"text": "independent", "location": [1118, 1129], "entities": [{"type": "Person", "text": "independent"}]}, {"text": "Appointed", "location": [1108, 1117], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "affectedBy", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.528311, "arguments": [{"text": "principal", "location": [15840, 15849], "entities": [{"type": "Person", "text": "principal"}]}, {"text": "notes", "location": [15834, 15839], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.792025, "arguments": [{"text": "September 30, 2018", "location": [16435, 16453], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "filed", "location": [16454, 16459], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.706518, "arguments": [{"text": "10-Q", "location": [16468, 16472], "entities": [{"type": "Date", "text": "10-Q"}]}, {"text": "filed", "location": [16454, 16459], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.867538, "arguments": [{"text": "Company", "location": [16631, 16638], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "Annual Report", "location": [16641, 16654], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.437868, "arguments": [{"text": "Annual Report", "location": [16641, 16654], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Form", "location": [16658, 16662], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.854838, "arguments": [{"text": "Form", "location": [16658, 16662], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "filed", "location": [16668, 16673], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "affectedBy", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.354072, "arguments": [{"text": "SEC", "location": [16683, 16686], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "filed", "location": [16668, 16673], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.515736, "arguments": [{"text": "June 27, 2018", "location": [16690, 16703], "entities": [{"type": "Date", "text": "June 27, 2018"}]}, {"text": "filed", "location": [16668, 16673], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.529991, "arguments": [{"text": "directors", "location": [1130, 1139], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Appointed", "location": [1108, 1117], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.860788, "arguments": [{"text": "Audrey D. Th\u00e9venon", "location": [1140, 1158], "entities": [{"type": "Person", "text": "Audrey D. Th\u00e9venon"}]}, {"text": "directors", "location": [1130, 1139], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.788308, "arguments": [{"text": "Ph.D.", "location": [1160, 1165], "entities": [{"type": "Person", "text": "Ph.D."}]}, {"text": "directors", "location": [1130, 1139], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.481698, "arguments": [{"text": "Charles Matine", "location": [1170, 1184], "entities": [{"type": "Person", "text": "Charles Matine"}]}, {"text": "board", "location": [1192, 1197], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "partOf", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.814686, "arguments": [{"text": "board", "location": [1192, 1197], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "its", "location": [1188, 1191], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}], "keywords": [{"text": "bionik laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.996534}, {"text": "forward-looking statements", "sentiment": {"score": -0.512597, "label": "negative"}, "relevance": 0.951767}, {"text": "inmotion arm", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.882263}, {"text": "cash equivalents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.862998}, {"text": "InMotion ARM therapy", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.852758}, {"text": "company", "sentiment": {"score": 0.0816728, "label": "positive"}, "relevance": 0.836306}, {"text": "quarter", "sentiment": {"score": 0.256846, "label": "positive"}, "relevance": 0.815471}, {"text": "Medical Technology Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.812062}, {"text": "Consolidated Interim Statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.799502}, {"text": "ARM therapy robots", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.797723}, {"text": "Weighted average number", "sentiment": {"score": 0.0516504, "label": "positive"}, "relevance": 0.789908}, {"text": "Condensed Consolidated Interim", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.787468}, {"text": "prior-year quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.783539}, {"text": "InMotion robotic products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.781945}, {"text": "Fair Value Adjustment", "sentiment": {"score": 0.716024, "label": "positive"}, "relevance": 0.781385}, {"text": "deferred revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.781306}, {"text": "InMotion Home product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.781}, {"text": "accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.77972}, {"text": "Quarter Financial Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.778066}, {"text": "next-generation InMotion ARM\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.777322}, {"text": "new InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.77585}, {"text": "InMotion ARM/HAND\u2122 Interactive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.772756}, {"text": "next-generation InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.772032}, {"text": "gross margin", "sentiment": {"score": -0.417995, "label": "negative"}, "relevance": 0.768727}, {"text": "promissory notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.762793}, {"text": "prior-year quarter Sold", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.761637}, {"text": "Nasdaq exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.760851}, {"text": "fiscal second quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759267}, {"text": "comprehensive loss", "sentiment": {"score": -0.436856, "label": "negative"}, "relevance": 0.759255}, {"text": "InMotion robots", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.755182}, {"text": "sales", "sentiment": {"score": 0.500544, "label": "positive"}, "relevance": 0.747858}, {"text": "Net cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.746619}, {"text": "BIONIK Laboratories Corp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.744244}, {"text": "shares", "sentiment": {"score": -0.0283821, "label": "negative"}, "relevance": 0.74297}, {"text": "robotics company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.741643}, {"text": "actual results", "sentiment": {"score": -0.570438, "label": "negative"}, "relevance": 0.74049}, {"text": "fiscal quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.733817}, {"text": "financial statements", "sentiment": {"score": -0.378336, "label": "negative"}, "relevance": 0.731554}, {"text": "related insufficient cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.727625}, {"text": "Corporation Continued development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.727036}, {"text": "Ginger Capital Investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.72537}, {"text": "convertible promissory loans", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.725356}, {"text": "capital structure", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.724847}, {"text": "long-term growth capital", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.724677}, {"text": "non-cash accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.722774}, {"text": "InMotion systems", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.722227}, {"text": "robotic rehabilitation products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.720885}, {"text": "InMotion WRIST\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.720611}, {"text": "common shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.72045}]}, "extracted_metadata": {"sha1": "21a3bf6e484299fdd44a8f9dbf60e616ff244f67", "filename": "1542116519834.zip-8a664f2780c8cdb891c6e5e41e26160d.xml", "file_type": "json"}, "external_links": ["http://www.prnewswire.com/news-releases/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues-300748813.html", "http://www.bioniklabs.com/", "https://blog.bioniklabs.com/news-media/press-releases/detail/44/chinese-fund-invests-in-bionik-laboratories-and-establishes", "http://www.xmlnews.org/ns/", "https://www.linkedin.com/company/bionik-labs/", "http://www.bioniklabs.com/news-media/press-releases/detail/46/bionik-laboratories-and-wistron-corporation-partner-to", "https://www.facebook.com/bioniklab/", "https://twitter.com/bioniklab"], "title": "BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results", "forum_title": "Banking &amp; Financial Services"}, {"id": "HLXgHL5MRjVg1kuhjVwhQUXlfz-iywKR9EN7igpZfBq-gyfPituEEBN4BUxSOlPD", "result_metadata": {"score": 20.672098}, "author": "PRESS RELEASE PR Newswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "147%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Generally Accepted Accounting Principles", "relevance": 0.862373, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}], "categories": [{"score": 0.938954, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Quarter Fiscal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.984225}, {"text": "Financial Results Feature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.868836}, {"text": "Revenues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413235}, {"text": "Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32599}, {"text": "Increase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315121}]}, "crawl_date": "2018-11-13T13:25:58Z", "url": "https://markets.businessinsider.com/news/stocks/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues-1027720149", "host": "markets.businessinsider.com", "text": "Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "main_image_url": "https://mma.prnewswire.com/media/258751/bionik_laboratories_logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T07:31:00-06:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories Corp", "relevance": 0.741748, "type": "Company"}, {"count": 9, "sentiment": {"score": 0.679723, "label": "positive"}, "text": "InMotion", "relevance": 0.611331, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.550115, "label": "positive"}, "text": "US", "relevance": 0.52761, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 7, "sentiment": {"score": 0.685767, "label": "positive"}, "text": "BIONIK", "relevance": 0.50994, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0.563843, "label": "positive"}, "text": "China", "relevance": 0.406613, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 3, "sentiment": {"score": -0.314878, "label": "negative"}, "text": "SEC", "relevance": 0.404898, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eric Dusseux", "relevance": 0.375998, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bionik", "relevance": 0.363945, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.355319, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.354901, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0.716823, "label": "positive"}, "text": "North America", "relevance": 0.342523, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.339095, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "partner", "relevance": 0.338805, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wistron Corporation", "relevance": 0.332137, "type": "Company", "disambiguation": {"subtype": [], "name": "Wistron Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Wistron_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ginger Capital Investment Holding Ltd", "relevance": 0.329902, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Technology Co.", "relevance": 0.325431, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.630342, "label": "positive"}, "text": "State Drug Administration", "relevance": 0.324843, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TORONTO", "relevance": 0.316615, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.31639, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "Cogmedix", "relevance": 0.314063, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "principal", "relevance": 0.312284, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "chief executive officer", "relevance": 0.312174, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.554755, "label": "positive"}, "text": "Twitter", "relevance": 0.299314, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Audrey D. Th\u00e9venon", "relevance": 0.29632, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Charles Matine", "relevance": 0.28156, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BOSTON", "relevance": 0.279016, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Facebook", "relevance": 0.274303, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Facebook", "dbpedia_resource": "http://dbpedia.org/resource/Facebook"}}, {"count": 1, "sentiment": {"score": 0.418092, "label": "positive"}, "text": "LinkedIn", "relevance": 0.263331, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "LinkedIn", "dbpedia_resource": "http://dbpedia.org/resource/LinkedIn"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Six months", "relevance": 0.263331, "type": "Quantity"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.001", "relevance": 0.263331, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Three months", "relevance": 0.263331, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$221,847", "relevance": 0.263331, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$547,085", "relevance": 0.263331, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "2017\n$", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,582,997", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,742,335", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,970,167", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2,750,000", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5,692,853", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six months", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six month", "relevance": 0.263331, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$122,667", "relevance": 0.263331, "type": "Quantity"}], "sentiment": {"document": {"score": 0.530341, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a robotics company", "keywords": [{"text": "robotics company"}], "entities": [{"type": "Company", "text": "BIONIK Laboratories"}]}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "object": {"text": "rehabilitation and assistive technology solutions", "keywords": [{"text": "assistive technology solutions"}, {"text": "rehabilitation"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "financial results", "keywords": [{"text": "financial results"}]}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the second quarter of fiscal year 2019,", "keywords": [{"text": "quarter"}], "entities": []}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "$547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots", "keywords": [{"text": "prior-year quarter Sold"}, {"text": "InMotion robots"}], "entities": [{"type": "Company", "text": "InMotion"}, {"type": "Quantity", "text": "$221,847"}, {"type": "Quantity", "text": "$547,085"}, {"type": "Quantity", "text": "147"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end", "keywords": [{"text": "quarter"}, {"text": "prior-year quarter"}, {"text": "quarter end"}, {"text": "Borrowings"}], "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "$1,742,335", "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "into shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "convert", "tense": "past"}, "text": "were converted", "normalized": "be convert"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000", "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "from the company's Chairman Effected a 1-for-150 reverse stock split on October 29", "keywords": [{"text": "reverse stock split"}, {"text": "Chairman Effected"}, {"text": "company"}], "entities": [{"type": "JobTitle", "text": "Chairman"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000 in convertible promissory loans", "keywords": [{"text": "convertible promissory loans"}], "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Organization", "text": "BIONIK"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "on the quarter", "keywords": [{"text": "quarter"}]}, "action": {"verb": {"text": "Commenting", "tense": "present"}, "text": "Commenting", "normalized": "Commenting"}}, {"subject": {"text": "Eric Dusseux, M.D., BIONIK's chief executive officer,", "keywords": [{"text": "chief executive officer"}, {"text": "Eric Dusseux"}, {"text": "M.D."}, {"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}, {"type": "Organization", "text": "BIONIK"}, {"type": "JobTitle", "text": "chief executive officer"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "Our sales momentum continued during the fiscal second quarter and recent weeks", "keywords": [{"text": "fiscal second quarter"}, {"text": "sales momentum"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Our sales momentum", "keywords": [{"text": "sales momentum"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "I"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "very pleased with the excellent progress we made towards achieving multiple milestones", "keywords": [{"text": "excellent progress"}, {"text": "multiple milestones"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "the excellent progress", "keywords": [{"text": "excellent progress"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "multiple milestones", "keywords": [{"text": "multiple milestones"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "We"}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "seven InMotion systems", "keywords": [{"text": "InMotion systems"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "seven InMotion systems during the quarter", "keywords": [{"text": "InMotion systems"}, {"text": "quarter"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "with five in the first quarter and two in the same quarterly period a year ago", "keywords": [{"text": "quarter"}, {"text": "quarterly period"}], "entities": []}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "our renewed sales efforts on all fronts, from R&D to manufacturing and financing", "keywords": [{"text": "sales efforts"}, {"text": "fronts"}, {"text": "R&D"}, {"text": "financing"}]}, "sentence": " These results clearly reflect our renewed sales efforts on all fronts, from R&D to manufacturing and financing.", "object": {"text": "These results", "keywords": [{"text": "results"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflect", "normalized": "reflect"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "launched the next-generation InMotion ARM in Europe", "keywords": [{"text": "next-generation InMotion ARM"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "the next-generation InMotion ARM", "keywords": [{"text": "next-generation InMotion ARM"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "we"}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the first sale of this product", "keywords": [{"text": "sale"}, {"text": "product"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "object": {"text": "to a facility", "keywords": [{"text": "facility"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "a facility", "keywords": [{"text": "facility"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "We"}, "sentence": " We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "object": {"text": "continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US", "keywords": [{"text": "stroke survivors"}, {"text": "continued sales"}, {"text": "rehabilitation"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "The new InMotion ARM", "keywords": [{"text": "new InMotion ARM"}]}, "sentence": " The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "object": {"text": "with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation", "keywords": [{"text": "mobility impairment"}, {"text": "neurological conditions"}, {"text": "commercial product"}, {"text": "previous generation"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The new version", "keywords": [{"text": "new version"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "a modern design that is smaller", "keywords": [{"text": "modern design"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "a modern design", "keywords": [{"text": "modern design"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "smaller, sleeker", "keywords": [{"text": "sleeker"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "object": {"text": "We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd", "keywords": [{"text": "InMotion ARM therapy"}, {"text": "Ginger Capital Investment"}, {"text": "Medical Technology Co."}, {"text": "joint venture"}], "entities": [{"type": "Person", "text": "Bionik"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Company", "text": "Medical Technology Co."}, {"type": "Person", "text": "Bionik"}, {"type": "Company", "text": "Ginger Capital Investment Holding Ltd"}]}, "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "for testing to support State Drug Administration approval in China", "keywords": [{"text": "Drug Administration approval"}, {"text": "State"}, {"text": "China"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "will be used", "normalized": "will be use"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "State Drug Administration approval", "keywords": [{"text": "Drug Administration approval"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "very excited"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by this progress", "keywords": [{"text": "progress"}]}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "We"}, "action": {"verb": {"text": "excite", "tense": "past"}, "text": "are very excited", "normalized": "be very excite"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China", "keywords": [{"text": "new stroke patients"}, {"text": "rehabilitation"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "hope", "tense": "present"}, "text": "hope", "normalized": "hope"}}, {"subject": {"text": "we"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "rehabilitation", "keywords": [{"text": "rehabilitation"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}, {"subject": {"text": "by advancements with manufacturing partner Cogmedix leading to increased production capacity", "keywords": [{"text": "partner Cogmedix"}, {"text": "production capacity"}, {"text": "advancements"}], "entities": [{"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "Our sales efforts", "keywords": [{"text": "sales efforts"}]}, "action": {"verb": {"text": "support", "tense": "past"}, "text": "are supported", "normalized": "be support"}}, {"subject": {"text": "Cogmedix", "keywords": [{"text": "Cogmedix"}], "entities": [{"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "to increased production capacity", "keywords": [{"text": "production capacity"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "permitting us to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "permit", "tense": "present"}, "text": "is permitting", "normalized": "be permit"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "we took important steps to improve our capital structure and secure long-term growth capital", "keywords": [{"text": "secure long-term growth"}, {"text": "important steps"}, {"text": "capital structure"}]}, "action": {"verb": {"text": "conclude", "tense": "past"}, "text": "concluded", "normalized": "conclude"}}, {"subject": {"text": "we"}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "our capital structure", "keywords": [{"text": "capital structure"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "to improve", "normalized": "to improve"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "a consolidation of shares", "keywords": [{"text": "consolidation"}, {"text": "shares"}]}, "action": {"verb": {"text": "effect", "tense": "past"}, "text": "effected", "normalized": "effect"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "the minimum bid requirement for listing on the Nasdaq exchange", "keywords": [{"text": "minimum bid requirement"}, {"text": "Nasdaq exchange"}, {"text": "listing"}], "entities": []}, "action": {"verb": {"text": "meet", "tense": "future"}, "text": "meeting", "normalized": "meet"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "funds", "keywords": [{"text": "funds"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "to develop our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to continue to develop", "normalized": "to continue to develop"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "to completing"}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "these initiatives", "keywords": [{"text": "initiatives"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "completing", "normalized": "complete"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "important solutions", "keywords": [{"text": "important solutions"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to expect to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "continue", "tense": "present"}, "text": "continues", "normalized": "continue"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "expect", "tense": "future"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "action": {"verb": {"text": "achieve", "tense": "future"}, "text": "continues to expect to achieve", "normalized": "continue to expect to achieve"}}], "concepts": [{"text": "Balance sheet", "relevance": 0.98304, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Generally Accepted Accounting Principles", "relevance": 0.816759, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Asset", "relevance": 0.683493, "dbpedia_resource": "http://dbpedia.org/resource/Asset"}, {"text": "Operating expense", "relevance": 0.626735, "dbpedia_resource": "http://dbpedia.org/resource/Operating_expense"}, {"text": "Income statement", "relevance": 0.614963, "dbpedia_resource": "http://dbpedia.org/resource/Income_statement"}, {"text": "Corporate finance", "relevance": 0.605904, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Fiscal year", "relevance": 0.587293, "dbpedia_resource": "http://dbpedia.org/resource/Fiscal_year"}, {"text": "Expense", "relevance": 0.529756, "dbpedia_resource": "http://dbpedia.org/resource/Expense"}, {"text": "Inventory", "relevance": 0.492993, "dbpedia_resource": "http://dbpedia.org/resource/Inventory"}, {"text": "Liability", "relevance": 0.441831, "dbpedia_resource": "http://dbpedia.org/resource/Liability_(financial_accounting)"}, {"text": "Shares authorized", "relevance": 0.430326, "dbpedia_resource": "http://dbpedia.org/resource/Shares_authorized"}, {"text": "Gross profit", "relevance": 0.411843, "dbpedia_resource": "http://dbpedia.org/resource/Gross_profit"}, {"text": "Stock", "relevance": 0.36094, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Revenue", "relevance": 0.358873, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Finance", "relevance": 0.358481, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Preferred stock", "relevance": 0.327815, "dbpedia_resource": "http://dbpedia.org/resource/Preferred_stock"}, {"text": "2010s", "relevance": 0.326528, "dbpedia_resource": "http://dbpedia.org/resource/2010s"}, {"text": "Stock market", "relevance": 0.320101, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.599217, "label": "/finance/financial news"}, {"score": 0.449893, "label": "/finance/investing"}, {"score": 0.449893, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.562025, "arguments": [{"text": "individuals", "location": [215, 226], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [232, 244], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "hasAttribute", "sentence": "About BIONIK Laboratories Corp. BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home.", "score": 0.562025, "arguments": [{"text": "individuals", "location": [7770, 7781], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [7787, 7799], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.34374, "arguments": [{"text": "directors", "location": [1175, 1184], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "board", "location": [1166, 1171], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "hasAttribute", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.40699, "arguments": [{"text": "investors", "location": [1658, 1667], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "$2,750,000", "location": [1677, 1687], "entities": [{"type": "Money", "text": "$2,750,000"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.804912, "arguments": [{"text": "Chairman", "location": [1750, 1758], "entities": [{"type": "Person", "text": "Effected"}]}, {"text": "company", "location": [1740, 1747], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.73019, "arguments": [{"text": "chief executive officer", "location": [1962, 1985], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "BIONIK", "location": [1953, 1959], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "locatedAt", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.485132, "arguments": [{"text": "We", "location": [2424, 2426], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "InMotion", "location": [2465, 2473], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "agentOf", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.933804, "arguments": [{"text": "we", "location": [2525, 2527], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "announced", "location": [2537, 2546], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.946332, "arguments": [{"text": "facility", "location": [2588, 2596], "entities": [{"type": "Facility", "text": "manufacturing facility"}]}, {"text": "France", "location": [2600, 2606], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "score": 0.386238, "arguments": [{"text": "survivors", "location": [2756, 2765], "entities": [{"type": "Person", "text": "survivors"}]}, {"text": "US", "location": [2778, 2780], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "score": 0.666528, "arguments": [{"text": "InMotion", "location": [2790, 2798], "entities": [{"type": "Person", "text": "InMotion robots"}]}, {"text": "ARM", "location": [2799, 2802], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}]}, {"type": "agentOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.995926, "arguments": [{"text": "Dusseux", "location": [3137, 3144], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "continued", "location": [3145, 3154], "entities": [{"type": "EventCommunication", "text": "continued"}]}]}, {"type": "timeOf", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.664948, "arguments": [{"text": "today", "location": [292, 297], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [298, 307], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.482106, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3246, 3274], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BIONIK", "location": [3229, 3235], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.698726, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3246, 3274], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [3238, 3243], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.852432, "arguments": [{"text": "patients", "location": [3588, 3596], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [3581, 3587], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.591839, "arguments": [{"text": "patients", "location": [3588, 3596], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "China", "location": [3610, 3615], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "score": 0.736435, "arguments": [{"text": "Cogmedix", "location": [3694, 3702], "entities": [{"type": "Person", "text": "Cogmedix"}]}, {"text": "partner", "location": [3686, 3693], "entities": [{"type": "GeopoliticalEntity", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "agentOf", "sentence": "\" Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "score": 0.998234, "arguments": [{"text": "Dusseux", "location": [3854, 3861], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "concluded", "location": [3862, 3871], "entities": [{"type": "EventCommunication", "text": "concluded"}]}]}, {"type": "locatedAt", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.886308, "arguments": [{"text": "InMotion WRIST\u2122", "location": [4659, 4674], "entities": [{"type": "Person", "text": "InMotion WRIST\u2122"}]}, {"text": "hospitals", "location": [4705, 4714], "entities": [{"type": "Organization", "text": "manufacturing facility"}]}]}, {"type": "agentOf", "sentence": "The Company reported a comprehensive loss for the quarter ended September 30, 2018 of $(3,983,105) , or a loss per share of $(1.62) , compared with a comprehensive loss of $(3,615,361) , or a loss per share of $(5.33) , for the quarter ended September 30, 2017 .", "score": 0.886256, "arguments": [{"text": "Company", "location": [6444, 6451], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "reported", "location": [6452, 6460], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.", "score": 0.655292, "arguments": [{"text": "patients", "location": [7978, 7986], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [7943, 7949], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "partOf", "sentence": "For more information, please visit www.BIONIKlabs.com and connect with us on Twitter , LinkedIn , and Facebook .", "score": 0.453554, "arguments": [{"text": "Twitter", "location": [8156, 8163], "entities": [{"type": "Organization", "text": "Twitter"}]}, {"text": "LinkedIn", "location": [8166, 8174], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.835171, "arguments": [{"text": "ARM", "location": [616, 619], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [607, 615], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.787644, "arguments": [{"text": "ARM", "location": [2474, 2477], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [2465, 2473], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.732993, "arguments": [{"text": "ARM", "location": [3183, 3186], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [3174, 3182], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.881539, "arguments": [{"text": "ARM/HAND\u2122 Interactive Therapy System", "location": [4618, 4654], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [4609, 4617], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "partOf", "sentence": "Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control.", "score": 0.421104, "arguments": [{"text": "Company", "location": [9857, 9864], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "which", "location": [9847, 9852], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "These and other factors are identified and described in more detail in the Company's filings with the SEC.", "score": 0.586541, "arguments": [{"text": "Company", "location": [10925, 10932], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "SEC", "location": [10952, 10955], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "locatedAt", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.771425, "arguments": [{"text": "Dollars", "location": [11129, 11136], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "US", "location": [11126, 11128], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.699858, "arguments": [{"text": "Dollars", "location": [12861, 12868], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [12856, 12860], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.788373, "arguments": [{"text": "Dollars", "location": [14484, 14491], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [14479, 14483], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.425193, "arguments": [{"text": "Total Assets", "location": [11649, 11661], "entities": [{"type": "Organization", "text": "Total Assets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Goodwill", "location": [11618, 11626], "entities": [{"type": "Organization", "text": "Goodwill"}]}]}, {"type": "partOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.613876, "arguments": [{"text": "Authorized", "location": [12113, 12123], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}, {"text": "Authorized", "location": [12041, 12051], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}]}, {"type": "agentOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.980693, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [12655, 12711], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [12712, 12722], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.984382, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [14302, 14358], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [14359, 14369], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "employedBy", "sentence": "Three months Six months Three months Six months ended ended ended ended September 30, 2018 September 30, 2018 September 30, 2017 September 30, 2017 $ $ $ $ Sales 547,085 1,048,418 221,847 309,367 Cost of Sales 384,073 637,236 59,825 89,125 Gross Margin 163,012 411,182 162,022 220,242 Operating expenses Sales and marketing 427,325 969,984 435,294 880,817 Research and development 679,049 1,355,792 715,400 1,401,309 General and administrative 931,477 1,910,956 1,505,528 2,133,134 Share-based compensation expense 439,328 1,034,740 762,208 1,013,256 Amortization 69,315 140,368 76,985 169,934 Depreciation 16,626 34,221 23,820 48,372 Total operating expenses 2,563,120 5,446,061 3,519,235 5,646,822 Other (income) expenses Foreign exchange (27,872) (69,006) 15,595 114,156 Accretion expense 1,970,167 2,104,418 74,073 74,073 Fair Value Adjustment (382,010) (337,923) - - Gain on mark to market reevaluation - (2,048,697) - -", "score": 0.395149, "arguments": [{"text": "Accretion", "location": [13644, 13653], "entities": [{"type": "Person", "text": "Accretion"}]}, {"text": "Fair Value Adjustment", "location": [13696, 13717], "entities": [{"type": "Organization", "text": "Fair Value Adjustment"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.698989, "arguments": [{"text": "Cash Flows", "location": [14373, 14383], "entities": [{"type": "Person", "text": "Cash Flows"}]}, {"text": "Statements", "location": [14359, 14369], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "timeOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.604194, "arguments": [{"text": "September 30, 2018", "location": [14417, 14435], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "Statements", "location": [14359, 14369], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "agentOf", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.980082, "arguments": [{"text": "Repayment of Demand", "location": [15788, 15807], "entities": [{"type": "Organization", "text": "Repayment of Demand"}]}, {"text": "notes", "location": [15808, 15813], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.809587, "arguments": [{"text": "independent", "location": [1092, 1103], "entities": [{"type": "Person", "text": "independent"}]}, {"text": "Appointed", "location": [1082, 1091], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "affectedBy", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.528311, "arguments": [{"text": "principal", "location": [15814, 15823], "entities": [{"type": "Person", "text": "principal"}]}, {"text": "notes", "location": [15808, 15813], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.792025, "arguments": [{"text": "September 30, 2018", "location": [16409, 16427], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "filed", "location": [16428, 16433], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.706518, "arguments": [{"text": "10-Q", "location": [16442, 16446], "entities": [{"type": "Date", "text": "10-Q"}]}, {"text": "filed", "location": [16428, 16433], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.867538, "arguments": [{"text": "Company", "location": [16605, 16612], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "Annual Report", "location": [16615, 16628], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.437868, "arguments": [{"text": "Annual Report", "location": [16615, 16628], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Form", "location": [16632, 16636], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.854838, "arguments": [{"text": "Form", "location": [16632, 16636], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "filed", "location": [16642, 16647], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "affectedBy", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.354072, "arguments": [{"text": "SEC", "location": [16657, 16660], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "filed", "location": [16642, 16647], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.515736, "arguments": [{"text": "June 27, 2018", "location": [16664, 16677], "entities": [{"type": "Date", "text": "June 27, 2018"}]}, {"text": "filed", "location": [16642, 16647], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "managerOf", "sentence": "View original content to download multimedia: https://www.prnewswire.com/news-releases/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues-300748813.html SOURCE BIONIK Laboratories Corp.", "score": 0.33696, "arguments": [{"text": "SOURCE", "location": [17170, 17176], "entities": [{"type": "Person", "text": "SOURCE"}]}, {"text": "BIONIK Laboratories Corp.", "location": [17177, 17202], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.529991, "arguments": [{"text": "directors", "location": [1104, 1113], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Appointed", "location": [1082, 1091], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.860788, "arguments": [{"text": "Audrey D. Th\u00e9venon", "location": [1114, 1132], "entities": [{"type": "Person", "text": "Audrey D. Th\u00e9venon"}]}, {"text": "directors", "location": [1104, 1113], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.788308, "arguments": [{"text": "Ph.D.", "location": [1134, 1139], "entities": [{"type": "Person", "text": "Ph.D."}]}, {"text": "directors", "location": [1104, 1113], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.481698, "arguments": [{"text": "Charles Matine", "location": [1144, 1158], "entities": [{"type": "Person", "text": "Charles Matine"}]}, {"text": "board", "location": [1166, 1171], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "partOf", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.814686, "arguments": [{"text": "board", "location": [1166, 1171], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "its", "location": [1162, 1165], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}], "keywords": [{"text": "bionik laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.915252}, {"text": "forward-looking statements", "sentiment": {"score": -0.512597, "label": "negative"}, "relevance": 0.850391}, {"text": "inmotion arm", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.781261}, {"text": "cash equivalents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.761992}, {"text": "InMotion ARM therapy", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.752038}, {"text": "company", "sentiment": {"score": 0.0816728, "label": "positive"}, "relevance": 0.734773}, {"text": "quarter", "sentiment": {"score": 0.256846, "label": "positive"}, "relevance": 0.714131}, {"text": "Medical Technology Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.711225}, {"text": "Consolidated Interim Statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.698879}, {"text": "ARM therapy robots", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.696975}, {"text": "Weighted average number", "sentiment": {"score": 0.0516504, "label": "positive"}, "relevance": 0.689149}, {"text": "Condensed Consolidated Interim", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.686751}, {"text": "prior-year quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.68299}, {"text": "InMotion robotic products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.681627}, {"text": "Fair Value Adjustment", "sentiment": {"score": 0.716024, "label": "positive"}, "relevance": 0.680684}, {"text": "InMotion Home product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680637}, {"text": "deferred revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680509}, {"text": "accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.679021}, {"text": "Quarter Financial Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.677777}, {"text": "next-generation InMotion ARM\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.676896}, {"text": "new InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.675505}, {"text": "InMotion ARM/HAND\u2122 Interactive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672348}, {"text": "next-generation InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.671657}, {"text": "gross margin", "sentiment": {"score": -0.417995, "label": "negative"}, "relevance": 0.667997}, {"text": "promissory notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662165}, {"text": "prior-year quarter Sold", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.661274}, {"text": "Nasdaq exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.660188}, {"text": "fiscal second quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.658963}, {"text": "comprehensive loss", "sentiment": {"score": -0.436856, "label": "negative"}, "relevance": 0.658699}, {"text": "InMotion robots", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.65483}, {"text": "sales", "sentiment": {"score": 0.500544, "label": "positive"}, "relevance": 0.646937}, {"text": "BIONIK Laboratories Corp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.643932}, {"text": "Net cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.643686}, {"text": "shares", "sentiment": {"score": -0.028382, "label": "negative"}, "relevance": 0.642092}, {"text": "robotics company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641263}, {"text": "actual results", "sentiment": {"score": -0.570438, "label": "negative"}, "relevance": 0.639918}, {"text": "fiscal quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.633661}, {"text": "financial statements", "sentiment": {"score": -0.378336, "label": "negative"}, "relevance": 0.631187}, {"text": "related insufficient cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627311}, {"text": "Corporation Continued development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626639}, {"text": "Ginger Capital Investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624969}, {"text": "convertible promissory loans", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624968}, {"text": "capital structure", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.624419}, {"text": "long-term growth capital", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.624259}, {"text": "non-cash accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622399}, {"text": "InMotion systems", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622026}, {"text": "robotic rehabilitation products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620602}, {"text": "InMotion WRIST\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620396}, {"text": "common shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620075}]}, "extracted_metadata": {"sha1": "c4f5b369194478250e09df1a6f9daaf7decbf8c0", "filename": "1542115558870.zip-7b70a45367974e7aa1c06ecf3bc3cf65.xml", "file_type": "json"}, "external_links": ["https://www.bioniklabs.com/", "https://blog.bioniklabs.com/news-media/press-releases/detail/44/chinese-fund-invests-in-bionik-laboratories-and-establishes", "https://www.prnewswire.com/news-releases/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues-300748813.html", "https://www.linkedin.com/company/bionik-labs/", "https://www.bioniklabs.com/news-media/press-releases/detail/46/bionik-laboratories-and-wistron-corporation-partner-to", "https://www.facebook.com/bioniklab/", "https://twitter.com/bioniklab"], "title": "BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results Feature 147% Increase in Revenues", "forum_title": "Stock Market News | Financial &amp; Business News | Markets Insider"}, {"id": "0R4hDHcdfcl-WCgPkVYgvsBReIe_ie8SJBsqD4nX70VwyaXsOMPwgrCPpIXEgG5h", "result_metadata": {"score": 20.663488}, "author": "BIONIK Laboratories Corp.", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "147%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Generally Accepted Accounting Principles", "relevance": 0.862373, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}], "categories": [{"score": 0.938954, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Quarter Fiscal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.984225}, {"text": "Financial Results Feature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.868836}, {"text": "Revenues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413235}, {"text": "Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32599}, {"text": "Increase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315121}]}, "crawl_date": "2018-11-13T12:37:32Z", "url": "https://www.prnewswire.com:443/news-releases/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues-300748813.html", "host": "prnewswire.com", "text": "Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "main_image_url": "https://mma.prnewswire.com/media/258751/bionik_laboratories_logo.jpg?p=facebook", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T12:31:00Z", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories Corp", "relevance": 0.867967, "type": "Company"}, {"count": 9, "sentiment": {"score": 0.679723, "label": "positive"}, "text": "InMotion", "relevance": 0.816127, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.550115, "label": "positive"}, "text": "US", "relevance": 0.703544, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 7, "sentiment": {"score": 0.685767, "label": "positive"}, "text": "BIONIK", "relevance": 0.680279, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0.563843, "label": "positive"}, "text": "China", "relevance": 0.542292, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 3, "sentiment": {"score": -0.314878, "label": "negative"}, "text": "SEC", "relevance": 0.539914, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BOSTON BIONIK Laboratories Corp", "relevance": 0.50566, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eric Dusseux", "relevance": 0.501468, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bionik", "relevance": 0.485533, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.474097, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.473264, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0.716823, "label": "positive"}, "text": "North America", "relevance": 0.45675, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.452216, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "partner", "relevance": 0.451799, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wistron Corporation", "relevance": 0.442955, "type": "Company", "disambiguation": {"subtype": [], "name": "Wistron Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Wistron_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ginger Capital Investment Holding Ltd", "relevance": 0.440196, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Technology Co.", "relevance": 0.434027, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.630342, "label": "positive"}, "text": "State Drug Administration", "relevance": 0.433184, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TORONTO", "relevance": 0.422163, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.421943, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "Cogmedix", "relevance": 0.418814, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "chief executive officer", "relevance": 0.416335, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "principal", "relevance": 0.416304, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.554755, "label": "positive"}, "text": "Twitter", "relevance": 0.399086, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Audrey D. Th\u00e9venon", "relevance": 0.395211, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Charles Matine", "relevance": 0.375516, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Facebook", "relevance": 0.365739, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Facebook", "dbpedia_resource": "http://dbpedia.org/resource/Facebook"}}, {"count": 1, "sentiment": {"score": 0.418092, "label": "positive"}, "text": "LinkedIn", "relevance": 0.351118, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "LinkedIn", "dbpedia_resource": "http://dbpedia.org/resource/LinkedIn"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Six months", "relevance": 0.351118, "type": "Quantity"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.001", "relevance": 0.351118, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Three months", "relevance": 0.351118, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$221,847", "relevance": 0.351118, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$547,085", "relevance": 0.351118, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "2017\n$", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,582,997", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,742,335", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,970,167", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2,750,000", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5,692,853", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six months", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six month", "relevance": 0.351118, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$122,667", "relevance": 0.351118, "type": "Quantity"}], "sentiment": {"document": {"score": 0.549393, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a robotics company", "keywords": [{"text": "robotics company"}], "entities": [{"type": "Company", "text": "BIONIK Laboratories"}]}, "sentence": "TORONTO and BOSTON BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "object": {"text": "rehabilitation and assistive technology solutions", "keywords": [{"text": "assistive technology solutions"}, {"text": "rehabilitation"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "financial results", "keywords": [{"text": "financial results"}]}, "sentence": "TORONTO and BOSTON BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the second quarter of fiscal year 2019,", "keywords": [{"text": "quarter"}], "entities": []}, "sentence": "TORONTO and BOSTON BIONIK Laboratories Corp . (OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "$547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots", "keywords": [{"text": "prior-year quarter Sold"}, {"text": "InMotion robots"}], "entities": [{"type": "Company", "text": "InMotion"}, {"type": "Quantity", "text": "$221,847"}, {"type": "Quantity", "text": "$547,085"}, {"type": "Quantity", "text": "147"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end", "keywords": [{"text": "quarter"}, {"text": "prior-year quarter"}, {"text": "quarter end"}, {"text": "Borrowings"}], "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "$1,742,335", "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "into shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "convert", "tense": "past"}, "text": "were converted", "normalized": "be convert"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000", "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "from the company's Chairman Effected a 1-for-150 reverse stock split on October 29", "keywords": [{"text": "reverse stock split"}, {"text": "Chairman Effected"}, {"text": "company"}], "entities": [{"type": "JobTitle", "text": "Chairman"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000 in convertible promissory loans", "keywords": [{"text": "convertible promissory loans"}], "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Organization", "text": "BIONIK"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "on the quarter", "keywords": [{"text": "quarter"}]}, "action": {"verb": {"text": "Commenting", "tense": "present"}, "text": "Commenting", "normalized": "Commenting"}}, {"subject": {"text": "Eric Dusseux, M.D., BIONIK's chief executive officer,", "keywords": [{"text": "chief executive officer"}, {"text": "Eric Dusseux"}, {"text": "M.D."}, {"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}, {"type": "Organization", "text": "BIONIK"}, {"type": "JobTitle", "text": "chief executive officer"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "Our sales momentum continued during the fiscal second quarter and recent weeks", "keywords": [{"text": "fiscal second quarter"}, {"text": "sales momentum"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Our sales momentum", "keywords": [{"text": "sales momentum"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "I"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "very pleased with the excellent progress we made towards achieving multiple milestones", "keywords": [{"text": "excellent progress"}, {"text": "multiple milestones"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "the excellent progress", "keywords": [{"text": "excellent progress"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "multiple milestones", "keywords": [{"text": "multiple milestones"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "We"}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "seven InMotion systems", "keywords": [{"text": "InMotion systems"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "seven InMotion systems during the quarter", "keywords": [{"text": "InMotion systems"}, {"text": "quarter"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "with five in the first quarter and two in the same quarterly period a year ago", "keywords": [{"text": "quarter"}, {"text": "quarterly period"}], "entities": []}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "our renewed sales efforts on all fronts, from R&D to manufacturing and financing", "keywords": [{"text": "sales efforts"}, {"text": "fronts"}, {"text": "R&D"}, {"text": "financing"}]}, "sentence": " These results clearly reflect our renewed sales efforts on all fronts, from R&D to manufacturing and financing.", "object": {"text": "These results", "keywords": [{"text": "results"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflect", "normalized": "reflect"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "launched the next-generation InMotion ARM in Europe", "keywords": [{"text": "next-generation InMotion ARM"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "the next-generation InMotion ARM", "keywords": [{"text": "next-generation InMotion ARM"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "we"}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the first sale of this product", "keywords": [{"text": "sale"}, {"text": "product"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "object": {"text": "to a facility", "keywords": [{"text": "facility"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "a facility", "keywords": [{"text": "facility"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "We"}, "sentence": " We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "object": {"text": "continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US", "keywords": [{"text": "stroke survivors"}, {"text": "continued sales"}, {"text": "rehabilitation"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "The new InMotion ARM", "keywords": [{"text": "new InMotion ARM"}]}, "sentence": " The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "object": {"text": "with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation", "keywords": [{"text": "mobility impairment"}, {"text": "neurological conditions"}, {"text": "commercial product"}, {"text": "previous generation"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The new version", "keywords": [{"text": "new version"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "a modern design that is smaller", "keywords": [{"text": "modern design"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "a modern design", "keywords": [{"text": "modern design"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "smaller, sleeker", "keywords": [{"text": "sleeker"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "object": {"text": "We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd", "keywords": [{"text": "InMotion ARM therapy"}, {"text": "Ginger Capital Investment"}, {"text": "Medical Technology Co."}, {"text": "joint venture"}], "entities": [{"type": "Person", "text": "Bionik"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Company", "text": "Medical Technology Co."}, {"type": "Person", "text": "Bionik"}, {"type": "Company", "text": "Ginger Capital Investment Holding Ltd"}]}, "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "for testing to support State Drug Administration approval in China", "keywords": [{"text": "Drug Administration approval"}, {"text": "State"}, {"text": "China"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "will be used", "normalized": "will be use"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "State Drug Administration approval", "keywords": [{"text": "Drug Administration approval"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "very excited"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by this progress", "keywords": [{"text": "progress"}]}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "We"}, "action": {"verb": {"text": "excite", "tense": "past"}, "text": "are very excited", "normalized": "be very excite"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China", "keywords": [{"text": "new stroke patients"}, {"text": "rehabilitation"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "hope", "tense": "present"}, "text": "hope", "normalized": "hope"}}, {"subject": {"text": "we"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "rehabilitation", "keywords": [{"text": "rehabilitation"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}, {"subject": {"text": "by advancements with manufacturing partner Cogmedix leading to increased production capacity", "keywords": [{"text": "partner Cogmedix"}, {"text": "production capacity"}, {"text": "advancements"}], "entities": [{"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "Our sales efforts", "keywords": [{"text": "sales efforts"}]}, "action": {"verb": {"text": "support", "tense": "past"}, "text": "are supported", "normalized": "be support"}}, {"subject": {"text": "Cogmedix", "keywords": [{"text": "Cogmedix"}], "entities": [{"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "to increased production capacity", "keywords": [{"text": "production capacity"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "permitting us to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "permit", "tense": "present"}, "text": "is permitting", "normalized": "be permit"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "we took important steps to improve our capital structure and secure long-term growth capital", "keywords": [{"text": "secure long-term growth"}, {"text": "important steps"}, {"text": "capital structure"}]}, "action": {"verb": {"text": "conclude", "tense": "past"}, "text": "concluded", "normalized": "conclude"}}, {"subject": {"text": "we"}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "our capital structure", "keywords": [{"text": "capital structure"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "to improve", "normalized": "to improve"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "a consolidation of shares", "keywords": [{"text": "consolidation"}, {"text": "shares"}]}, "action": {"verb": {"text": "effect", "tense": "past"}, "text": "effected", "normalized": "effect"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "the minimum bid requirement for listing on the Nasdaq exchange", "keywords": [{"text": "minimum bid requirement"}, {"text": "Nasdaq exchange"}, {"text": "listing"}], "entities": []}, "action": {"verb": {"text": "meet", "tense": "future"}, "text": "meeting", "normalized": "meet"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "funds", "keywords": [{"text": "funds"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "to develop our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to continue to develop", "normalized": "to continue to develop"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "to completing"}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "these initiatives", "keywords": [{"text": "initiatives"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "completing", "normalized": "complete"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "important solutions", "keywords": [{"text": "important solutions"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to expect to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "continue", "tense": "present"}, "text": "continues", "normalized": "continue"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "expect", "tense": "future"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "action": {"verb": {"text": "achieve", "tense": "future"}, "text": "continues to expect to achieve", "normalized": "continue to expect to achieve"}}], "concepts": [{"text": "Balance sheet", "relevance": 0.984899, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Generally Accepted Accounting Principles", "relevance": 0.821045, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Asset", "relevance": 0.686007, "dbpedia_resource": "http://dbpedia.org/resource/Asset"}, {"text": "Operating expense", "relevance": 0.627905, "dbpedia_resource": "http://dbpedia.org/resource/Operating_expense"}, {"text": "Income statement", "relevance": 0.617901, "dbpedia_resource": "http://dbpedia.org/resource/Income_statement"}, {"text": "Corporate finance", "relevance": 0.609764, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Fiscal year", "relevance": 0.587302, "dbpedia_resource": "http://dbpedia.org/resource/Fiscal_year"}, {"text": "Expense", "relevance": 0.531292, "dbpedia_resource": "http://dbpedia.org/resource/Expense"}, {"text": "Inventory", "relevance": 0.494399, "dbpedia_resource": "http://dbpedia.org/resource/Inventory"}, {"text": "Liability", "relevance": 0.443652, "dbpedia_resource": "http://dbpedia.org/resource/Liability_(financial_accounting)"}, {"text": "Shares authorized", "relevance": 0.430342, "dbpedia_resource": "http://dbpedia.org/resource/Shares_authorized"}, {"text": "Gross profit", "relevance": 0.412707, "dbpedia_resource": "http://dbpedia.org/resource/Gross_profit"}, {"text": "Stock", "relevance": 0.36331, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Finance", "relevance": 0.360877, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Revenue", "relevance": 0.360389, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Preferred stock", "relevance": 0.329024, "dbpedia_resource": "http://dbpedia.org/resource/Preferred_stock"}, {"text": "2010s", "relevance": 0.327697, "dbpedia_resource": "http://dbpedia.org/resource/2010s"}, {"text": "Stock market", "relevance": 0.321143, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.597546, "label": "/finance/financial news"}, {"score": 0.450754, "label": "/finance/investing"}, {"score": 0.450754, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "basedIn", "sentence": "TORONTO and BOSTON BIONIK Laboratories Corp .", "score": 0.812657, "arguments": [{"text": "BIONIK Laboratories Corp", "location": [19, 43], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "BOSTON", "location": [12, 18], "entities": [{"type": "GeopoliticalEntity", "text": "BOSTON"}]}]}, {"type": "partOf", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.814686, "arguments": [{"text": "board", "location": [1134, 1139], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "its", "location": [1130, 1133], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.34374, "arguments": [{"text": "directors", "location": [1143, 1152], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "board", "location": [1134, 1139], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "hasAttribute", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.40699, "arguments": [{"text": "investors", "location": [1626, 1635], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "$2,750,000", "location": [1645, 1655], "entities": [{"type": "Money", "text": "$2,750,000"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.804912, "arguments": [{"text": "Chairman", "location": [1718, 1726], "entities": [{"type": "Person", "text": "Effected"}]}, {"text": "company", "location": [1708, 1715], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.73019, "arguments": [{"text": "chief executive officer", "location": [1930, 1953], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "BIONIK", "location": [1921, 1927], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "locatedAt", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.485132, "arguments": [{"text": "We", "location": [2392, 2394], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "InMotion", "location": [2433, 2441], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "agentOf", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.933804, "arguments": [{"text": "we", "location": [2493, 2495], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "announced", "location": [2505, 2514], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.946332, "arguments": [{"text": "facility", "location": [2556, 2564], "entities": [{"type": "Facility", "text": "manufacturing facility"}]}, {"text": "France", "location": [2568, 2574], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "score": 0.386238, "arguments": [{"text": "survivors", "location": [2724, 2733], "entities": [{"type": "Person", "text": "survivors"}]}, {"text": "US", "location": [2746, 2748], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "score": 0.666528, "arguments": [{"text": "InMotion", "location": [2758, 2766], "entities": [{"type": "Person", "text": "InMotion robots"}]}, {"text": "ARM", "location": [2767, 2770], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}]}, {"type": "hasAttribute", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.562025, "arguments": [{"text": "individuals", "location": [183, 194], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [200, 212], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "hasAttribute", "sentence": "About BIONIK Laboratories Corp. BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home.", "score": 0.562025, "arguments": [{"text": "individuals", "location": [7738, 7749], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [7755, 7767], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "agentOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.995926, "arguments": [{"text": "Dusseux", "location": [3105, 3112], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "continued", "location": [3113, 3122], "entities": [{"type": "EventCommunication", "text": "continued"}]}]}, {"type": "partOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.482106, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3214, 3242], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BIONIK", "location": [3197, 3203], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.698726, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3214, 3242], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [3206, 3211], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.852432, "arguments": [{"text": "patients", "location": [3556, 3564], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [3549, 3555], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.591839, "arguments": [{"text": "patients", "location": [3556, 3564], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "China", "location": [3578, 3583], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "score": 0.736435, "arguments": [{"text": "Cogmedix", "location": [3662, 3670], "entities": [{"type": "Person", "text": "Cogmedix"}]}, {"text": "partner", "location": [3654, 3661], "entities": [{"type": "GeopoliticalEntity", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "agentOf", "sentence": "\" Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "score": 0.998234, "arguments": [{"text": "Dusseux", "location": [3822, 3829], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "concluded", "location": [3830, 3839], "entities": [{"type": "EventCommunication", "text": "concluded"}]}]}, {"type": "locatedAt", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.886308, "arguments": [{"text": "InMotion WRIST\u2122", "location": [4627, 4642], "entities": [{"type": "Person", "text": "InMotion WRIST\u2122"}]}, {"text": "hospitals", "location": [4673, 4682], "entities": [{"type": "Organization", "text": "manufacturing facility"}]}]}, {"type": "agentOf", "sentence": "The Company reported a comprehensive loss for the quarter ended September 30, 2018 of $(3,983,105) , or a loss per share of $(1.62) , compared with a comprehensive loss of $(3,615,361) , or a loss per share of $(5.33) , for the quarter ended September 30, 2017 .", "score": 0.886256, "arguments": [{"text": "Company", "location": [6412, 6419], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "reported", "location": [6420, 6428], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.", "score": 0.655292, "arguments": [{"text": "patients", "location": [7946, 7954], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [7911, 7917], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "timeOf", "sentence": "(OTCQB: BNKLD) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.664948, "arguments": [{"text": "today", "location": [260, 265], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [266, 275], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "For more information, please visit www.BIONIKlabs.com and connect with us on Twitter , LinkedIn , and Facebook .", "score": 0.453554, "arguments": [{"text": "Twitter", "location": [8124, 8131], "entities": [{"type": "Organization", "text": "Twitter"}]}, {"text": "LinkedIn", "location": [8134, 8142], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control.", "score": 0.421104, "arguments": [{"text": "Company", "location": [9825, 9832], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "which", "location": [9815, 9820], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "These and other factors are identified and described in more detail in the Company's filings with the SEC.", "score": 0.586541, "arguments": [{"text": "Company", "location": [10893, 10900], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "SEC", "location": [10920, 10923], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "locatedAt", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.771425, "arguments": [{"text": "Dollars", "location": [11097, 11104], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "US", "location": [11094, 11096], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.699858, "arguments": [{"text": "Dollars", "location": [12829, 12836], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [12824, 12828], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.788373, "arguments": [{"text": "Dollars", "location": [14452, 14459], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [14447, 14451], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.425193, "arguments": [{"text": "Total Assets", "location": [11617, 11629], "entities": [{"type": "Organization", "text": "Total Assets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Goodwill", "location": [11586, 11594], "entities": [{"type": "Organization", "text": "Goodwill"}]}]}, {"type": "partOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.613876, "arguments": [{"text": "Authorized", "location": [12081, 12091], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}, {"text": "Authorized", "location": [12009, 12019], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}]}, {"type": "agentOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.980693, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [12623, 12679], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [12680, 12690], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.984382, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [14270, 14326], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [14327, 14337], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "employedBy", "sentence": "Three months Six months Three months Six months ended ended ended ended September 30, 2018 September 30, 2018 September 30, 2017 September 30, 2017 $ $ $ $ Sales 547,085 1,048,418 221,847 309,367 Cost of Sales 384,073 637,236 59,825 89,125 Gross Margin 163,012 411,182 162,022 220,242 Operating expenses Sales and marketing 427,325 969,984 435,294 880,817 Research and development 679,049 1,355,792 715,400 1,401,309 General and administrative 931,477 1,910,956 1,505,528 2,133,134 Share-based compensation expense 439,328 1,034,740 762,208 1,013,256 Amortization 69,315 140,368 76,985 169,934 Depreciation 16,626 34,221 23,820 48,372 Total operating expenses 2,563,120 5,446,061 3,519,235 5,646,822 Other (income) expenses Foreign exchange (27,872) (69,006) 15,595 114,156 Accretion expense 1,970,167 2,104,418 74,073 74,073 Fair Value Adjustment (382,010) (337,923) - - Gain on mark to market reevaluation - (2,048,697) - -", "score": 0.395149, "arguments": [{"text": "Accretion", "location": [13612, 13621], "entities": [{"type": "Person", "text": "Accretion"}]}, {"text": "Fair Value Adjustment", "location": [13664, 13685], "entities": [{"type": "Organization", "text": "Fair Value Adjustment"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.698989, "arguments": [{"text": "Cash Flows", "location": [14341, 14351], "entities": [{"type": "Person", "text": "Cash Flows"}]}, {"text": "Statements", "location": [14327, 14337], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "timeOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.604194, "arguments": [{"text": "September 30, 2018", "location": [14385, 14403], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "Statements", "location": [14327, 14337], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "basedIn", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.835171, "arguments": [{"text": "ARM", "location": [584, 587], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [575, 583], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.787644, "arguments": [{"text": "ARM", "location": [2442, 2445], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [2433, 2441], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.732993, "arguments": [{"text": "ARM", "location": [3151, 3154], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [3142, 3150], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.881539, "arguments": [{"text": "ARM/HAND\u2122 Interactive Therapy System", "location": [4586, 4622], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [4577, 4585], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "agentOf", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.980082, "arguments": [{"text": "Repayment of Demand", "location": [15756, 15775], "entities": [{"type": "Organization", "text": "Repayment of Demand"}]}, {"text": "notes", "location": [15776, 15781], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "affectedBy", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.528311, "arguments": [{"text": "principal", "location": [15782, 15791], "entities": [{"type": "Person", "text": "principal"}]}, {"text": "notes", "location": [15776, 15781], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.792025, "arguments": [{"text": "September 30, 2018", "location": [16377, 16395], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "filed", "location": [16396, 16401], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.706518, "arguments": [{"text": "10-Q", "location": [16410, 16414], "entities": [{"type": "Date", "text": "10-Q"}]}, {"text": "filed", "location": [16396, 16401], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.867538, "arguments": [{"text": "Company", "location": [16573, 16580], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "Annual Report", "location": [16583, 16596], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.437868, "arguments": [{"text": "Annual Report", "location": [16583, 16596], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Form", "location": [16600, 16604], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.854838, "arguments": [{"text": "Form", "location": [16600, 16604], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "filed", "location": [16610, 16615], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "affectedBy", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.354072, "arguments": [{"text": "SEC", "location": [16625, 16628], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "filed", "location": [16610, 16615], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.515736, "arguments": [{"text": "June 27, 2018", "location": [16632, 16645], "entities": [{"type": "Date", "text": "June 27, 2018"}]}, {"text": "filed", "location": [16610, 16615], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "hasAttribute", "sentence": "SOURCE BIONIK Laboratories Corp. Related Links http://www.BIONIKlabs.com", "score": 0.624885, "arguments": [{"text": "SOURCE BIONIK Laboratories Corp.\nRelated Links", "location": [16938, 16984], "entities": [{"type": "Organization", "text": "SOURCE BIONIK Laboratories Corp.\nRelated Links"}]}, {"text": "http://www.BIONIKlabs.com", "location": [16985, 17010], "entities": [{"type": "Web", "text": "http://www.BIONIKlabs.com"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.809587, "arguments": [{"text": "independent", "location": [1060, 1071], "entities": [{"type": "Person", "text": "independent"}]}, {"text": "Appointed", "location": [1050, 1059], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.529991, "arguments": [{"text": "directors", "location": [1072, 1081], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Appointed", "location": [1050, 1059], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.860788, "arguments": [{"text": "Audrey D. Th\u00e9venon", "location": [1082, 1100], "entities": [{"type": "Person", "text": "Audrey D. Th\u00e9venon"}]}, {"text": "directors", "location": [1072, 1081], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.788308, "arguments": [{"text": "Ph.D.", "location": [1102, 1107], "entities": [{"type": "Person", "text": "Ph.D."}]}, {"text": "directors", "location": [1072, 1081], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.481698, "arguments": [{"text": "Charles Matine", "location": [1112, 1126], "entities": [{"type": "Person", "text": "Charles Matine"}]}, {"text": "board", "location": [1134, 1139], "entities": [{"type": "Organization", "text": "board"}]}]}], "keywords": [{"text": "bionik laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.916368}, {"text": "forward-looking statements", "sentiment": {"score": -0.512597, "label": "negative"}, "relevance": 0.851326}, {"text": "inmotion arm", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.782226}, {"text": "cash equivalents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.762775}, {"text": "InMotion ARM therapy", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.752967}, {"text": "company", "sentiment": {"score": 0.0816728, "label": "positive"}, "relevance": 0.735304}, {"text": "quarter", "sentiment": {"score": 0.256846, "label": "positive"}, "relevance": 0.714828}, {"text": "Medical Technology Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.71184}, {"text": "Consolidated Interim Statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.699488}, {"text": "ARM therapy robots", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.6976}, {"text": "Condensed Consolidated Interim", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.68733}, {"text": "prior-year quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.683684}, {"text": "InMotion robotic products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.682363}, {"text": "InMotion Home product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.681368}, {"text": "Fair Value Adjustment", "sentiment": {"score": 0.716024, "label": "positive"}, "relevance": 0.681198}, {"text": "deferred revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680995}, {"text": "accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.679578}, {"text": "Quarter Financial Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.678499}, {"text": "next-generation InMotion ARM\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.677619}, {"text": "new InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.676232}, {"text": "InMotion ARM/HAND\u2122 Interactive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.673018}, {"text": "next-generation InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672381}, {"text": "Weighted average number", "sentiment": {"score": 0.0516505, "label": "positive"}, "relevance": 0.670714}, {"text": "gross margin", "sentiment": {"score": -0.417995, "label": "negative"}, "relevance": 0.668502}, {"text": "promissory notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662603}, {"text": "prior-year quarter Sold", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.66197}, {"text": "Nasdaq exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.660635}, {"text": "fiscal second quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.659691}, {"text": "comprehensive loss", "sentiment": {"score": -0.436856, "label": "negative"}, "relevance": 0.659129}, {"text": "InMotion robots", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.65547}, {"text": "sales", "sentiment": {"score": 0.500544, "label": "positive"}, "relevance": 0.647309}, {"text": "Net cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646611}, {"text": "BIONIK Laboratories Corp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.644434}, {"text": "robotics company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641678}, {"text": "actual results", "sentiment": {"score": -0.570438, "label": "negative"}, "relevance": 0.640286}, {"text": "shares", "sentiment": {"score": 0.0516505, "label": "positive"}, "relevance": 0.640092}, {"text": "fiscal quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.634353}, {"text": "financial statements", "sentiment": {"score": -0.378336, "label": "negative"}, "relevance": 0.631525}, {"text": "related insufficient cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629196}, {"text": "Corporation Continued development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627066}, {"text": "convertible promissory loans", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625407}, {"text": "Ginger Capital Investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625352}, {"text": "capital structure", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.624767}, {"text": "long-term growth capital", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.624633}, {"text": "non-cash accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622824}, {"text": "InMotion systems", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622566}, {"text": "robotic rehabilitation products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620977}, {"text": "InMotion WRIST\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620915}, {"text": "common shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620387}]}, "extracted_metadata": {"sha1": "8978cf55912c81c7a8a90b5268a9797c44b6d646", "filename": "1542112652570.zip-ff45a5037b0a759fa26fcd65058c3756.xml", "file_type": "json"}, "external_links": ["http://www.bioniklabs.com/", "https://blog.bioniklabs.com/news-media/press-releases/detail/44/chinese-fund-invests-in-bionik-laboratories-and-establishes", "https://www.linkedin.com/company/bionik-labs/", "http://www.bioniklabs.com/news-media/press-releases/detail/46/bionik-laboratories-and-wistron-corporation-partner-to", "https://www.facebook.com/bioniklab/", "https://twitter.com/bioniklab"], "title": "BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results Feature 147% Increase in Revenues", "forum_title": "PR Newswire:"}, {"id": "rC_HBFSBokmLNpvC1ku0hhASWvApqQo8DR1Rmq5eECE8Q6Tajs4FnGtdGGia8S08", "result_metadata": {"score": 20.661509}, "author": "PRNewswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "147%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Generally Accepted Accounting Principles", "relevance": 0.862373, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}], "categories": [{"score": 0.938954, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Quarter Fiscal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.984225}, {"text": "Financial Results Feature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.868836}, {"text": "Revenues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.413235}, {"text": "Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32599}, {"text": "Increase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315121}]}, "crawl_date": "2018-11-13T12:51:12Z", "url": "https://www.benzinga.com/pressreleases/18/11/r12683452/bionik-laboratories-second-quarter-fiscal-2019-financial-results-featu", "host": "benzinga.com", "text": "Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T07:31:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories Corp", "relevance": 0.741745, "type": "Company"}, {"count": 9, "sentiment": {"score": 0.679723, "label": "positive"}, "text": "InMotion", "relevance": 0.611321, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.550115, "label": "positive"}, "text": "US", "relevance": 0.527627, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 7, "sentiment": {"score": 0.685767, "label": "positive"}, "text": "BIONIK", "relevance": 0.509928, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 4, "sentiment": {"score": 0.563843, "label": "positive"}, "text": "China", "relevance": 0.406606, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 3, "sentiment": {"score": -0.314878, "label": "negative"}, "text": "SEC", "relevance": 0.404888, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "U.S. Securities and Exchange Commission", "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eric Dusseux", "relevance": 0.37599, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bionik", "relevance": 0.363936, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BIONIK Laboratories", "relevance": 0.355287, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.354896, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0.716823, "label": "positive"}, "text": "North America", "relevance": 0.342508, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.339092, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 2, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "partner", "relevance": 0.33879, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Wistron Corporation", "relevance": 0.332135, "type": "Company", "disambiguation": {"subtype": [], "name": "Wistron Corporation", "dbpedia_resource": "http://dbpedia.org/resource/Wistron_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ginger Capital Investment Holding Ltd", "relevance": 0.329893, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Technology Co.", "relevance": 0.325426, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.630342, "label": "positive"}, "text": "State Drug Administration", "relevance": 0.324834, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TORONTO", "relevance": 0.316615, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chairman", "relevance": 0.316388, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.436086, "label": "positive"}, "text": "Cogmedix", "relevance": 0.314053, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "principal", "relevance": 0.312235, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "chief executive officer", "relevance": 0.312171, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.554755, "label": "positive"}, "text": "Twitter", "relevance": 0.299286, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Audrey D. Th\u00e9venon", "relevance": 0.296318, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Charles Matine", "relevance": 0.281559, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BOSTON", "relevance": 0.279016, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Facebook", "relevance": 0.274275, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Facebook", "dbpedia_resource": "http://dbpedia.org/resource/Facebook"}}, {"count": 1, "sentiment": {"score": 0.418092, "label": "positive"}, "text": "LinkedIn", "relevance": 0.263302, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "LinkedIn", "dbpedia_resource": "http://dbpedia.org/resource/LinkedIn"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Six months", "relevance": 0.263302, "type": "Quantity"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.001", "relevance": 0.263302, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Three months", "relevance": 0.263302, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$221,847", "relevance": 0.263302, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$547,085", "relevance": 0.263302, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "2017\n$", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,582,997", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,742,335", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1,970,167", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2,750,000", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5,692,853", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six months", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "six month", "relevance": 0.263302, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$122,667", "relevance": 0.263302, "type": "Quantity"}], "sentiment": {"document": {"score": 0.530341, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a robotics company", "keywords": [{"text": "robotics company"}], "entities": [{"type": "Company", "text": "BIONIK Laboratories"}]}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD ) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "object": {"text": "rehabilitation and assistive technology solutions", "keywords": [{"text": "assistive technology solutions"}, {"text": "rehabilitation"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "financial results", "keywords": [{"text": "financial results"}]}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD ) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the second quarter of fiscal year 2019,", "keywords": [{"text": "quarter"}], "entities": []}, "sentence": "TORONTO and BOSTON , Nov. 13, 2018 /PRNewswire/ -- BIONIK Laboratories Corp . (OTCQB: BNKLD ) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "action": {"verb": {"text": "end", "tense": "past"}, "text": "ended", "normalized": "end"}}, {"subject": {"text": "$547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots", "keywords": [{"text": "prior-year quarter Sold"}, {"text": "InMotion robots"}], "entities": [{"type": "Company", "text": "InMotion"}, {"type": "Quantity", "text": "$221,847"}, {"type": "Quantity", "text": "$547,085"}, {"type": "Quantity", "text": "147"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end", "keywords": [{"text": "quarter"}, {"text": "prior-year quarter"}, {"text": "quarter end"}, {"text": "Borrowings"}], "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "$1,742,335", "entities": [{"type": "Quantity", "text": "$1,742,335"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "into shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "convert", "tense": "past"}, "text": "were converted", "normalized": "be convert"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000", "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "from the company's Chairman Effected a 1-for-150 reverse stock split on October 29", "keywords": [{"text": "reverse stock split"}, {"text": "Chairman Effected"}, {"text": "company"}], "entities": [{"type": "JobTitle", "text": "Chairman"}]}, "sentence": " Reported sales of $547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary", "object": {"text": "$2,750,000 in convertible promissory loans", "keywords": [{"text": "convertible promissory loans"}], "entities": [{"type": "Quantity", "text": "$2,750,000"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Organization", "text": "BIONIK"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "on the quarter", "keywords": [{"text": "quarter"}]}, "action": {"verb": {"text": "Commenting", "tense": "present"}, "text": "Commenting", "normalized": "Commenting"}}, {"subject": {"text": "Eric Dusseux, M.D., BIONIK's chief executive officer,", "keywords": [{"text": "chief executive officer"}, {"text": "Eric Dusseux"}, {"text": "M.D."}, {"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}, {"type": "Organization", "text": "BIONIK"}, {"type": "JobTitle", "text": "chief executive officer"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "Our sales momentum continued during the fiscal second quarter and recent weeks", "keywords": [{"text": "fiscal second quarter"}, {"text": "sales momentum"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Our sales momentum", "keywords": [{"text": "sales momentum"}]}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "I"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "very pleased with the excellent progress we made towards achieving multiple milestones", "keywords": [{"text": "excellent progress"}, {"text": "multiple milestones"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "the excellent progress", "keywords": [{"text": "excellent progress"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "we"}, "sentence": " Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "object": {"text": "multiple milestones", "keywords": [{"text": "multiple milestones"}]}, "action": {"verb": {"text": "achieve", "tense": "present"}, "text": "achieving", "normalized": "achieve"}}, {"subject": {"text": "We"}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "seven InMotion systems", "keywords": [{"text": "InMotion systems"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "sold", "normalized": "sell"}}, {"subject": {"text": "seven InMotion systems during the quarter", "keywords": [{"text": "InMotion systems"}, {"text": "quarter"}], "entities": [{"type": "Company", "text": "InMotion"}]}, "sentence": " We sold seven InMotion systems during the quarter, compared with five in the first quarter and two in the same quarterly period a year ago.", "object": {"text": "with five in the first quarter and two in the same quarterly period a year ago", "keywords": [{"text": "quarter"}, {"text": "quarterly period"}], "entities": []}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "our renewed sales efforts on all fronts, from R&D to manufacturing and financing", "keywords": [{"text": "sales efforts"}, {"text": "fronts"}, {"text": "R&D"}, {"text": "financing"}]}, "sentence": " These results clearly reflect our renewed sales efforts on all fronts, from R&D to manufacturing and financing.", "object": {"text": "These results", "keywords": [{"text": "results"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflect", "normalized": "reflect"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "launched the next-generation InMotion ARM in Europe", "keywords": [{"text": "next-generation InMotion ARM"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " \"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "object": {"text": "the next-generation InMotion ARM", "keywords": [{"text": "next-generation InMotion ARM"}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "we"}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the first sale of this product", "keywords": [{"text": "sale"}, {"text": "product"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "object": {"text": "to a facility", "keywords": [{"text": "facility"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "a facility", "keywords": [{"text": "facility"}]}, "sentence": " As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "action": {"verb": {"text": "occur", "tense": "past"}, "text": "occurred", "normalized": "occur"}}, {"subject": {"text": "We"}, "sentence": " We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "object": {"text": "continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US", "keywords": [{"text": "stroke survivors"}, {"text": "continued sales"}, {"text": "rehabilitation"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "The new InMotion ARM", "keywords": [{"text": "new InMotion ARM"}]}, "sentence": " The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "object": {"text": "with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation", "keywords": [{"text": "mobility impairment"}, {"text": "neurological conditions"}, {"text": "commercial product"}, {"text": "previous generation"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The new version", "keywords": [{"text": "new version"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "a modern design that is smaller", "keywords": [{"text": "modern design"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "a modern design", "keywords": [{"text": "modern design"}]}, "sentence": " The new version offers a modern design that is smaller, sleeker and intended for use with a large number of patients.", "object": {"text": "smaller, sleeker", "keywords": [{"text": "sleeker"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd.", "object": {"text": "We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd", "keywords": [{"text": "InMotion ARM therapy"}, {"text": "Ginger Capital Investment"}, {"text": "Medical Technology Co."}, {"text": "joint venture"}], "entities": [{"type": "Person", "text": "Bionik"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Company", "text": "Medical Technology Co."}, {"type": "Person", "text": "Bionik"}, {"type": "Company", "text": "Ginger Capital Investment Holding Ltd"}]}, "action": {"verb": {"text": "continue", "tense": "past"}, "text": "continued", "normalized": "continue"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "for testing to support State Drug Administration approval in China", "keywords": [{"text": "Drug Administration approval"}, {"text": "State"}, {"text": "China"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "will be used", "normalized": "will be use"}}, {"subject": {"text": "The robots", "keywords": [{"text": "robots"}]}, "sentence": " The robots will be used for testing to support State Drug Administration approval in China.", "object": {"text": "State Drug Administration approval", "keywords": [{"text": "Drug Administration approval"}], "entities": [{"type": "Organization", "text": "State Drug Administration"}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "very excited"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by this progress", "keywords": [{"text": "progress"}]}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "We"}, "action": {"verb": {"text": "excite", "tense": "past"}, "text": "are very excited", "normalized": "be very excite"}}, {"subject": {"text": "We"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China", "keywords": [{"text": "new stroke patients"}, {"text": "rehabilitation"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "action": {"verb": {"text": "hope", "tense": "present"}, "text": "hope", "normalized": "hope"}}, {"subject": {"text": "we"}, "sentence": " We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "object": {"text": "rehabilitation", "keywords": [{"text": "rehabilitation"}]}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "to address", "normalized": "to address"}}, {"subject": {"text": "by advancements with manufacturing partner Cogmedix leading to increased production capacity", "keywords": [{"text": "partner Cogmedix"}, {"text": "production capacity"}, {"text": "advancements"}], "entities": [{"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "Our sales efforts", "keywords": [{"text": "sales efforts"}]}, "action": {"verb": {"text": "support", "tense": "past"}, "text": "are supported", "normalized": "be support"}}, {"subject": {"text": "Cogmedix", "keywords": [{"text": "Cogmedix"}], "entities": [{"type": "Company", "text": "Cogmedix"}]}, "sentence": " \"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "object": {"text": "to increased production capacity", "keywords": [{"text": "production capacity"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "permitting us to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This excellent outsourced manufacturing facility", "keywords": [{"text": "excellent outsourced manufacturing"}, {"text": "facility"}]}, "sentence": " This excellent outsourced manufacturing facility is permitting us to fill customer orders more quickly.\"", "object": {"text": "to fill customer orders more quickly", "keywords": [{"text": "customer orders"}]}, "action": {"verb": {"text": "permit", "tense": "present"}, "text": "is permitting", "normalized": "be permit"}}, {"subject": {"text": "Dr. Dusseux", "keywords": [{"text": "Dr. Dusseux"}], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "we took important steps to improve our capital structure and secure long-term growth capital", "keywords": [{"text": "secure long-term growth"}, {"text": "important steps"}, {"text": "capital structure"}]}, "action": {"verb": {"text": "conclude", "tense": "past"}, "text": "concluded", "normalized": "conclude"}}, {"subject": {"text": "we"}, "sentence": " Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "object": {"text": "our capital structure", "keywords": [{"text": "capital structure"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "to improve", "normalized": "to improve"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "a consolidation of shares", "keywords": [{"text": "consolidation"}, {"text": "shares"}]}, "action": {"verb": {"text": "effect", "tense": "past"}, "text": "effected", "normalized": "effect"}}, {"subject": {"text": "We"}, "sentence": " We effected a consolidation of shares with the goal of meeting the minimum bid requirement for listing on the Nasdaq exchange.", "object": {"text": "the minimum bid requirement for listing on the Nasdaq exchange", "keywords": [{"text": "minimum bid requirement"}, {"text": "Nasdaq exchange"}, {"text": "listing"}], "entities": []}, "action": {"verb": {"text": "meet", "tense": "future"}, "text": "meeting", "normalized": "meet"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "funds", "keywords": [{"text": "funds"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "to develop our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "our innovative products and support the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "innovative products"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to continue to develop", "normalized": "to continue to develop"}}, {"subject": {"text": "We"}, "sentence": " We also raised funds to continue to develop our innovative products and support the manufacture of our robotic systems.", "object": {"text": "the manufacture of our robotic systems", "keywords": [{"text": "robotic systems"}, {"text": "manufacture"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "to completing"}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "these initiatives", "keywords": [{"text": "initiatives"}]}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "completing", "normalized": "complete"}}, {"subject": {"text": "We"}, "sentence": " We look forward to completing these initiatives and broadening awareness for BIONIK among the investment community, while providing important solutions for patients with impaired mobility due to neurological conditions.\"", "object": {"text": "important solutions", "keywords": [{"text": "important solutions"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to expect to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "continue", "tense": "present"}, "text": "continues", "normalized": "continue"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "object": {"text": "to achieve the following milestones", "keywords": [{"text": "following milestones"}]}, "action": {"verb": {"text": "expect", "tense": "future"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "BIONIK", "keywords": [{"text": "BIONIK"}], "entities": [{"type": "Person", "text": "Bionik"}]}, "sentence": " BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019:", "action": {"verb": {"text": "achieve", "tense": "future"}, "text": "continues to expect to achieve", "normalized": "continue to expect to achieve"}}], "concepts": [{"text": "Balance sheet", "relevance": 0.983038, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Generally Accepted Accounting Principles", "relevance": 0.816747, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Asset", "relevance": 0.683494, "dbpedia_resource": "http://dbpedia.org/resource/Asset"}, {"text": "Operating expense", "relevance": 0.626736, "dbpedia_resource": "http://dbpedia.org/resource/Operating_expense"}, {"text": "Income statement", "relevance": 0.614962, "dbpedia_resource": "http://dbpedia.org/resource/Income_statement"}, {"text": "Corporate finance", "relevance": 0.605895, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Fiscal year", "relevance": 0.587293, "dbpedia_resource": "http://dbpedia.org/resource/Fiscal_year"}, {"text": "Expense", "relevance": 0.529758, "dbpedia_resource": "http://dbpedia.org/resource/Expense"}, {"text": "Inventory", "relevance": 0.492989, "dbpedia_resource": "http://dbpedia.org/resource/Inventory"}, {"text": "Liability", "relevance": 0.44183, "dbpedia_resource": "http://dbpedia.org/resource/Liability_(financial_accounting)"}, {"text": "Shares authorized", "relevance": 0.430326, "dbpedia_resource": "http://dbpedia.org/resource/Shares_authorized"}, {"text": "Gross profit", "relevance": 0.411838, "dbpedia_resource": "http://dbpedia.org/resource/Gross_profit"}, {"text": "Stock", "relevance": 0.360939, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Revenue", "relevance": 0.358871, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Finance", "relevance": 0.35848, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Preferred stock", "relevance": 0.32781, "dbpedia_resource": "http://dbpedia.org/resource/Preferred_stock"}, {"text": "2010s", "relevance": 0.326529, "dbpedia_resource": "http://dbpedia.org/resource/2010s"}, {"text": "Stock market", "relevance": 0.320099, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.599115, "label": "/finance/financial news"}, {"score": 0.449946, "label": "/finance/investing"}, {"score": 0.449946, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "(OTCQB: BNKLD ) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.562025, "arguments": [{"text": "individuals", "location": [216, 227], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [233, 245], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "hasAttribute", "sentence": "About BIONIK Laboratories Corp. BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home.", "score": 0.562025, "arguments": [{"text": "individuals", "location": [7771, 7782], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "neurological", "location": [7788, 7800], "entities": [{"type": "HealthCondition", "text": "neurological"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.34374, "arguments": [{"text": "directors", "location": [1176, 1185], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "board", "location": [1167, 1172], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "hasAttribute", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.40699, "arguments": [{"text": "investors", "location": [1659, 1668], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "$2,750,000", "location": [1678, 1688], "entities": [{"type": "Money", "text": "$2,750,000"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.804912, "arguments": [{"text": "Chairman", "location": [1751, 1759], "entities": [{"type": "Person", "text": "Effected"}]}, {"text": "company", "location": [1741, 1748], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "managerOf", "sentence": "547,085 , up 147% over $221,847 in the prior-year quarter Sold seven InMotion robots, compared with two in the prior-year quarter and five in the first quarter of fiscal 2019 Borrowings during the quarter were $1,742,335 which were converted into shares as of July 20, 2018 and subsequent to quarter end, investors provided $2,750,000 in convertible promissory loans, including from the company's Chairman Effected a 1-for-150 reverse stock split on October 29, 2018 as part of planned application to uplist on the Nasdaq exchange Management Commentary Commenting on the quarter, Eric Dusseux, M.D., BIONIK's chief executive officer, said, \"Our sales momentum continued during the fiscal second quarter and recent weeks, and I am very pleased with the excellent progress we made towards achieving multiple milestones.", "score": 0.73019, "arguments": [{"text": "chief executive officer", "location": [1963, 1986], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "BIONIK", "location": [1954, 1960], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "locatedAt", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.485132, "arguments": [{"text": "We", "location": [2425, 2427], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "InMotion", "location": [2466, 2474], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "agentOf", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.933804, "arguments": [{"text": "we", "location": [2526, 2528], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "announced", "location": [2538, 2547], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "As we recently announced, the first sale of this product was to a facility in France , which occurred during our fiscal second quarter.", "score": 0.946332, "arguments": [{"text": "facility", "location": [2589, 2597], "entities": [{"type": "Facility", "text": "manufacturing facility"}]}, {"text": "France", "location": [2601, 2607], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "We expect continued sales of this new interactive robotic system for the rehabilitation of stroke survivors outside the US.", "score": 0.386238, "arguments": [{"text": "survivors", "location": [2757, 2766], "entities": [{"type": "Person", "text": "survivors"}]}, {"text": "US", "location": [2779, 2781], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "managerOf", "sentence": "The new InMotion ARM provides those with mobility impairment due to neurological conditions a commercial product with the same innovative, active-assisted robotic therapy that has been clinically proven with the previous generation.", "score": 0.666528, "arguments": [{"text": "InMotion", "location": [2791, 2799], "entities": [{"type": "Person", "text": "InMotion robots"}]}, {"text": "ARM", "location": [2800, 2803], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}]}, {"type": "agentOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.995926, "arguments": [{"text": "Dusseux", "location": [3138, 3145], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "continued", "location": [3146, 3155], "entities": [{"type": "EventCommunication", "text": "continued"}]}]}, {"type": "timeOf", "sentence": "(OTCQB: BNKLD ) (\"BIONIK\" or the \"Company\"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2019, ended September 30, 2018 .", "score": 0.664948, "arguments": [{"text": "today", "location": [293, 298], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [299, 308], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.482106, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3247, 3275], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BIONIK", "location": [3230, 3236], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.698726, "arguments": [{"text": "Medical Technology Co., Ltd.", "location": [3247, 3275], "entities": [{"type": "Organization", "text": "Medical Technology Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "China", "location": [3239, 3244], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.852432, "arguments": [{"text": "patients", "location": [3589, 3597], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [3582, 3588], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "locatedAt", "sentence": "We are very excited by this progress and hope that we will be able to address rehabilitation for the 2.4 million new stroke patients each year in China .", "score": 0.591839, "arguments": [{"text": "patients", "location": [3589, 3597], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "China", "location": [3611, 3616], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\"Our sales efforts are supported by advancements with manufacturing partner Cogmedix leading to increased production capacity.", "score": 0.736435, "arguments": [{"text": "Cogmedix", "location": [3695, 3703], "entities": [{"type": "Person", "text": "Cogmedix"}]}, {"text": "partner", "location": [3687, 3694], "entities": [{"type": "GeopoliticalEntity", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "agentOf", "sentence": "\" Dr. Dusseux concluded, \"During the quarter and recent weeks we took important steps to improve our capital structure and secure long-term growth capital.", "score": 0.998234, "arguments": [{"text": "Dusseux", "location": [3855, 3862], "entities": [{"type": "Person", "text": "Eric Dusseux"}]}, {"text": "concluded", "location": [3863, 3872], "entities": [{"type": "EventCommunication", "text": "concluded"}]}]}, {"type": "locatedAt", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.886308, "arguments": [{"text": "InMotion WRIST\u2122", "location": [4660, 4675], "entities": [{"type": "Person", "text": "InMotion WRIST\u2122"}]}, {"text": "hospitals", "location": [4706, 4715], "entities": [{"type": "Organization", "text": "manufacturing facility"}]}]}, {"type": "agentOf", "sentence": "The Company reported a comprehensive loss for the quarter ended September 30, 2018 of $(3,983,105) , or a loss per share of $(1.62) , compared with a comprehensive loss of $(3,615,361) , or a loss per share of $(5.33) , for the quarter ended September 30, 2017 .", "score": 0.886256, "arguments": [{"text": "Company", "location": [6445, 6452], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "reported", "location": [6453, 6461], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.", "score": 0.655292, "arguments": [{"text": "patients", "location": [7979, 7987], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "stroke", "location": [7944, 7950], "entities": [{"type": "HealthCondition", "text": "stroke"}]}]}, {"type": "partOf", "sentence": "For more information, please visit www.BIONIKlabs.com and connect with us on Twitter , LinkedIn , and Facebook .", "score": 0.453554, "arguments": [{"text": "Twitter", "location": [8157, 8164], "entities": [{"type": "Organization", "text": "Twitter"}]}, {"text": "LinkedIn", "location": [8167, 8175], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.835171, "arguments": [{"text": "ARM", "location": [617, 620], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [608, 616], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\"We have now launched the next-generation InMotion ARM in Europe following receipt of the CE mark.", "score": 0.787644, "arguments": [{"text": "ARM", "location": [2475, 2478], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [2466, 2474], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "Dr. Dusseux continued, \"We shipped three InMotion ARM therapy robots to our 2017 joint venture, BIONIK ( China ) Medical Technology Co., Ltd., which was formed through an agreement between Bionik and Ginger Capital Investment Holding Ltd. The robots will be used for testing to support State Drug Administration approval in China.", "score": 0.732993, "arguments": [{"text": "ARM", "location": [3184, 3187], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [3175, 3183], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "basedIn", "sentence": "\" BIONIK continues to expect to achieve the following milestones during the second half of fiscal year 2019: Launch the next generation of InMotion ARM/HANDM Interactive Therapy System and InMotion WRISTM to rehabilitation centers and hospitals Continue to expand sales channels in North America and abroad Further develop InMotion robotic products for in-home use Continue development of the Company's first lower-cost, lower-limb assistive exoskeleton for the large and growing elderly population, both in North America and abroad Enhance the effectiveness of all commercial outsourced manufacturing to support the expected increase in product demand and introduction of new products Increase sales of service contracts and warranties Make substantial progress towards the desired uplisting of BIONIK's common stock on the Nasdaq exchange Second Quarter Financial Results Sales for the quarter ended September 30, 2018 were $547,085 , compared with $", "score": 0.881539, "arguments": [{"text": "ARM/HAND\u2122 Interactive Therapy System", "location": [4619, 4655], "entities": [{"type": "Organization", "text": "ARM/HAND\u2122 Interactive Therapy System"}]}, {"text": "InMotion", "location": [4610, 4618], "entities": [{"type": "GeopoliticalEntity", "text": "InMotion Home"}]}]}, {"type": "partOf", "sentence": "Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control.", "score": 0.421104, "arguments": [{"text": "Company", "location": [9858, 9865], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "which", "location": [9848, 9853], "entities": [{"type": "Organization", "text": "LinkedIn", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "These and other factors are identified and described in more detail in the Company's filings with the SEC.", "score": 0.586541, "arguments": [{"text": "Company", "location": [10926, 10933], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "SEC", "location": [10953, 10956], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "locatedAt", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.771425, "arguments": [{"text": "Dollars", "location": [11130, 11137], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "US", "location": [11127, 11129], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.699858, "arguments": [{"text": "Dollars", "location": [12862, 12869], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [12857, 12861], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.788373, "arguments": [{"text": "Dollars", "location": [14485, 14492], "entities": [{"type": "Facility", "text": "Dollars"}]}, {"text": "U.S.", "location": [14480, 14484], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Bionik Laboratories Corp. Condensed Consolidated Interim Balance Sheets (Amounts expressed in US Dollars) As at As at September 30, March 31, 2018 2018 (Unaudited) (Audited) $ $ Assets Current Cash and cash equivalents 305,757 507,311 Accounts receivable, net of allowance for doubtful accounts of $17,699 (March 31, 2018 - $19,694) 517,758 212,730 Prepaid expenses and other receivables 851,179 433,655 Inventories 192,626 237,443 Due from related parties 18,913 18,897 Total Current Assets 1,886,233 1,410,036 Equipment 139,380 159,961 Technology and other assets 4,566,351 4,706,719 Goodwill 22,308,275 22,308,275 Total Assets 28,900,239 28,584,991 Liabilities and Shareholders' Equity Current Accounts Payable 906,438 724,673 Accrued liabilities 962,185 1,529,505 Customer advances - 800 Demand Loans - 51,479 Deferred revenue 134,161 122,667 Shares to be issued, stock options and warrants - 5,692,853 Total Current Liabilities 2,002,784 8,121,977 Shareholders'", "score": 0.425193, "arguments": [{"text": "Total Assets", "location": [11650, 11662], "entities": [{"type": "Organization", "text": "Total Assets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Goodwill", "location": [11619, 11627], "entities": [{"type": "Organization", "text": "Goodwill"}]}]}, {"type": "partOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.613876, "arguments": [{"text": "Authorized", "location": [12114, 12124], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}, {"text": "Authorized", "location": [12042, 12052], "entities": [{"type": "EventCommunication", "text": "Authorized"}]}]}, {"type": "agentOf", "sentence": "Equity Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2018 - 1) - - Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 2,337,462 and 273,575 Exchangeable Shares (March 31, 2018 - 1,368,855 and 295,146 Exchangeable Shares) 2,611 1,664 Additional paid in capital 67,379,122 56,195,541 Deficit (40,526,427) (35,776,340) Accumulated other comprehensive income 42,149 42,149 Total Shareholders' Equity 26,897,455 20,463,014 Total Liabilities and Shareholders' Equity 28,900,239 28,584,991 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) for the six month periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars)", "score": 0.980693, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [12656, 12712], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [12713, 12723], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.984382, "arguments": [{"text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim", "location": [14303, 14359], "entities": [{"type": "Organization", "text": "Bionik Laboratories Corp.\nCondensed Consolidated Interim Balance Sheets", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Statements", "location": [14360, 14370], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "employedBy", "sentence": "Three months Six months Three months Six months ended ended ended ended September 30, 2018 September 30, 2018 September 30, 2017 September 30, 2017 $ $ $ $ Sales 547,085 1,048,418 221,847 309,367 Cost of Sales 384,073 637,236 59,825 89,125 Gross Margin 163,012 411,182 162,022 220,242 Operating expenses Sales and marketing 427,325 969,984 435,294 880,817 Research and development 679,049 1,355,792 715,400 1,401,309 General and administrative 931,477 1,910,956 1,505,528 2,133,134 Share-based compensation expense 439,328 1,034,740 762,208 1,013,256 Amortization 69,315 140,368 76,985 169,934 Depreciation 16,626 34,221 23,820 48,372 Total operating expenses 2,563,120 5,446,061 3,519,235 5,646,822 Other (income) expenses Foreign exchange (27,872) (69,006) 15,595 114,156 Accretion expense 1,970,167 2,104,418 74,073 74,073 Fair Value Adjustment (382,010) (337,923) - - Gain on mark to market reevaluation - (2,048,697) - -", "score": 0.395149, "arguments": [{"text": "Accretion", "location": [13645, 13654], "entities": [{"type": "Person", "text": "Accretion"}]}, {"text": "Fair Value Adjustment", "location": [13697, 13718], "entities": [{"type": "Organization", "text": "Fair Value Adjustment"}]}]}, {"type": "agentOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.698989, "arguments": [{"text": "Cash Flows", "location": [14374, 14384], "entities": [{"type": "Person", "text": "Cash Flows"}]}, {"text": "Statements", "location": [14360, 14370], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "timeOf", "sentence": "Other expense 22,712 60,132 168,480 241,068 Total other expenses (income) 1,582,997 (291,076) 258,148 429,297.00 Net loss and comprehensive loss for the period (3,983,105) (4,743,803) (3,615,361) (5,855,877) Loss per share - basic and diluted (1.62) (2.02) (5.33) (8.84) Loss per share - diluted (1.62) (2.02) (5.33) (8.84) Weighted average number of shares outstanding - basic 2,459,169 2,351,587 678,631 662,237 Weighted average number of shares outstanding - diluted 2,459,169 2,351,587 678,631 662,237 Bionik Laboratories Corp. Condensed Consolidated Interim Statements of Cash Flows for the six months periods ended September 30, 2018 and 2017 (unaudited) (Amounts expressed in U.S. Dollars) Six months ended Six months ended September 30, 2018 September 30, 2017 $ $", "score": 0.604194, "arguments": [{"text": "September 30, 2018", "location": [14418, 14436], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "Statements", "location": [14360, 14370], "entities": [{"type": "EventCommunication", "text": "Statements"}]}]}, {"type": "agentOf", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.980082, "arguments": [{"text": "Repayment of Demand", "location": [15789, 15808], "entities": [{"type": "Organization", "text": "Repayment of Demand"}]}, {"text": "notes", "location": [15809, 15814], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.809587, "arguments": [{"text": "independent", "location": [1093, 1104], "entities": [{"type": "Person", "text": "independent"}]}, {"text": "Appointed", "location": [1083, 1092], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "affectedBy", "sentence": "3,059,849) Investing activities Acquisition of equipment (13,640) (17,182) Net cash (used in) investing activities (13,640) (17,182) Financing activities Proceeds from convertible loans 4,676,633 1,598,715 Proceeds on exercise of warrants - 1,125,038 Repayment of Promissory notes principal - (12,319) Repayment of Promissory notes interest - (41,973) Repayment of Demand notes principal (50,000) - Repayment of Demand notes interest (2,975) - Net cash provided by financing activities 4,623,658 2,669,461 Net (decrease) increase in cash and cash equivalents for the period (201,554) (407,570) Cash and cash equivalents, beginning of period 507,311 543,650 Cash and cash equivalents, end of period 305,757 136,080 The Financial Statements have been adjusted to retroactively reflect the 150-to-1 reverse stock split effected on October 29, 2018 .", "score": 0.528311, "arguments": [{"text": "principal", "location": [15815, 15824], "entities": [{"type": "Person", "text": "principal"}]}, {"text": "notes", "location": [15809, 15814], "entities": [{"type": "EventCommunication", "text": "notes"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.792025, "arguments": [{"text": "September 30, 2018", "location": [16410, 16428], "entities": [{"type": "Date", "text": "September 30, 2018"}]}, {"text": "filed", "location": [16429, 16434], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.706518, "arguments": [{"text": "10-Q", "location": [16443, 16447], "entities": [{"type": "Date", "text": "10-Q"}]}, {"text": "filed", "location": [16429, 16434], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.867538, "arguments": [{"text": "Company", "location": [16606, 16613], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}, {"text": "Annual Report", "location": [16616, 16629], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.437868, "arguments": [{"text": "Annual Report", "location": [16616, 16629], "entities": [{"type": "Organization", "text": "Annual Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Form", "location": [16633, 16637], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.854838, "arguments": [{"text": "Form", "location": [16633, 16637], "entities": [{"type": "Organization", "text": "Form", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "filed", "location": [16643, 16648], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "affectedBy", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.354072, "arguments": [{"text": "SEC", "location": [16658, 16661], "entities": [{"type": "Organization", "text": "SEC", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "filed", "location": [16643, 16648], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "timeOf", "sentence": "The above financial information has been derived from the Company's interim unaudited consolidated financial statements as of September 30, 2018 filed on Form 10-Q with the SEC on November 13, 2018 and the Company's audited consolidated financial statements as of and for the fiscal year ended March 31, 2018 found in the Company's Annual Report on Form 10-K filed with the SEC on June 27, 2018 .", "score": 0.515736, "arguments": [{"text": "June 27, 2018", "location": [16665, 16678], "entities": [{"type": "Date", "text": "June 27, 2018"}]}, {"text": "filed", "location": [16643, 16648], "entities": [{"type": "EventLegal", "text": "filed"}]}]}, {"type": "managerOf", "sentence": "View original content to download multimedia: http://www.prnewswire.com/news-releases/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues-300748813.html SOURCE BIONIK Laboratories Corp.", "score": 0.33696, "arguments": [{"text": "SOURCE", "location": [17170, 17176], "entities": [{"type": "Person", "text": "SOURCE"}]}, {"text": "BIONIK Laboratories Corp.", "location": [17177, 17202], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}, {"type": "affectedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.529991, "arguments": [{"text": "directors", "location": [1105, 1114], "entities": [{"type": "Person", "text": "directors"}]}, {"text": "Appointed", "location": [1083, 1092], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.860788, "arguments": [{"text": "Audrey D. Th\u00e9venon", "location": [1115, 1133], "entities": [{"type": "Person", "text": "Audrey D. Th\u00e9venon"}]}, {"text": "directors", "location": [1105, 1114], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "partOfMany", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.788308, "arguments": [{"text": "Ph.D.", "location": [1135, 1140], "entities": [{"type": "Person", "text": "Ph.D."}]}, {"text": "directors", "location": [1105, 1114], "entities": [{"type": "Person", "text": "directors"}]}]}, {"type": "employedBy", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.481698, "arguments": [{"text": "Charles Matine", "location": [1145, 1159], "entities": [{"type": "Person", "text": "Charles Matine"}]}, {"text": "board", "location": [1167, 1172], "entities": [{"type": "Organization", "text": "board"}]}]}, {"type": "partOf", "sentence": "Corporate highlights for the second fiscal quarter and recent weeks include: Following CE marking of InMotion Arm system, consummated the first sale of the next-generation InMotion ARMM in France Shipped three InMotion ARM therapy robots to BIONIK ( China ) Medical Technology Co., Ltd. as part of a joint venture entered into in 2017 Continued development of a lower-limb assistive exoskeleton for individuals with impaired mobility through a previously announced manufacturing partnership with Wistron Corporation Continued development of an InMotion Home product, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products Appointed independent directors Audrey D. Th\u00e9venon, Ph.D. and Charles Matine to its board of directors, serving on the Compensation and Audit Committees, respectively Financial highlights for the second quarter of fiscal 2019 and recent weeks include: Reported sales of $", "score": 0.814686, "arguments": [{"text": "board", "location": [1167, 1172], "entities": [{"type": "Organization", "text": "board"}]}, {"text": "its", "location": [1163, 1166], "entities": [{"type": "Organization", "text": "BIONIK Laboratories Corp.\nBIONIK Laboratories"}]}]}], "keywords": [{"text": "bionik laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.915242}, {"text": "forward-looking statements", "sentiment": {"score": -0.512597, "label": "negative"}, "relevance": 0.850348}, {"text": "inmotion arm", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.781256}, {"text": "cash equivalents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.761968}, {"text": "InMotion ARM therapy", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.752034}, {"text": "company", "sentiment": {"score": 0.0816728, "label": "positive"}, "relevance": 0.734754}, {"text": "quarter", "sentiment": {"score": 0.256846, "label": "positive"}, "relevance": 0.714123}, {"text": "Medical Technology Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.711221}, {"text": "Consolidated Interim Statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.698898}, {"text": "ARM therapy robots", "sentiment": {"score": 0.299053, "label": "positive"}, "relevance": 0.696971}, {"text": "Condensed Consolidated Interim", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.686769}, {"text": "prior-year quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.682985}, {"text": "InMotion robotic products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.681616}, {"text": "Fair Value Adjustment", "sentiment": {"score": 0.716024, "label": "positive"}, "relevance": 0.680697}, {"text": "InMotion Home product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680636}, {"text": "deferred revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.680479}, {"text": "accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.679025}, {"text": "Quarter Financial Results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.677766}, {"text": "next-generation InMotion ARM\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.676895}, {"text": "new InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.6755}, {"text": "InMotion ARM/HAND\u2122 Interactive", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672338}, {"text": "next-generation InMotion ARM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.671654}, {"text": "Weighted average number", "sentiment": {"score": 0.0516505, "label": "positive"}, "relevance": 0.670248}, {"text": "gross margin", "sentiment": {"score": -0.417995, "label": "negative"}, "relevance": 0.668005}, {"text": "promissory notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.662139}, {"text": "prior-year quarter Sold", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.661272}, {"text": "Nasdaq exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.660181}, {"text": "fiscal second quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.65896}, {"text": "comprehensive loss", "sentiment": {"score": -0.436856, "label": "negative"}, "relevance": 0.658696}, {"text": "InMotion robots", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.654824}, {"text": "sales", "sentiment": {"score": 0.500544, "label": "positive"}, "relevance": 0.646941}, {"text": "Net cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.646141}, {"text": "BIONIK Laboratories Corp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.643932}, {"text": "robotics company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.641256}, {"text": "actual results", "sentiment": {"score": -0.570438, "label": "negative"}, "relevance": 0.6399}, {"text": "shares", "sentiment": {"score": 0.0516505, "label": "positive"}, "relevance": 0.63975}, {"text": "fiscal quarter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.633661}, {"text": "financial statements", "sentiment": {"score": -0.378336, "label": "negative"}, "relevance": 0.631188}, {"text": "related insufficient cash", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.627294}, {"text": "Corporation Continued development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.626639}, {"text": "convertible promissory loans", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624967}, {"text": "Ginger Capital Investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624965}, {"text": "capital structure", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.624409}, {"text": "long-term growth capital", "sentiment": {"score": 0.607723, "label": "positive"}, "relevance": 0.624254}, {"text": "non-cash accretion expense", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622388}, {"text": "InMotion systems", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622024}, {"text": "robotic rehabilitation products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620587}, {"text": "InMotion WRIST\u2122", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620389}, {"text": "common shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620049}]}, "extracted_metadata": {"sha1": "3d2cccc435b4ad3e481cf7dcc7631e20a2788a2c", "filename": "1542113472062.zip-f2f1e935eae2454cc7309df54cfe8bb7.xml", "file_type": "json"}, "external_links": ["http://www.prnewswire.com/news-releases/bionik-laboratories-second-quarter-fiscal-2019-financial-results-feature-147-increase-in-revenues-300748813.html", "http://www.bioniklabs.com/", "https://blog.bioniklabs.com/news-media/press-releases/detail/44/chinese-fund-invests-in-bionik-laboratories-and-establishes", "https://www.linkedin.com/company/bionik-labs/", "http://www.bioniklabs.com/news-media/press-releases/detail/46/bionik-laboratories-and-wistron-corporation-partner-to", "https://www.facebook.com/bioniklab/", "https://twitter.com/bioniklab"], "title": "BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results Feature 147% Increase in Revenues", "forum_title": "Press Releases"}]}